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Abstract
Breast cancer is the most common female malignancy and presents a major
health issue both worldwide and in New Zealand. Individuals with a fam-
ily history of either breast or ovarian cancer have an increased lifetime risk of
breast cancer. Furthermore, approximately 10% of breast cancers are thought to
be caused by rare inherited genetic variants, of which variants in BRCA1 and
BRCA2 are the most prominent. Individuals carrying a pathogenic BRCA1 or
BRCA2 variant have up to a 87% and 84% lifetime risk of developing breast
cancer compared to 12% for the general population.
BRCA1 and BRCA2 functions are critical to genomic stability, which is essen-
tial to maintaining a healthy cell state in all tissues. However, there is a lack
of disease risk in the majority of non-breast and ovarian tissues. Additionally,
there are thousands of different sequence variants across each gene that present
distinct risk profiles ranging from benign to pathogenic. A large proportion of
these are considered variants of uncertain significance (VUS) resulting in no
additional information to aid clinical management. The effect of pathogenic
variants on gene expression is a potential source of information that can help to
identify genes involved in tissue-specific risk and a phenotype that can be used
to help classify VUS.
Previous studies have explored BRCA1- and BRCA2-associated gene expression
profiles, however, there has been a lack of consistency between genes identified
as associated with BRCA1- and BRCA2 variant status. These studies have typ-
ically focused on identifying differences by comparing the mean level of gene
expression, however, the variability of gene expression is also under genetic
control and has been under-explored in BRCA1- and BRCA2-associated tissues.
BRCA1 and BRCA2-associated gene expression variability was calculated across
three familial breast tumours datasets. Additionally, as BRCA1-associated tu-
mours are typically subtyped as basal-like, gene expression variability was cal-
culated between basal and non-basal breast tumours in four datasets. BRCA1-
associated and basal-like tumours exhibited greater global gene expression vari-
ability compared to familial breast tumour with no BRCA1 or BRCA2 pathogenic
variant (BRCAx) and non-basal tumours. By comparison, the mean level of
gene expression was similar between all tumour-types. Three genes (DSC3,
EN1 and IGF2BP3) were found to be differentially variable in BRCA1-associated
i
and basal-like breast tumours compared to BRCAx and non-basal tumours, re-
spectively. RNA in situ hybridisation (RNA ISH) was used to explore EN1 ex-
pression in 503 breast tumour cores, including 151 BRCA1-associated tumours.
Consistent with mircoarray analyses, RNA ISH found the expression of EN1
was variable in BRCA1-associated tumours.
Two breast cell lines were used to measure gene expression variability in BRCA1
heterozygous models. In contrast to tumour analysis, MCF-10A BRCA1mut/+
cells displayed less global gene expression variability compared to wild type
MCF-10A cells. Additionally, BRCA1 knock-down in MCF-7 cells showed no
change in gene expression variability. The knock-down of BRCA1 was, how-
ever, associated with a decrease in luminal and an increase in basal marker
expression. To further explore these observations, CRISPR-Cas genome engi-
neering was used to generate a MCF-7 cell that harboured a BRCA1 pathogenic
variant. Similar to BRCA1 knock-down models, MCF-7 BRCA1 mutant cells
exhibited a decrease in expression of the luminal marker ESR1. However, im-
munocytochemistry was unable to detect the basal maker CK5/6 in any of the
MCF-7 mutant clones.
Rare high risk breast cancer variants displayed an association between geno-
type and gene expression variability. Therefore, I also investigated the relation-
ship between common risk variants and gene expression variability by con-
ducting variable expression quantitative trait loci analysis (veQTL). This anal-
ysis showed that of the 181 published common breast cancer risk variants, 27
had breast-specific veQTL associations with 60 genes. One variant, rs11075995,
was associated with four genes (CYP11B1, CYP17A1, HSD3B2 and STAR), all of
which were involved in C21-steroid biosyntheisis.
These studies successfully demonstrated the potential utility of gene expression
variability analysis to identify candidate breast cancer risk associated genes.
The application of this approach may lead to a better understanding of the
mechanisms involved in the development of disease. Furthermore, these meth-
ods may transform how researchers interpret the results form published and
future genome-wide association studies.
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Breast cancer is the most common female malignancy worldwide with greater
than 2 million new cases annually, accounting for a quarter of all new can-
cer cases (Bray et al., 2018). One in eight females will develop breast cancer
throughout their lifetime, typically presenting after the age of 50 years (Barnard
et al., 2015). In New Zealand this translates to 3,300 new cases and approxi-
mately 600 deaths annually(Ministry of Health, 2019).
1.1.1 Histological Classification
Breast cancer encompasses several distinct diseases which are classified by sev-
eral histopathological and molecular features. As with most cancers, the ma-
jority of breast cancers develop from epithelial cells (carcinomas) with less than
1% of breast malignancies developing from mesenchymal tissues (sarcomas).
Breast carcinomas are classified by both location (ducts or lobules) and by the
invasiveness of the tumour (invasive or in situ). A tumour is considered inva-
sive if it has breached the myoepithelial layer. Invasive breast tumours include
several different subsets of disease with invasive ductal carcinomas (IDCs) and
invasive lobular carcinomas (ILCs) accounting for 75-80% and approximately
10% of all invasive breast tumours, respectively (Arpino et al., 2004; Li et al.,
2005; Wasif et al., 2010; Jacobs et al., 2016). The remaining invasive carcinomas
include several rare tumours collectively contributing <5% of invasive carcino-
mas.
1
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IDCs encompasses a group of heterogeneous cancers with an absence of defin-
ing characteristics, although typically presenting in the ducts before invad-
ing neighbouring tissue. In contrast, ILCs are well defined by the presence
of small cells without distinct cellular polarisation. ILC originates in lobules
of the breast and subsequently invades the stroma in singular fashion (Jacobs
et al., 2016). ILCs are more likely to be hormone receptor positive and have
marginally better prognosis than IDCs (Wasif et al., 2010).
Tumours that are confined to the origin site, in situ tumours, are similarly sub-
categorised by tissue sites. The most common, ductal carcinoma in situ (DCIS),
are considered a precursor of IDCs that has not breached the myoeptihelial
wall. Lastly, lobular carcinoma in situ are characterised by abnormal epithelial
cell growth that is confined to the lobules of the breast which does not typically
develop to the invasive disease (Foote and Stewart, 1982).
1.1.2 Molecular Classification
To aid clinical decisions, tumours are classified based on the expression of marker
proteins that predict treatment response (Figure 1.1). The presence of the hor-
mone receptors, oestrogen receptor (ER) or the progesterone receptor (PgR),
predicts response to hormone therapies (Tamoxifen or aromatase inhibitors).
However, the predictive value of PgR is limited compared to ER which better
predicts patient response to endocrine therapies (Mohsin et al., 2004). Hor-
monal receptor (ER or PgR) positive breast tumours are classified as luminal,
implying development from epithelial cells from the lumen of the breast. To
reflect intrinsic subtypes identified (discussed below) luminal tumours can fur-
ther classified by the proliferation marker Ki67 (Figure 1.1). Luminal A tumours
are defined by the low presence (<14% positive tumour cells) of Ki67. Con-
versely, luminal B tumours are marked by the expression of Ki67 in greater
than 14% of tumour cells (Cheang et al., 2009). Luminal B tumours, identified
by either RNA expression profiles or molecular markers, have worse outcomes
compared to luminal A breast tumours (Sørlie et al., 2001; Cheang et al., 2009).
The over-expression of human epidermal growth factor receptor 2 (HER2) is
predictive for response to treatment with trastuzumab and defines the tumour
subtype HER2 (Slamon et al., 2001). Tumours devoid of hormonal receptor
expression and HER2 over-expression define the triple negative breast cancer
(TNBC) subtype. A subset of TNBC are described as basal breast cancers which
are characterised by one or more of the basal cytokertain (CK) markers (CK5,
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CK5/6, CK14 and CK17) or epidermal growth factor receptor (EGFR). These
molecular classifications broadly overlap the intrinsic RNA profile discussed in
Section 1.1.2.1 (Figure 1.1).
1.1.2.1 Intrinsic Molecular Subtype
Early cDNA microarray studies of normal and tumour breast tissue revealed an
intrinsic gene expression profile (Perou et al., 2000; Sørlie et al., 2001; Parker et
al., 2009). In 65 tissue samples, Perou et al. identified 496 probes that were well
expressed across all samples and were more similar in paired tissue samples
than between samples. Hierarchical clustering of the 496 probes split breast
tissue based on ER status. The ER positive arm also had positive histologi-
cal staining of the luminal epithelial marker cytokeratins 8/18. The ER nega-
tive arm was further subdivided into a basal-like, HER2 (encoded by the gene
ERRB2) expressing and a normal-like group. The basal-like group consisted
of six tumours, all of which had positive staining of the basal markers, cytok-
eratins 5/6 and 17. The normal-like group consisted of all the normal breast
tissue and eight breast tumours.
Sørlie and colleagues replicated these molecular classifications and further clus-
tered the ER positive arm into two robust luminal groups, luminal A and lu-
minal B (Sørlie et al., 2001). Gene set reduction and cross-validation identi-
fied 50 genes that best distinguish these five (basal-like, luminal A, luminal B,
HER2, normal) molecular subtypes (Parker et al., 2009). The 50-gene classi-
fier is commonly referred to as PAM50, referring to both the method of pre-
diction and gene list size. Parker et al., showed that the PAM50 prediction
had good concordance with immunohistochemistry (IHC). By definition, basal
tumours do not express the ER, however 5% of IHC-ER positive tumours were
predicted as basal-like by PAM50 classification (Parker et al., 2009). PAM50 pre-
dictions were compared to clinical immunohistochemical subtypes in 348 breast
tumours with relatively high agreement observed (Chia et al., 2012). Basal tu-
mours were most accurately classified with 94% agreement between the two
methods. Similarly, 78%, 57% and 66% of tumours were correctly classified by
PAM50 for the luminal A, luminal B or HER2 subtypes, respectively.
1.2 Familial Breast Cancer
The majority of breast cancers are sporadic, presenting in patients with mini-
mal inherited risk or family history. New Zealand and Australia have amongst
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the highest incidence rates for breast cancer (Bray et al., 2018). However, these
country-specific risks are believed to be associated with lifestyle factors as chil-
dren of migrants, from low risk countries, have increased breast cancer risk
upon settlement in higher risk countries (Ziegler et al., 1993).
Familial breast cancer arises when the diagnosis of a new breast cancer occurs in
individual that has first-degree relatives with a history of breast cancer. Family
history of either breast or ovarian cancer is a major risk factor for the develop-
ment of breast cancer (Easton et al., 1993; Collaborative Group on Hormonal
Factors in Breast Cancer., 2001; Barnard et al., 2015). Individuals with a first-
degree relative with either breast or ovarian cancer have up to a two fold in-
crease in breast cancer risk, which is further increased if multiple first-degree
relatives have a history of disease (Collaborative Group on Hormonal Factors
in Breast Cancer., 2001). The clustering of disease within a family is suggestive
of inherited genetic risk, however, pathogenic variants in moderate and high-
risk genes (e.g. BRCA1 and BRCA2) accounts for only a fraction (<25%) of the
familial relative risk and a significant proportion of the hereditary component
to breast cancer has yet to be explained (Bahcall, 2019).
1.2.1 BRCA1 and BRCA2 Breast Cancer
The first genetic association with breast cancer risk was described through link-
age studies in the early 90’s (Hall et al., 1990). Mary-Claire King and colleagues
identified deleterious variants located on chromosome 17q21 that were asso-
ciated with early onset breast cancer. This research led to the isolation and
cloning of the gene breast cancer type 1 susceptibility protein (BRCA1) as the
specific site of risk (Narod et al., 1991; Miki et al., 1994). A second high pene-
trance gene, BRCA2, was later identified to be associated with early onset breast
cancers (Wooster et al., 1994, 1995). Subsequently, variants within each gene
have been identified and the clinical importance of each variant assessed. Col-
lectively, pathogenic variants in BRCA1 and BRCA2 account for approximately
5% of all breast cancers, contributing the largest portion of familial breast can-
cer risk (Mehrgou and Akouchekian, 2016).
Retrospective studies have estimated the cumulative life-time risk for BRCA1-
or BRCA2-associated breast cancer to range from 40% to 87%, and 27% to 84%,
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respectively (Table 1.1)(Antoniou et al., 2003; King et al., 2003; Chen and Parmi-
giani, 2007; Mavaddat et al., 2013). A large prospective study of 9856 individu-
als accurately estimated the cumulative risk of developing BRCA1- and BRCA2-
associated breast cancer as 72% (95% CI, 65%-79%) and 69% (95% CI, 61%-77%)
by 80 years of age, respectively (Kuchenbaecker et al., 2017). In comparison,
general population breast cancer risk is approximately 12% (Gao et al., 2003).
The estimated risk of contralateral breast cancer 20 years after the first breast
cancer was estimated at 40% (95% CI, 35%-45%) and 26% (95% CI, 20%-33%)
for BRCA1 and BRCA2 pathogenic carriers, respectively (Kuchenbaecker et al.,
2017). Notably, ongoing treatment with hormonal therapies, such as tamox-
ifen, are known to reduce the risk of contralateral disease (Phillips et al., 2018).
BRCA2-associated, but not BRCA1-associated, breast cancers are typically hor-
monal positive. Thus BRCA2-associated disease is more likely to be treated
with tamoxifen. It could therefore be reasoned that the observed BRCA2-associated
risk estimates may be underestimated due to treatment.
1.2.1.1 BRCA1 and BRCA2 Disease Risk in Non-Breast Tissue
Pathogenic variants in BRCA1 and BRCA2 have been associated with tissue-
specific tumour risk in several non-breast tissues (Breast Cancer Linkage Con-
sortium, 1999; Thompson, 2002; van Asperen et al., 2005; Iqbal et al., 2012;
Mavaddat et al., 2013; Mersch et al., 2015; Kuchenbaecker et al., 2017). How-
ever, only ovarian tissue showed a comparable risk of disease to breast tissue
(Table 1.1). Individuals with pathogenic variants in BRCA1 and BRCA2 are
estimated to have a cumulative risk of ovarian cancer by age 70 years from
16% to 68% and from 10% to 35%, respectively (Mavaddat et al., 2013; Kuchen-
baecker et al., 2017). Lesser risks have also been described in the pancreas,
prostate, bone, pharynx, cervix, bile duct and gall bladder (Breast Cancer Link-
age Consortium, 1999; Thompson, 2002; van Asperen et al., 2005; Iqbal et al.,
2012; Mersch et al., 2015). However, only prostate and pancreatic cancer risk
are consistently associated with either BRCA1 or BRCA2 pathogenic variants.
BRCA2-carriers have reported to have increased risk for pancreatic (RR 2.13-
21.75) and prostate cancers (RR 2.5-4.5) (Breast Cancer Linkage Consortium,
1999; van Asperen et al., 2005; Iqbal et al., 2012; Mersch et al., 2015). Mersch et
al., reported a significantly higher relative risk (RR) for pancreatic cancer than
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previously reported, 21.75 compared to 2.13-5.9 (Mersch et al., 2015). The dif-
ference in observed risk is unclear, however, Mersch et al., noted that half of
the cases were reported as smokers which is a major risk factor of pancreatic
cancers.
For BRCA1-carriers, Thompson et al., estimated no overall increased risk for
prostate cancer (RR 1.07, 95% CI 0.75-1.54) (Thompson, 2002). However, there
was an increased risk of prostate cancer in males under 65 years old (RR 1.82,
95% CI 1.01-3.29). A meta-analysis of fifteen datasets with BRCA1-carriers, es-
timated a modest increase in risk of prostate cancer (OR 1.35, 95% CI 1.03-1.76)
(Oh et al., 2019). Similarly, Moran et al., observed no increased risk for BRCA1-
carriers and pancreatic cancer (Moran et al., 2012). However, in larger studies,
including a prospective study by Iqbal et al., a 2.6-4.7 fold increased in pancre-
atic cancer risk has been observed in BRCA1 carriers (Iqbal et al., 2012; Mersch
et al., 2015).
TABLE 1.1: Cancer risk in BRCA1 and BRCA2 carriers.
Tissue General risk BRCA1 risk BRCA2 risk
Breast 12% 40-87% 27-84%
– Contralateral breast cancera 12% 40% 26%
Ovary 1-2% 16-68% 10-35%
Prostate 15-18% 1.07-1.35b 2.5-4.5b
Pancreas 1.5% 0.8-4.7b 2.13-21.75b
aCumulative risk after 20 years post first breast cancer diagnosis
bRelative risk
1.2.2 Other Breast Cancer Susceptibility Genes
Since the discovery of BRCA1 and BRCA2 as breast cancer susceptibility genes
many other risk genes have been proposed. These included high-risk vari-
ants in genes (CDH1, PALB2, PTEN, STK11 and TP53) that are typically associ-
ated with cancer syndromes. The evidence for many proposed moderate- and
modest-risk breast cancer susceptibility genes is less clear.
1.2.2.1 Genes High Risk for Breast Cancer
TP53
Germline variants in TP53 are associated with Li-Fraumeni syndrome (LFS)
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(Malkin et al., 1990). LFS is characterised by five cancers: breast cancers, brain
tumours, sarcomas, adrenocortical carcinoma and leukaemia, of which breast
cancer is the most common (approximately 35-49%) (Birch et al., 1998; Hwang
et al., 2003). In addition, breast cancer in LFS presents early in life (<40) and
may present with little familial history of breast cancer. The lack of family his-
tory, is in part due to the array of cancer types that may family members may
presents.
PTEN
Individuals with pathogenic variants in the phosphatase and tensin homolog
gene (PTEN) are associated with the PTEN hamartoma tumour syndrome (PHTS).
PHTS encompasses several syndromes including Cowden syndrome, of which
approximately 80% carry a PTEN variant (Marsh et al., 1998; Tan et al., 2012).
PHTS is characterised by the risk of numerous cancers including breast, col-
orectal, endometrium, kidney and thyroid. Women with a PTEN variant have a
lifetime risk of developing a breast cancer of 25-50% (Tan et al., 2012; Apostolou
and Fostira, 2013). PTEN-associated breast cancers are rare and account for less
than 1% of all breast cancers (Nelen et al., 1999).
STK11
Peutz-Jeghers syndrome, is linked to mutations in the serine/threonine kinase
(STK11) gene. It is characterised by hamartomas and mucocutaneous pigmen-
tations with colorectal and breast amongst the more common cancers (van Lier
et al., 2010). Cancers develop in at least 37% of individuals, with the cumulative
risk of breast cancer between 32-54% by 70 years of age (Giardiello et al., 2000;
Lim et al., 2004).
CDH1
Mutations in the E-cadherin gene (CDH1) cause hereditary diffuse gastric car-
cinoma, however, there is also a substantially increased risk for lobular breast
cancer (Hansford et al., 2015). Women who carry CDH1 mutation have a 40-
54% lifetime risk of lobular breast cancer (Kaurah et al., 2007; Hansford et al.,
2015). In contrast, there is an approximately a 70% lifetime risk of diffuse gas-
tric cancer. Interestingly, Salvin et al., described two families with the same
CDH1 variant that were associated with early breast cancer and not gastric
cancer (Slavin et al., 2017). Subsequent to Salvin et al., the described variant
(c.1118C>T) was classified as likely-benign for hereditary diffuse gastric cancer
Chapter 1. Introduction 9
(https://www.ncbi.nlm.nih.gov/clinvar/). Although the study by Slavin et al.,
was under-powered to make any conclusion around the CDH1 c.1118C>T vari-
ant, the possibility of variants-specific disease risk remains for CDH1.
PALB2
Partner and Localizer of BRCA2 (PALB2) is essential in facilitating BRCA2 roles
in genome maintenance (Xia et al., 2006). Mutations in PABL2 are not asso-
ciated with any syndromes, however, there is a substantial increased risk of
breast cancer. First reports suggested at least a 2.3-fold increased risk of devel-
oping breast cancer (Rahman et al., 2007; Couch et al., 2017). However, specific
rare variants have risk profiles that range in severity (OR = 1.03-5.93) (Southey
et al., 2016). In New Zealand and Australian women, the PALB2 c.3113G>A
risk variant has a 91% cumulative risk of developing breast by age 70 (Southey
et al., 2010). These risk estimates are much greater than observed in other Eu-
ropean populations which are estimated to have a 35% cumulative risk by age
70 (Antoniou et al., 2014).
1.2.2.2 Moderate and Modest Breast Cancer Risk Genes
Discussed above are genes that when mutated confer a high level of breast can-
cer risk. However, in a significant proportion of individuals with a history of
hereditary disease there is an absence of variants in these high-risk genes. A
proportion of these cases are due to variants identified in moderate and low
risk breast cancer susceptibility genes. The risk profile of many remain con-
tentious.
There are several genes (ATM, BARD1, CHEK2,RAD51D and RAD51C) pro-
posed to be associated with a low to moderate increase in breast cancer risk
(Hollestelle et al., 2010; Slavin et al., 2017; Yang et al., 2020). Case-control stud-
ies have generated strong evidence for genes as moderate and modest breast
cancer susceptibility genes (Slavin et al., 2017; Couch et al., 2017). Each of these
studies described ATM (OR=2.78-3.28) and BARD1 (OR=2.16-3.18) as moderate
breast cancer susceptibility genes. For CHEK2, Slavin and colleague observed a
modest increased in risk of breast cancer (OR=1.6). Whereas Couch et al., pro-
posed a moderate increased risk (OR=2.26) for breast cancer when excluding
common missense variants. In addition, both studies described a significant
Chapter 1. Introduction 10
increased in risk (OR=3.07-8.33) for variants in RAD51C. However, the asso-
ciation of RAD51D with breast cancer risk (OR=8.33) from Slavin et al., was
based on only four cases and should be interpreted with caution. Recently,
segregation analysis of more than 6000 families with breast or ovarian cancer
estimated breast cancer relative risk at 1.99 and 1.83 for RAD51C and RAD51D,
respectively (Yang et al., 2020).
1.2.2.3 Common Genetic Breast Cancer Risk Variants
Through large multi-site collaborations, several consortia have searched for as-
sociations of single nucleotide polymorphisms (SNPs) and breast cancer risk.
Supplementary Table D.1) presents a comprehensive list of common variants
associated with breast cancer risk.
The Breast Cancer Association Consortium (BCAC) performed a meta-analysis
of 18 case-control studies totalling approximately 30,000 cases and 30,000 con-
trols (The Breast Cancer Association Consortium, 2006). BCAC restricted anal-
ysis to 16 high confidence SNP calls that were called in at least three studies
across at least 10,000 individuals. No SNP association reached genome wide
significance (p < 0.5x10−8), however, three variants showed an nominal asso-
ciation (p < 0.05). Subsequently, a three tier genome-wide association study
(GWAS) identified five loci that were associated with increased risk of disease
(Easton et al., 2007). The first stage genotyped approximately 200,000 SNPs
across 390 and 364 breast cancer cases and controls, respectively. The second
stage analysed 12,000 SNPs in a larger cohort of approximately 4000 cases and
controls. The third stage genotyped the 30 most significant SNPs from stage one
an two on approximately 20,000 breast cancer cases and approximately 20,000
controls. Five SNPs were associated (OR 1.08-1.13) with breast cancer risk at
genome significance level, of which four were near or within genes (Supple-
mentary Table D.1).
A multi-discipline collaboration was established between consortia involved
in breast, ovarian and prostate cancer research, along with a partnership with
Illumina. The Collaborative Oncologic Gene-environment Study (COGS) cus-
tomised an iSelect SNP genotyping array (iCOGS). Michailidou and colleagues
analysed the 45,290 breast cancer cases and 41,880 controls that were included
on the iCOGS along with a meta-analysis of 9 previously published GWAS
(Michailidou et al., 2013). Analysis validated 23 of the previous 27 variants
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associated with breast cancer risk. Furthermore, they identified 41 new risk
variants across 37 loci at a genome significance level (p < 5x10−8).
The 1000 genomes project also allowed the imputation of the iCOGs dataset so
that approximately 11.6 million SNPs were able to be profiled (Michailidou et
al., 2015). There was high concordance with previous association studies with
71/79 previously described risk alleles significant for breast cancer or subtype
specific breast cancer (e.g. ER negative disease) risk. However, the recapture of
risk variants is partially driven by reanalysis of the same data, in particular the
iCOGS dataset which accounted for the majority of genetic data. Interestingly,
of the previous risk variants that were not validated, two variants shared a lo-
cus with a second variant that was associated with disease risk. One of which
was in linkage disequilibrium (r2 = 0.98 between rs6964587, chr7:91681597).
In contrast, rs2380205 (originally associated variant) and rs1830298 are not in
linkage disequilibrium (r2 = 0.06). As the latest study has significantly greater
power, it is likely that the earlier reported SNPs was a false positive call. In
addition to recapturing previous associations, 15 new loci were associated with
breast cancer risk (Michailidou et al., 2015).
The continual exploration of unexplained risk lead to the establishment of the
OncoArray Consortium. This enabled the development of a SNP array (On-
coArray Beadchip) that covers approximately 570,000 SNP loci (Amos et al.,
2017). Approximately 60,000 breast cancer cases and 45,000 controls were col-
lated from BCAC and Discovery, Biology and Risk of Inherited Variants in
Breast Cancer Consortium (DRIVE) and genotypes were called on the OncoAr-
ray BeadChip (Michailidou et al., 2017). This project led to the identification of
a further 65 novel loci associated with breast cancer risk. To date, studies have
identified greater than 170 variants associated with breast cancer or subtype-
specific breast cancer risk. Taken together, these common variants attribute
approximately 18% of all breast cancer risk (Michailidou et al., 2017).
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1.2.3 Breast Cancer Gene Expression Profiles
1.2.3.1 Prognostic Signatures
Gene expression signatures have been developed as potential prognostic tools
and predictors of variant status. OncotypeDx (Genomic Health Inc., San Fran-
cisco) predicts distant recurrence in women with ER positive breast cancer re-
ceiving hormone therapy (Tamoxifen), limiting its use to this subset of breast
cancer patients (Paik et al., 2004). OncotypeDx was developed by identifying
genes that were consistently correlated with recurrence and/or outcome across
three independent studies. A panel of 16 genes were selected, along with 5 con-
trol genes, for their consistent correlation to disease recurrence or outcome and
quantitative reverse transcription polymerase chain reaction (qRT-PCR) perfor-
mance (Paik et al., 2004). The performance of OncotypeDx may be limited by
the inclusion of several genes with weak correlation to outcomes (p > 0.05).
The clinical utility of OncotypeDx is limited to subtype specific disease and
may have low clinical information. This is highlighted by the similar prog-
nostic value compared to the widely used clinical immunohistochemical mark-
ers (Milburn et al., 2013; Khoury et al., 2015; Neely et al., 2018). A prognos-
tic trial (TAILORx) investigated the effect of adjuvant chemotherapy in over
6,000 hormone-positive breast with intermediate OnctypeDx recurrence scores
(Sparano et al., 2018). The trial highlighted that there was no benefit from
chemotherapy above endocrine therapy.
A second 70-gene classifier (MammaPrint) was developed in lymph node neg-
ative breast cancers (van’t Veer et al., 2002). The gene-panel was selected for
genes that correlated with disease outcome (distant metastasis after five years)
and was optimised by a leave-one-out cross validation method. The classifier
accurately predicted outcomes in 83% of the training set, however, in an at-
tempt to be more sensitive (only allowing 10% misclassification of poor prog-
nostic samples) the author decreased the accuracy (81%). These accuracies were
confirmed in a small validation set (19 tumours) and later in a much larger co-
hort of 295 breast tumours (61 of which overlapped the training set and were
excluded) (van de Vijver et al., 2002). Furthermore, van de Vijver validated
the 15 fold increase in odd ratio of developing distant metastases for patients
identified as ‘poor prognosis’ compared to ‘good prognosis’. The utility of
MammaPrint in identifying women that may not require chemotherapy was
Chapter 1. Introduction 13
tested in the MINDACT trial (Cardoso et al., 2016). Individuals that were con-
sidered high risk for distant metastasis clinically and low risk by MammaPrint
were randomised into chemotherapy or no chemotherapy groups. In these co-
horts there was only 0.9 and 2.6% improvement in five and eight year distant
metastasis free survivals for individuals that received chemotherapy, respec-
tively (Cardoso et al., 2020).
1.2.4 Gene Expression Profile in BRCA1 and BRCA2 Carriers
Studies have investigated the effect of BRCA1 and BRCA2 pathogenic variants
on gene expression in breast and ovarian tumour tissue and several normal tis-
sues (blood tissues and breast fibroblasts). Despite these studies, there remains
no clear gene expression profile and there is little agreement between gene lists
of studies (Table 1.2).
1.2.4.1 BRCA1/2 Expression Profiles in Breast Cancer
The first study that attempted to identify a BRCA1/2 like expression pheno-
type quantified the expression of 5000 probes across 21 breast tumours (Heden-
falk et al., 2001). The expression of 51 genes were able to accurately segregate
the three tumour genotypes (BRCA1, BRCA2 and sporadic). Furthermore, nine
genes were associated with BRCA1-related breast tumours and 11 genes were
associated with BRCA2-related breast tumours. The nine genes associated with
BRCA1 carriers accurately classified 95% (21/22) of breast tumours. Similarly,
the 11 gene BRCA2 gene list correctly classified 82% (18/22) of tumours. Inter-
estingly, the only misclassified tumour by the BRCA1 gene list had BRCA1 pro-
moter hypermethylation and reduced BRCA1 expression, suggesting tumours
without a pathogenic variant may display a ‘BRCA-like’ phenotype. These clas-
sifications were, however, performed on the same samples used to generate the
classifier making interpretation of accuracy difficult. In an independent dataset,
the 51 genes were not able to segregate BRCA1-associated tumours from spo-
radic tumours (Dudaladava et al., 2006). However, Dudaladava et al., only
had expression profiles for 40/51 genes and all tumours were ER negative. It
remains possible that the strength of the classifier is dependent on the eleven
missing genes and tumour phenotypes. The Hedenfalk study was further con-
founded by the ER status of samples selected. All the BRCA1-associated tu-
mours were ER negative, compared with 33% of the non-BRCA1-associated tu-
mours. ER status has since been revealed as a major driver of gene expression
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differences, irrespective of genotypes (van’t Veer et al., 2002; Lisowska, 2011).
In an attempt to account for BRCA1-associated tumour phenotypes investiga-
tors have explored BRCA1-associated gene expression profiles in hormonal re-
ceptor negative tumours (van’t Veer et al., 2002; Dudaladava et al., 2006; Martin
et al., 2007). van’t Veer and colleagues optimised a 100 gene BRCA1 classifier
by exploring gene expression profiles of 38 ER negative breast tumours (van’t
Veer et al., 2002). The 100 gene classifier accurately classified 95% (36/38) of ER
negative breast tumours. Similarly to Hedenfalk et al., one tumour misclassi-
fied as a BRCA1-associated tumour was reported to have hypermethylation of
the BRCA1 promoter. Martin and colleagues (Martin et al., 2007) utilised the
data generated by van’t Veer et al., and investigated genes involved in BRCA1-
related functions. Three genes (RAD51, RAD54 and RAD51AP1) involved in
homologous recombination were differentially expressed in BRCA1-associated
ER negative tumours. Despite using the same dataset, none of these three genes
were present in van’t Veer’s 100 gene classifier.
Dudaladava et al., (Dudaladava et al., 2006) selected the 100 most differentially
expressed BRCA1-associated genes, however, as significance was not provided
it is difficult to interpret the likelihood of a real difference between tumour
types. Nevertheless, these 100 genes were able to accurately cluster 93% (13/14)
of breast tumours based on BRCA1 variant status.
The development of breast tumour intrinsic subtype predictions allowed in-
vestigators to interrogate tumours based on subtype (Parker et al., 2009; Wad-
dell et al., 2010a; Lisowska, 2011; Larsen et al., 2013, 2014). Similar to ER sta-
tus, subtype has a major influence on gene expression profiles (Waddell et al.,
2010a; Lisowska, 2011). Lisowska and colleagues were able to identify 423
genes significantly (p < 0.001) differentially expressed in BRCA1-associated
tumours. The 423 genes were a poor predictor for variants status, only cor-
rectly classifying 69% of tumours in the training dataset. Similarly, the 423
gene poorly classified the 21 tumours from the Hedenfalk et al., with only 64%
correctly classified (Lisowska, 2011). Gene expression profiles from BRCA1-
associated tumours were observed to be more similar to sporadic breast tu-
mours than non-BRCA1/2 (BRCAx) hereditary breast tumours. The similarity
of some sporadic tumours with BRCA1-associated tumours is consistent with
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those observations in tumours with hypermethylated BRCA1 promoters de-
scribed in early studies (Hedenfalk et al., 2001; van’t Veer et al., 2002). One large
study (n=577) combined tumours containing hypermethylated BRCA1 promot-
ers with BRCA1 carriers (Jönsson et al., 2012). BRCA1 impaired (pathogenic
carriers and hypermethylated BRCA1 promoter) tumours had 321 genes differ-
entially expressed from basal-like sporadic tumours. Unfortunately only four
genes (RB1, BRCA1, CDK6, CCDN1) in text could be identified making inter-
pretation of their findings difficult.
Three studies employed well-utilised expression arrays (Illumina and Affymetrix)
which consisted of approximately 40,000 probes targeting approximately 25,000
RefSeq annotated genes (Waddell et al., 2010a; Larsen et al., 2013, 2014). Wad-
dell et al., (Waddell et al., 2010a) assessed familial breast tumours from 75 pa-
tients who carried pathogenic variants in BRCA1 or BRCA2, or were BRCAx
to determine molecular heterogeneity between and within each subgroup. A
total of 277 genes were differentially expressed between BRCA1 and BRCAx tu-
mours, and 31 genes were differentially expressed between BRCA2-pathogenic
variants and BRCAx tumours. The difference observed in the size of the gene
lists suggested that BRCAx tumours are more similar to tumours from BRCA2
pathogenic variant carriers than BRCA1 pathogenic variant carriers. This hy-
pothesis is reinforced by the intrinsic subtypes of BRCA1, BRCA2 and non-
BRCA-related tumours. BRCA1 carriers were largely (74%) basal-like, while
tumours from BRCA2 carriers and BRCAx were largely (73% and 60%) lumi-
nal, an observation which has also been observed in subsequent studies (Jöns-
son et al., 2012; Larsen et al., 2013; Massink et al., 2015). Larsen and colleagues
studied 183 breast tumours (33 BRCA1, 22 BRCA2) and developed a 110-probe
signature to classify BRCA1 breast tumour within the basal-like tumours with
an accuracy of 83% (sensitivity: 82%, specificity 85%) (Larsen et al., 2013). Simi-
larly, a 100-probe signature was identified for classification of luminal B BRCA2
carriers with an accuracy of 89% (sensitivity: 88%; specificity: 90%).
A meta-analysis using four published datasets (Waddell et al., 2010a,b; Larsen
et al., 2014; Massink et al., 2015) was conducted to identify differentially ex-
pressed genes between different familial (BRCA1 or BRCA2 pathogenic variant
carriers and BRCAx) and sporadic breast tumours (Akbari et al., 2019). Two-
hundred and seventy eight genes were consistently differentially expressed
(p < 0.05,0.6 < log2 < −0.6) between the four studies. Differentially expressed
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genes were mapped with transcription factor binding sites to identify key regu-
lators, including five transcription factors (FOXM1, TFAP2C, FOXA1, ESR1 and
GATA3) that were differentially expressed (p < 0.05, FC > 1.5) in at least three
studies.
Table 1.2 highlights the poor overlap between studies of gene expression pro-
files in breast tumours. The largest overlap being seen between analyses per-
formed by Waddell et al., and Akbari et al (Waddell et al., 2010a; Akbari et al.,
2019). However, the overlap may be driven by Akbari et al., using data gener-
ated by Waddell et al. Furthermore, each of these analyses produced the great-
est amount of genes associated with BRCA1 or BRCA2 pathogenic status. Only
one gene, TOB1, was identified as associated with BRCA1 carrier status by more
than two studies (Hedenfalk et al., 2001; Dudaladava et al., 2006; Lisowska,
2011).
1.2.4.2 BRCA1/2 Expression Profiles in Ovarian Tumours
In addition to breast tumours, three studies have been published that assessed
differences in gene expression profiles between BRCA1/2-associated and BR-
CAx ovarian tumours (Jazaeri et al., 2002; Konstantinopoulos et al., 2010; George
et al., 2013). A further study identified a precancerous signature in fallopian
tube tissue of BRCA1 pathogenic variant carriers (Press et al., 2010).
Jazaeri and colleagues quantified gene expression for 61 ovarian tumours, which
included 18 BRCA1- and 16 BRCA2-associated tumours (Jazaeri et al., 2002).
The expression of all approximately 7,500 probes was able to distinguish BRCA1-
associated tumours from BRCA2-associated tumours. However, the sporadic
ovarian tumours were mixed amongst these two populations, reinforcing the
hypothesis of a potential ‘BRCA-like’ expression profile that may exist in a sub-
set of sporadic tumours. This hypothesis is consistent with previous observa-
tions described in breast tumour analyses (Hedenfalk et al., 2001; van’t Veer
et al., 2002; Lisowska, 2011). In addition, only 9 and 3 genes were differen-
tially expressed between sporadic tumours and BRCA1- and BRCA2-associated
tumours, respectively. By comparison, 110 genes were differentially expressed
between BRCA1- and BRCA2-associated ovarian tumours. Interesting, in a later
study, George et al., (George et al., 2013) was unable to replicate the tumour
clustering despite performing the analysis on the same dataset, implicating
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these results may be a false positive.
The Jazaeri dataset was analysed by Konstantinopoulos et al., and a 60 gene
‘BRCA-like’ signature was identified using a selective sample exclusion crite-
ria (Konstantinopoulos et al., 2010). Samples were excluded based on tran-
scriptome wide unsupervised clustering which generated three distinct clus-
ters termed ‘sporadic’, ‘BRCA1’ and ‘BRCA2’. In an attempt to purify these
groups, samples that were misclassified were excluded from further analysis,
leaving only 23 familial (13 BRCA1, 10 BRCA2) and 14 sporadic ovarian tumour
samples. These 37 samples were used to identify a 60 gene signature that accu-
rately classified (94%) the selected BRCA1/2 associated ovarian tumours from
sporadic tumours. As the accuracy was only tested on the training dataset it
is difficult to determine the classifiers utility. Furthermore, the highly selective
exclusion criteria implemented limits its translation to any real world clinical
samples.
George et al., used three public datasets (Jazaeri et al., 2002; Tothill et al., 2008;
The Cancer Genome Atlas Research Network, 2011) to identify differences be-
tween ovarian tumours defective for BRCA1 and BRCA2 compared to sporadic
tumours (George et al., 2013). Expression data from The Cancer Genome Atlas
(TCGA) (The Cancer Genome Atlas Research Network, 2011) network was used
to identify genes differentially expressed and associated to BRCA1- and BRCA2-
mutation status (somatic or germline variants). Sixty-five genes were differen-
tially expressed between BRCA1/2-mutated and non-mutated ovarian tumours.
On its own, 34 genes were differentially expressed between BRCA1-mutated
and non-BRCA1/2 mutated ovarian tumours. No genes were differentially ex-
pressed between BRCA2 mutated and non-BRCA1/2 mutated ovarian tumours.
In addition to identifying differentially expressed genes, George et al., inves-
tigated the discriminatory power of Konstantinopoulos’ 60 gene ‘BRCA-like’
classifier (Konstantinopoulos et al., 2010). Three independent datasets (Jazaeri
et al., 2002; Tothill et al., 2008; The Cancer Genome Atlas Research Network,
2011) were used to compare classifiers from George et al., and Konstantinopou-
los et al. All three cohorts showed the TCGA derived classifiers to outperform
the previously published 60-gene ‘BRCA-like’ signature with area under the
ROC curve ranging from 0.77-0.89 versus 0.55-0.63, respectively.
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To assess early tumorigenic events, Press et al., conducted a study of non-
cancerous fallopian tube (with and without BRCA1 pathogenic variants), and
ovarian carcinomas from individuals with BRCA1 pathogenic variants (Press
et al., 2010). This study identified 152 probes differentially expressed (FC > 1.8
and p < 0.01) between non-cancerous BRCA1 and BRCAx fallopian tubes. A
further 4,079 probes were differentially expressed between non-cancerous fal-
lopian tubes from non-BRCA1/2 pathogenic variant carriers and BRCA1-associated
ovarian tumours. A preneoplastic signature was defined by the 41 probes dif-
ferentially expressed in the same direction across each analysis (Press et al.,
2010). Unsupervised hierarchical clustering was performed with an additional
12 normal fallopian tube samples with BRCA1 pathogenic variants. Interest-
ingly, five samples clustered with BRCA1-associated tumours (fallopian or ovar-
ian), the remaining seven clustered with normal fallopian tube with no pathogenic
variant. This highlighted the limited utility of classifiers developed in tumour
tissue to predict variant status in normal tissue. Similar to that seen in breast
tissue, there was overwhelmingly poor overlap of genes between studies (Ta-
ble 1.2). Pairwise comparison saw no more than two genes in common between
BRCA1-associated ovarian studies.
1.2.4.3 BRCA1/2 Expression Profiles in Non-Tumour Tissue
To assess gene expression patterns of BRCA-variant carriers, studies have also
investigated stromal non-cancerous tissue (Kote-Jarai et al., 2004, 2006), lym-
phoblastoid cell lines (LCLs) (Waddell et al., 2008; Walker et al., 2010; Feilotter
et al., 2014; Pouliot et al., 2017), lymphocytes (Salmon et al., 2013; Zahavi et al.,
2018) and peripheral blood mononuclear cells (Vuillaume et al., 2009; Tanaka
et al., 2018).
Fibroblasts
Using the hypothesis that DNA repair is impaired in different human tissues
of BRCA1/2 pathogenic variant carriers, two studies explored induced DNA
damage in short-term cultures of fibroblast after γ-irradiation. Kote-Jarai and
colleagues established short-term fibroblasts cultures from 14 women (9 BRCA1
pathogenic variant carriers) who underwent prophylactic mastectomy or breast
reductive surgery (Kote-Jarai et al., 2004). Across two independent methods
(differential expression and class prediction) 122 BRCA1-associated genes were
identified, of which 79 were identified by both methods. Genes differentially
expressed accurately clustered BRCA1-associated fibroblasts, only one sample
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was misclassified as wild type BRCA1.
A subsequent study utilised skin biopsies of 30 (10 BRCA1, 10 BRCA2, 10 spo-
radic) women with a history of breast cancer who were disease free at time of
recruitment (Kote-Jarai et al., 2006). The top 200 genes that best discriminated
between each genotype post γ-irradiation were identified. Thus, three gene
panels were developed (BRCA1 vs BRCAx, BRCA2 vs BRCAx and BRCA1 vs
BRCA2). All three gene panels performed well, accurately clustering all sam-
ples based on genotype. However, hierarchical clustering was performed on
the training dataset and no inclusion of the third genotype was tested. There-
fore, the accuracy and robustness of the genes discriminative power was not
examined. Furthermore, each of the studies by Kote-Jarai et al., (Kote-Jarai et
al., 2004, 2006) has poor overlap in discriminative genes, with only four genes
(ADNP, CDKN1B, FYN and SPIN) in common. One explanation for the lack of
concordance may be due to sample type. In the later study normal breast was
acquired from women post cancer and post treatment. It is plausible that the
development and treatment of breast cancer may have altered the expression
profile of local normal breast tissue.
Lymphoblastoid cell lines (LCLs)
Eight studies investigated the effect of a BRCA1/2 pathogenic variants on gene
expression in immortalised LCLs (Waddell et al., 2008; Walker et al., 2010; Feilot-
ter et al., 2014; Pouliot et al., 2017) or peripheral blood (Vuillaume et al., 2009;
Salmon et al., 2013; Tanaka et al., 2018; Zahavi et al., 2018). Waddell et al.,
(Waddell et al., 2008) assessed the effects of BRCA1/2 pathogenic variants type
(missense and truncating) in 78 LCLs (23 BRCA1, 22 BRCA2, 27 BRCAx) post γ-
irradiation. Compared to missense pathogenic variants, truncating pathogenic
variants had a larger effect on expression profiles. Truncating BRCA1 pathogenic
variant carriers had 2,474 genes differentially expressed compared with BR-
CAx cases, while missense BRCA1 pathogenic variant carriers only had 599
genes differentially expressed. Similarly, BRCA2 pathogenic variant carriers,
had 3,932 and 788 genes differentially expressed for truncating and missense
variants, respectively. The top 200 genes (ranked by p-value) of each gene list
was used to predict the pathogenic variant status of LCLs. For the two BRCA1-
associated gene lists (truncating and missense), the truncating variant classi-
fier was most accurate, correctly predicting the mutation status in 76% (38/50)
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of the LCLs. By comparison, both the truncating and missense BRCA2 classi-
fiers correctly predicted 73% of the LCLs. However, the classifier derived from
BRCA2 truncating variants misclassified all BRCA2 missense associated LCLs.
It is unclear whether inclusion of all differentially expressed genes would im-
prove accuracy.
Walker et al., (Walker et al., 2010) used a pooled-RNA strategy to assess 27 LCLs
derived from affected women in high-risk breast cancer families (nine BRCA1,
nine BRCA2 pathogenic variant carriers and nine BRCAx) and nine LCLs from
healthy individuals, before and after treatment with mitomycin C. This study
identified 36 genes which overlapped three different analyses that compared
samples based on: 1) BRCA1/2 variant status, 2) mitomycin C treatment sta-
tus and 3) disease status. A classifier was built using the expression profile of
nine RT–qPCR validated genes which distinguished BRCA1 from BRCA2 vari-
ant carriers with 83% accuracy. However, inclusion of all BRCA1, BRCA2 and
BRCAx LCLs decreased the performance with a maximum of 59% prediction
accuracy.
Feilotter et al., (Feilotter et al., 2014) compared the expression profiles of 31
BRCA1-associated against 38 control LCLs post γ-irradiation. Genes were iden-
tified based on the predictive value of classifying BRCA1 status. Interestingly,
the authors used raw mircoarray data along with quantile normalised expres-
sion data to identify candidate genes. The analysis of raw intensity values may
introduce biases especially with fluctuations in sample RNA load. In total, 43
genes where identified that best classified the 53 samples used as a training set.
All 16 test samples were correctly classified and in total the gene set performed
accurately (sensitivity=84%, specificity=92%). However, only 3/43 genes were
validated by RT-qPCR.
Pouliot et al., (Pouliot et al., 2017) investigated expression profiles in LCLs from
117 women with (affected) and without breast cancer (unaffected) from related
individuals with or without pathogenic BRCA1 or BRCA2 variants. Ninety-
five transcripts were differentially expressed between unaffected non-BRCA1/2
LCLs and either BRCA1 pathogenic variants, BRCA2 pathogenic variants or
affected non-BRCA1/2. These 95 transcripts segregated BRCA1 and BRCA2
pathogenic variants from non-BRCA1/2, however, they were not able to dis-
criminate each variant type. Post-hoc analysis suggested that 69 transcripts
were differentially expressed between LCLs with a BRCA1 pathogenic variant
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and unaffected non-BRCA1/2 LCLs. Seventy-one transcripts were differentially
expressed between LCLs with a BRCA2 pathogenic variant and unaffected non-
BRCA1/2 LCLs.
Peripheral blood
Expression profiles of 30 peripheral blood samples identified 133 genes differ-
entially expressed associated with BRCA1-pathogenic variants (Vuillaume et
al., 2009). However, after adjusting for multiple testing no genes were statisti-
cally significant. The 133 genes were able to accurately classify 80% (11/15) of
the BRCA1 pathogenic variants and 100% (15/15) of the non-variants. Again,
the classification was only performed on the training dataset and not validated
in an independent cohort.
Salmon and colleagues used peripheral blood (lymphocytes) from 80 individ-
uals, including BRCA1 (n=13) and BRCA2 (n=10) pathogenic variant carriers
(Salmon et al., 2013). Analysis of γ-irradiated lymphocytes from BRCA1 pathogenic
variants revealed 137 probes that were differentially expressed compared to
control lymphocytes. Interestingly, a greater effect was observed in BRCA2-
associated lymphocytes with 1,345 probes differentially expressed compared
to controls. In an attempt to select the most discriminate genes, only genes
with fold changes greater than two and consistent expression patterns across
all samples were considered. Thirty-six genes met this criteria, the majority of
which were enriched for transcription and DNA binding processes. Further-
more, RT-qPCR was used to test the accuracy of classification and refine these
discriminatory genes. Firstly, of the 36 genes, 21 showed significant differences
(measured by RT-qPCR) associated with BRCA1 or BRCA2 status. The classifier
was further refined by ROC curve analysis of each gene. ROC curve analysis
concluded that three genes performed poorly and these were excluded from the
classifier. The remaining 18 genes accurately classified lymphocytes based on
BRCA1 and BRCA2 status in an independent cohort of 57 individuals.
In contrast to findings in irradiated lymphocytes, non-irradiated lymphocytes
displayed a greater change in expression profiles for carriers of pathogenic
BRCA1 variants compared to BRCA2 variants (Zahavi et al., 2018). Compared
to wild type controls, 203 and 29 genes were differentially expressed associated
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with BRCA1 and BRCA2 pathogenic variants. The discrepancy between irradi-
ated and non-irradiated lymphocytes and variant status may be due to differ-
ential dependency of BRCA1 and BRCA2 and the response to γ-irradiation. In
addition, immortalised LCLs BRCA1- but not BRCA2-associated LCLs are sen-
sitive to γ-irradiated (Bourton et al., 2013).
Due to the association of BRCA1 and BRCA2 proteins with telomere mainte-
nance (Rosen, 2013), peripheral blood was collected from 40 women (31 with
breast cancer) and telomere-associated genes expression levels were assessed
(Tanaka et al., 2018). BRCA1 pathogenic variants had a greater disruption on
telomere-associated genes. Forty-six and eight genes were differentially ex-
pressed between BRCA1 and BRCA2 carriers, respectively. Despite greater dis-
ruption to the expression of telomere-associated genes, there was no difference
in telomere length between BRCA1 and BRCA2 carriers.
1.2.4.4 Reproducibility Between BRCA1/2 Gene Expression Studies
Table 1.2 highlights the poor overlap of gene consensus between the studies
discussed above, irrespective of tissue type. The lack of consensus in candidate
gene lists amongst studies may be attributed to numerous factors discussed in
detail below.
Sample selection
Differences in sample selection can be summarised as three broad ideas: 1) Def-
initions of experimental and control groups, 2) Tumour matching and 3) purity
of tumour samples. Control arms can broadly be split into two categories: un-
selected (e.g. sporadic cancer) or BRCAx individuals. BRCAx and sporadic
tumours themselves are heterogeneous and generate distinct gene expression
profiles (Fernández-Ramires et al., 2011). Fernàndez-Ramires et al., identified
two BRCAx subgroups and two sporadic subgroups based on expression pro-
filing. Although there was some overlap between the BRCAx and sporadic
subgroups results suggest that there are sub-populations of tumours that differ
within each control group. Therefore, comparison of BRCA1 or BRCA2 variant
carriers would be expected to exhibit distinct differences between each control
group.
For the experimental arms, studies generally incorporated all pathogenic vari-
ants into a BRCA1 or BRCA2-associated arm. However, Waddell et al., observed
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differences between truncating and missense pathogenic variants (Waddell et
al., 2008). Mixed populations of variant types used by other studies may con-
found any observed differences. Furthermore, two studies highlighted that
sporadic tumours with hypermethylated BRCA1 promoter exhibit expression
profiles similar to BRCA1 pathogenic variants (Hedenfalk et al., 2001; van’t Veer
et al., 2002). Two further studies directly addressed hypermethylated BRCA1
promoter by excluding (George et al., 2013) or combining with pathogenic vari-
ants (Jönsson et al., 2012). Furthermore, George et al., combined tumours with
BRCA1 and BRCA2 somatic mutations with germline pathogenic variants. It is
unclear whether tumours that harbour somatic mutations would exhibit simi-
lar expression profiles to germline pathogenic variants. In addition, one study
had particularly extreme exclusion criteria for both control and experimental
ovarian tumours (Konstantinopoulos et al., 2010). Konstantinopoulos and col-
leagues, selected only those tumours which clustered in the correct groups, ef-
fectively removing tumours that clouded the classifications. It is unlikely that
this method of sample selection would generate a gene expression signature re-
flective of all BRCA1 or BRCA2 carriers. This was highlight by an independent
study which demonstrated poor accuracy of the Konstantinopoulos ‘BRCA-
like’ signature (George et al., 2013).
Secondly, the importance of sample matching was highlighted by the early
studies in breast tumours which identified ER status as a major driver of ex-
pression variation (van’t Veer et al., 2002). Subsequent studies showed that
tumour subtypes were also a major driver of variability in expression (Waddell
et al., 2010a; Lisowska, 2011; Massink et al., 2015). The development of ovar-
ian subtypes is not yet as well defined as those in breast. However, Tothill et
al., (Tothill et al., 2008) identified six molecular subtypes in high grade ovarian
tumours using k-means clustering. Subsequently, BRCA1-associated ovarian
tumours were shown to be enriched for immunoreactive (C2) subtype (George
et al., 2013), which is characterised by lymphocytic infiltrate in the epithelium
(Tothill et al., 2008). Despite inconsistencies in tumour matching between stud-
ies, the similarities between a small subset of studies suggests that differences
in expression profiles are not solely due to sample matching. For example,
three studies investigated BRCA1-associated expression profiles in ER negative
breast cancers (van’t Veer et al., 2002; Dudaladava et al., 2006; Martin et al.,
2007). No genes was common between these three studies (Table 1.2).
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Third, is the heterogeneity of cell types, in particular the presence of tumour in-
vading infiltrate. Subsequent to the majority of studies, Massink et al., (Massink
et al., 2015) highlighted the importance of cell make up on expression profiles.
The presence of invading tumour lymphocytes, a feature of BRCA1-associated
breast tumours, added complexity to gene expression profiles (Massink et al.,
2015). Although the effect of lymphocyte presence was not tested, George et al.,
highlighted the enrichment of BRCA1-associated ovarian tumours for the C2
molecular subtype. The C2 subtype is characterised by the presence of lympho-
cytes in the epithelial fraction (Tothill et al., 2008). Four studies (van’t Veer et al.,
2002; Waddell et al., 2010a; Larsen et al., 2013, 2014) selected samples based on
>50% tumour content as assessed by histological review, and one study (Press
et al., 2010) enriched for tumour content using laser capture microdissection.
The remaining studies digested tumour samples with no apparent knowledge
of cellular content.
Taken together, there are subtle differences in sample selection criteria across
all studies. It is difficult to determine the effect these differences have on re-
capturing gene expression changes. However, there were several consistent
observations between studies, for example the ability to identify the ER status
of tumours based on expression profiles (van’t Veer et al., 2002; Lisowska, 2011)
and the consistent association of BRCA1-associated breast tumours with basal-
like subtype (Waddell et al., 2010a; Lisowska, 2011; Massink et al., 2015). As
these observations were consistent, it can be assumed that any BRCA1/2 gene
expression profile is more subtle, and would be confounded, by differences in
sample matching for ER status and subtype.
Differences in DNA damaging treatments of normal tissue
Several studies induced DNA damage to elicit a change in expression, under
the hypothesis that BRCA1 and BRCA2-carriers would have impaired DNA
damage response (Kote-Jarai et al., 2004, 2006; Waddell et al., 2008; Walker et
al., 2010; Salmon et al., 2013; Feilotter et al., 2014). Walker et al., was the only
study to use Mitomycin C as a DNA damage inducing reagent as the authors
observed a greater effect on expression compared to γ-irradiation (Walker et
al., 2010). The remaining five studies treated fibroblast (Kote-Jarai et al., 2004,
2006), lymphocytes (Salmon et al., 2013) and LCLs (Waddell et al., 2008; Feilot-
ter et al., 2014) with γ-irradiation. A further four studies analysed expression
profiles in untreated lymphocytes (Zahavi et al., 2018), LCLs (Pouliot et al.,
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2017) and whole blood (Vuillaume et al., 2009; Tanaka et al., 2018). Despite
LCLs requiring Epstein-Barr virus transformation to become immortal, there is
evidence that transformation has little effect on expression profiles (Caliskan et
al., 2011). However, BRCA1-associated LCLs are not susceptible to DNA dam-
age, a phenotype expected for functionally damaged BRCA1 (Trenz et al., 2005).
Advancement in technologies and statistical approaches
Early gene expression studies were limited by both cost and microarray tech-
nology. The earliest studies used cDNA spotted arrays which were limited to
1000s of targets, while the more modern arrays are able to detect 10,000s of
targets and next generation sequencing platforms are able to detect the entire
transcriptome. Such advancement in gene expression technology means that
the latter studies are measuring transcripts not tested in the earlier studies. Fur-
thermore, transcript annotations and guidelines around publishing large gene
expression array studies have developed alongside these studies. This led to
occasions where early gene panels could not be validated in later, much larger
expression arrays. For example Dudaladava et al., only had expression data
for 40 of the Hedenfalk 51 gene panel, making validation of earlier results dif-
ficult (Hedenfalk et al., 2001; Dudaladava et al., 2006). The reduced cost of
performing transcriptome analysis and ongoing importance of tissue biobank-
ing has allowed more recent studies to test a greater number of samples, thus
increasing statistical power (Waddell et al., 2010a; Larsen et al., 2013). Impor-
tantly, genome-wide transcriptome analysis requires considerations of multiple
testing to control the false positives rate. Fourteen of the 23 studies discussed
here used no p-value adjustments, two however (Jazaeri et al., 2002; Zahavi
et al., 2018) set a strict p-value threshold (p < 0.0001). Eight of the remaining
nine studies controlled the false-discovery rate, an attempt to reduce false posi-
tives, whilst the last used the more conservative Bonferroni correction method.
Although p-values were not adjusted in the majority of studies, given suffi-
cient power and effect size we would still expect that true positive results to
be shared between different expression datasets, independent of the method
and technology applied. Indeed, only a small overlap of genes associated with
BRCA1/2 pathogenic variant status was observed between studies (Table 1.2).
Methods of transcriptome analysis
Two general approaches, class prediction and differential expression analysis,
were undertaken to identify gene differences between tumour genotypes.
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Class prediction attempts to identify genes with the ability to segregate sam-
ples into distinct subgroups, whilst differential expression identifies genes that
differ between multiple subgroups. The latter approach requires knowledge
of the genotypes and/or tumour subtypes. If the major driver of expression
variability was due to the variant status of the tissue then it would be reason-
able to expect a large overlap of gene lists between methodologies, as seen by
Kote-Jarai et al., (Kote-Jarai et al., 2004). However, the aforementioned differ-
ences in study design and sample selection has likely led to study biases and
confounding variables which dilute any genotype-associated expression differ-
ences. Furthermore, the selection of genes lists was inconsistent. For example,
studies using class prediction methods typically optimised gene lists to contain
the smallest number of genes required to accurately segregate samples into sub-
groups.
A common limitation between studies was the lack of validation in an inde-
pendent datasets. To be able to fully appreciate the strength of classifier and
to compare performance between studies these independent validation need to
be performed.
1.3 BRCA1 and BRCA2 Structure and Function
BRCA1 is located on chromosome 17q21.31 and spans 125 kb coding 23 exons
which translate to a 1863 amino acid protein. The 1863 amino acid protein con-
sists of a N-terminal RING (Really Interesting New Gene) domain, a nuclear
localisation sequence (NLS), a coiled-coil domain, a SQ/TQ cluster domain
(SCD) and BRCA1 C-terminal (BRCT) repeats (Roy et al., 2011). Several serine
residues in the SCD are phosphorylated by ATM or ataxia telangiectasia and
RAD3-related (ATR), while serine 988 is phosphorylated by CHEK2 (Beckta et
al., 2015). The several binding partners and domains of BRCA1 provide insight
into the protein’s many functions (see Section 1.3.2).
BRCA2 is located on chromosome 13q13.1 and spans 84 kb coding 27 exons
which translates to a 3418 amino acid protein. BRCA2 has three domains, a
central BRC-motif repeat, a DNA binding domain and a c-terminal NLS domain
(Roy et al., 2011). The BRC-motif repeats are known to interact with RAD51
while PALB2 interacts with the N-terminal region of the protein (Shahid et al.,
2014).
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1.3.1 BRCA1 and BRCA2 Variants
The discovery of association of BRCA1 and BRCA2 with disease risk has led to
clinical genetic testing, through which 7505 BRCA1 variants and 10,487 BRCA2
have been described (https://www.ncbi.nlm.nih.gov/clinvar/, accessed July
2019). Each of these unique variants confer a varying amount of disease risk
from non-pathogenic variants (benign) to disease causative (pathogenic). Clin-
ical management relies on reliable variant classification of genetic test. For
BRCA1 and BRCA2 there are three possible test results: Positive (a pathogenic
variant is identified), uninformative (no pathogenic variant) or a variant of
uncertain significance (VUS). Variants of uncertain significance are typically
rare alterations to the gene sequence that have been assessed for association
with cancer phenotype/s but risk association remains uncertain (Spurdle et
al., 2019). The importance of timely and reliable classification is significant,
however, due to the rare nature of variants multi-factorial analysis is typically
difficult. To aid in classification lab-based methods are increasingly desired,
however, the reliability is limited.
1.3.2 BRCA1 Function
1.3.2.1 DNA repair
The earliest and most well described function of BRCA1 is the involvement in
DNA repair. BRCA1 interacts with RAD51 and co-localises to the nuclear foci
during DNA replication (Scully et al., 1997). In addition, cells that are BRCA1-
deficient are hypersensitive to γ-irradiation and hydrogen peroxide suggest-
ing an involvement in genome maintenance (Gowen et al., 1998). Through a
cascade of protein interactions BRCA1 is localises to the site of DNA damage
by the recognition of phosphorylated H2AX (γH2AX). BRCA1 is largely recog-
nised to be involved in homologous recombination repair (HRR). HRR is criti-
cal to maintain genome stability by accurately repairing double stranded breaks
(DSB) through the invasion of sister chromatin. BRCA1 forms a protein com-
plex with Abraxas (CCDC98) and RAP80 which recognises and associates with
ubiquitinated histones at the site of DSB. BRCA1 recruits CtIP and the MRN
complex to the break site to resect the DNA, an essential step in DSB repair
(Chen et al., 2008). BRCA1 also interacts with PALB2 and BRCA2 to recruit
RAD51 to the site of DNA damage leading to the identification of homologous
regions on the sister chromatin and strand invasion.
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1.3.2.2 Cell Cycle Control
The cycle of cells consists of four phases (G1, S, G2, M), three (G1, S, G2) of which
occur during interphase (before a cell enters cell division). The last phase, mi-
tosis (M), occurs at the end of the interphase state and results in the division
of a cell into two daughter cells. Cellular machinery ensures that each phase
is adequately completed before transitioning. If inadequate, the cell may stall,
allowing appropriate process to be completed, or the cell may undergo degra-
dation.
The down regulation of the heterodimer of BRCA1:BARD1 by reduction of ei-
ther protein through siRNA knockdown, causes an impaired G1/S checkpoint
response (Fabbro et al., 2004). The BRCA1:BARD1 heterodimer is essential for
ATM mediated phosphorylation of TP53, which is necessary for DNA damage
associated cell cycle arrest (Fabbro et al., 2004). Furthermore, BRCA1 moder-
ates TP53 independent G1/S cell cycle arrest after UV damage (Shorrocks et al.,
2004).
Xu et al., illustrated the importance of BRCA1 in the regulation of S-phase
checkpoint arrest (Xu et al., 2001). Cells with impaired BRCA1 had limited
response to S-phase DNA damage, however, the introduction of functional
BRCA1 resulted in adequate cell cycle arrest. Similarly, BRCA1 is essential
to the activation of the G2/M checkpoint. ATM mediated phosphorylation of
BRCA1 occurs at Ser1387 and Ser1423 in S-phase and G1/M checkpoint activa-
tion, respectively (Yu and Chen, 2004). Thus, BRCA1 may have different roles
in phase specific checkpoint control.
1.3.2.3 Transcription Regulation
BRCA1 can regulate gene expression through direct interaction with transcrip-
tional elements and through epigenetic remodelling. Compared to sporadic
breast tumour, BRCA1-associated breast tumour have less DNA methylation at
CpG sites (Bernardino et al., 1997; Shukla et al., 2010; Downs and Wang, 2015),
where mutated BRCA1 has impaired DNA binding to the promoter of DNA
methyltransferases 1 (DNMT1) (Shukla et al., 2010). Additionally, BRCA1 can
interact and modify histones altering chromatin states (Yarden and Brody, 1999;
Zhu et al., 2011). The BRCA1 RING domain can interact with BARD1 to form
a heterodimer that can ubiquitinate H2A histones to form a repressive state of
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DNA, a modification that is not produced by other ubiquin ligases (Zhu et al.,
2011). Furthermore, in mice Brca1 mutations alter histone acetylation, whereby
wild type Brca1 had histone modifications associated with a repressive chro-
matin state (Shukla et al., 2010).
BRCA1 was purified with both RNA polymerase II and RNA helicase A, im-
plicating a role in transcription (Scully et al., 1997). Where BRCA1 may be
involved in R-loop (a natural DNA:RNA hybrid produced in transcription) res-
olution preventing genomic instability (Hatchi et al., 2015; Zhang et al., 2017).
In addition, BRCA1 is known to associate with several transcription factors and
alter transcriptional activity (Mullan et al., 2006; Hosey et al., 2007; Gorski et al.,
2011). The effects of many of these regulations are important to both cell cycle
control and DNA repair. For example, BRCA1 stabilises TP53 transcription ac-
tivity of genes involved in DNA repair and growth arrest, however, not genes
involved in apoptotic response (MacLachlan et al., 2002; Ongusaha et al., 2003).
Furthermore, BRCA1 and CtIP are able to repress transcription of DNA dam-
age response genes and upon DNA damage the phosphorylation of BRCA1 and
CtIP results in transcriptional activity of these DNA damage response genes (Li
et al., 2000).
The interplay between oestrogen signalling and BRCA1 remains complex (Fig-
ure 1.2). BRCA1 is able to repress hormonal mediated signalling through the
repression of the ER and PR receptors (Fan et al., 2001; Kawai et al., 2002; Jeffy
et al., 2005; Mullan et al., 2006; Ma et al., 2010). BRCA1 can repress ER activ-
ity by protein interaction, ubiquitination and the repression of TP300 (Figure
1.2). BRCA1 is able to inhibit ER transcritional activity by inhibiting EP300
dependent acetylation both directly and by reducing EP300 gene expression
(Ma et al., 2010). Furthermore, BRCA1 can directly ubiquitinate the ER at
the site of acetylation, further inhibiting transactivating acetylation (Ma et al.,
2010). BRCA1 stimulates the expression of ESR1 through the interaction with
OCT1 (Hosey et al., 2007). Additionally, BRCA1 expression is increased in an
oestrogen-dependent manner, likely through the recruitment of ER and EP300
to the BRCA1 promotor region (Jeffy et al., 2005).






FIGURE 1.2: Schematic of the complex relationship between oestrogen (E2) and BRCA1.
BRCA1 represses (red arrows) the activity of oestrogren response through direct inter-
action with ERα and indirect interactions with EP300. BRCA1 down-regulates the ER
coactivator EP300 but down-regulating EP300 and inhibiting EP300 dependent acety-
lation (Ac). BRCA1 can ubiquitinate the ER further repressing the ER transcriptional
activity. BRCA1 also promotes the expression of ESR1. E2 in turn promotes the expres-
sion of BRCA1.
1.3.3 BRCA2 Function
1.3.3.1 DNA repair and Genomic Stability
Similar to BRCA1, BRCA2 functions in the repair of double stranded breaks via
HRR (Roy et al., 2011). BRCA2 is recruited to the site of DNA damage through
interaction with PALB2 and BRCA1 at the stage of DNA resection. BRCA2
binds to RAD51 via the BRC-motif repeat and facilitates the loading of RAD51
onto single stranded resected DNA for the repair of DNA DSB by HRR (Davies
and Pellegrini, 2007; Fradet-Turcotte et al., 2016). Cells deficient for BRCA2 are
unable to recruit RAD51 to the site of DSB after exposure to ionising radiation
(Yuan et al., 1999). Furthermore, the C-terminus of BRCA2 is important for sta-
bilisation of RAD51 nucleoprotein filaments (Esashi et al., 2007).
BRCA2 is also involved the protection of DNA during replication stress. During
replication the DNA is separated so that cellular machinery can bind and DNA
replication can commence. The molecule machinery, known as the replication
fork, can stall under stress leaving ssDNA exposed to MRE11 nuclease. Cells
defective for the BRCA2 C-terminus are vulnerable to MRE11 nuclease, whilst
functional BRCA2 were able to protect the nascent DNA strand (Schlacher et
al., 2011).
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1.3.4 BRCA1 and BRCA2 Tissue-Specific Tumour Risk
The respective roles of BRCA1 and BRCA2 in the maintenance of genome sta-
bility has been well described and often suggested as the causative mechanism
of disease. However, the essential nature of genome stability and the lack of
disease risk in some tissues highlights the incomplete understand of disease
risk. There are several hypotheses proposed which are discussed below.
1.3.4.1 Oestrogen
The breast and ovary, unlike other tissues, are under control of steroid sex hor-
mones, most notably oestrogen. A mechanism whereby these hormones inter-
act with BRCA1/2 deficient cells leading to a survival advantage could explain
the tissue-specific tumour development. This mechanism would suggest that
the removal of oestrogen by prophylactic oophorectomy and chemoprevention
with tamoxifen would be protective. Additionally, the reintroduction of oe-
strogens through hormone replacement therapy should increase the risk of dis-
ease. Early studies demonstrated a 45-50% reduction of breast cancer incidence
in BRCA1/2 carriers after oophorectomy (Rebbeck et al., 2005; Domchek et al.,
2010). However, the accuracy of these results were limited due to study biases,
specifically, cancer-induced testing bias, immortal person-time bias, and infor-
mative censoring (Klaren et al., 2003; Heemskerk-Gerritsen et al., 2015; Mavad-
dat et al., 2020). Using a method to limit cancer-induced testing and immor-
tal person-time biases, Heemskerk-Gerritsen et al., showed no protective ef-
fect from oophorectomy in BRCA1/2 carriers (OR =1.09) (Heemskerk-Gerritsen
et al., 2015). This observation was replicated in a recent prospective study of
9856 BRCA1/2 mutation carriers (Mavaddat et al., 2020). Furthermore, there is
no evidence for hormone replacement therapy associated breast cancer risk in
BRCA1/2 carriers after oophorectomy (Rebbeck et al., 1999; Kotsopoulos et al.,
2018; Gordhandas et al., 2019).
Tamoxifen has demonstrated an approximately 50% reduction in the incidence
of contralateral breast cancer in individuals with ER positive pimary breast tu-
mour, irrespective of BRCA1/2 status (Fisher et al., 1998; Gronwald et al., 2014).
However, as tamoxifen treatment is dependent on ER positivity it is difficult
to determine the effect on ER negative BRCA1-associated tumours. Tamoxifen
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appears to have no protective effect for BRCA1-associated primary breast can-
cers (King, 2001). King observed a reduced incidence in BRCA2-associated pri-
mary tumours that received tamoxifen. However, these observations were on
11 BRCA2-carriers and the risk ratio’s confidence intervals encompassed one
(0.38, CI 0.06-1.56), suggesting equivocal risk between treatment and placebo.
Taken together, studies of oophorectomies and tamoxifen chemoprevention on
breast cancer risk are inconsistent and it remains unclear whether oestrogen
plays a critical role in BRCA1 or BRCA2 tumour development. Molecular pro-
files of BRCA1-associated tumours highlight an enrichment for ER negative tu-
mours (Waddell et al., 2010a), further adding complexity into the mechanism
of oestrogen and BRCA1-associated tissue-specific risk. It is conceivable that
oestrogen acts independently of ER or that ER expression is lost during tumour
development. Additionally, oestrogen may act upon neighbouring cells and a
paracrine response cause ER negative epithelium to become cancerous (Nolan
et al., 2016).
1.3.4.2 Differential Tissue Requirements
Tissue-specific requirement for BRCA1 and BRCA2, or a lack of redundancy
in the breast and ovary may, provide evidence for tissue-specific tumour risk
(Sedic and Kuperwasser, 2016). There is little research exploring mechanisms
of BRCA1 haploinsufficiency compensation in non-breast and ovarian tissues.
However, tissue-specific tolerance to haploinsufficiency has been explored in
blood tissues (Mgbemena et al., 2017). Brca1 null hematopoietic stem cells
were unable to reconstitute white blood cell populations in mice. These results
may explain the lack of BRCA1-associated haematological cancers observed,
whereby hematopoietic stem cells are not tolerant to loss of BRCA1 heterozy-
gosity and undergo cell death whereas breast and ovarian epithelium are toler-
ant and transform to cancer. However, in humans, women receiving cytotoxic
chemotherapies and carrying BRCA1 and BRCA2 pathogenic variants did not
exhibit higher severity or number of hematologic toxicities, an expected out-
come if hematopoiesis was impaired (West et al., 2019).
Tissue-specific expression of BRCA1 and BRCA2 do not show a dependency
for breast or ovarian tissue on these genes compared to other tissues (Figure
1.3). Only the testis exhibit expression levels of BRCA1 and BRCA2 distinctly
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different to all other tissues. However, there may be a difference in redun-
dancy between the breast and ovary that could explain the tumour-specific risk.
Replication stress and exposure to DNA damaging agents (either endogenous
or exogenous) are tissue-specific and the requirement of BRCA1 or BRCA2 to
resolve damage could explain tissue-specific risk. In skin and mammary pri-
mary cells, BRCA1 variants displayed an impaired ability to resolve stall repli-
cation forks (Pathania et al., 2014). Additionally, both tissues are exposed to
heightened DNA-damage induction (skin by exposure to UV light and breast
tissue by exposure to oestrogen), however, only breast tissue exhibits BRCA1-
associated tumour risk. No clear mechanism of tissue-specific redundancy has


































































































































































































































































































































































































































































































































FIGURE 1.3: Tissue-specific expression of BRCA1 (Top) and BRCA2 (Bottom). Tissue-
specific boxplots were generated from the GTEx expression data and ordered by me-
dian tissue expression. Breast (pink) and ovary (teal) tissues are highlighted in respec-
tive plots.
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1.4 RNA Expression
Ribonucleic acid (RNA) is a polymer consisting of the organised arrangement
of four macromolecules/nucleic acids (guanine, adenine, cytosine and uracil)
and is synthesised by one of three RNA-polymerases as it transcribes regions
of DNA. The Encyclopedia of DNA Elements (ENCODE) project has sought
to catalogue all transcribed RNAs, to date there is evidence that ∼ 80% of the
genome is transcribed (Djebali et al., 2012). However, it is unclear which tran-
scribed regions code for functional or non-functional (‘junk’) RNA (Palazzo and
Lee, 2015).
Several RNA species exist, all of which fit into one of two categories: coding
RNA or non-coding RNAs. Coding RNAs or messenger RNAs (mRNAs), con-
tains sequence that is translated to a protein amino acid sequence by the ribo-
some. Non-coding RNAs (ncRNA) encompass all untranslated RNA including
microRNA (miRNA), ribosomal RNA (rRNA), tansfer RNAs (tRNA), small nu-
cleolar RNA (snoRNA) and long non-coding RNA (lncRNA). The most abun-
dantly expressed RNAs are those involved in the ribosome and the translation
process, namely rRNA and tRNA. Together these contribute∼ 90% of all RNAs
transcribed (Palazzo and Lee, 2015). Functions of ncRNA are vast and include
involvement in transcription, RNA splicing, translation, DNA replication and
chromatin stability, amongst others (O’Brien et al., 2018; Liang et al., 2019; Yao
et al., 2019).
RNA abundance and stability of expression is modulated by the level of tran-
scription and the rate of consumption. Transcription is a complex molecular
mechanism which can be regulated at several steps including initiation, elon-
gation and termination (Lee and Young, 2000). Initiation involves the process
of RNA polymerase attaching to promoter regions of DNA. A process which is
facilitated by transcription factors and activator proteins (Nikolov and Burley,
1997; Lee and Young, 2000). Equally, inhibition of these events leads to the re-
pression of RNA polymerase interaction with DNA.
The elongation phase of transcription by RNA polymerase is also under dy-
namic control. Early termination of elongation leads to an incomplete RNA se-
quence, which is subjected to destruction via non-sense mediate decay (NMD)
(Brogna and Wen, 2009; Hug et al., 2015). The final step of transcription is ter-
mination, which requires the disassociation of the RNA polymerase at the ter-
minal sequence. For mRNA there is a subsequent addition of several adenines
(poly-adenylation) which is critical for mRNA stability (Wu and Brewer, 2012).
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1.4.1 Genome-wide RNA Expression Analysis
The ability to quantify 1,000-10,000s of RNA molecules, through the devel-
opment of microarrays and next-generation sequencing (NGS) technologies,
has led to better understanding of human biology and disease. Early spot-
ted microarrays had the advantage of flexibility as target specific probes could
be generated easily and spotted onto glass slides. However, these spotted
microarrays demonstrated greater technical variability compared to modern
oligonucleotide arrays (Woo et al., 2004). Oligonucleotide arrays are generated
by directly synthesising target sequences to the array. Two manufacturers of
oligonucleotide arrays, Affymetrix and Agilent, have demonstrated low tech-
nical variability and the data generated from these arrays correlated well (Yauk
et al., 2004). Furthermore, the Agilent platform offers the ability to perform
two-colour array experiments allowing researchers to quantify two samples on
a single array. Illumina offers a novel oligonucleotide array technology, termed
‘beadchip’ microarrays, that contain silica beads coated with many copies of
an oligonucleotide probe which targets a specific RNA transcript. All array
platforms share the common approach of hybridising sample RNA or cDNA to
oligonucleotide probes and measuring relative expression by quantification of
a target-specific fluorescent marker.
Raw intensity values need to be normalised to adjust for RNA load and techni-
cal variations whilst conserving biological variation (Steinhoff, 2006; Liu et al.,
2019). Normalisation methods typically assume that the majority of genes re-
main unchanged between experimental groups (Liu et al., 2019). However, it
is possible to use tailored methods (e.g. spike-in RNA) to identify global shifts
in expression changes (Steinhoff, 2006) or normalise each sample to a universal
known RNA on a two coloured array platform (Larsen et al., 2013).
Normalisation can be within each array (e.g. locally weighted scatterplot smooth-
ing, LOWESS) and across arrays (e.g. quantile normalisation). However, LOWESS
normalisation is a method limited to dual-colour arrays and utilises the inten-
sities of each channel (Quackenbush, 2002). Furthermore, multiple array plat-
form specific normalisations have been developed, particularly for the Affymetrix
platforms. For example, Affymetrix arrays utilise two probe types, perfect
match (PM) and mismatch (MM) probes, which can be used to correct signals
(Steinhoff, 2006; Liu et al., 2019).However, Irizarry and colleagues have devel-
oped an Affymetrix correction method that ignores MM probes termed Robust
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Multi-array Analysis (RMA) (Irizarry et al., 2003). In addition to the back-
ground correction, the RMA method performs between array quantile normal-
isation. Quantile normalisation is a commonly applied normalisation method
applied to all platforms, whereby the distribution of gene expression for each
array is the same (Bolstad et al., 2003).
Next-generation sequencing (NGS) of RNA (termed RNA-sequencing/RNA-
seq) allows the quantification of the entire transcriptome, assuming sufficient
depth. Similar to microarrays, RNA-seq represents several different sequenc-
ing platform, largely represented by the short-read sequencing platform. The
vast majority perform sequence-by-synthesis with the aid of a DNA polymerase
(Heather and Chain, 2016). Short-read sequencing platforms include products
from Roche (Guffanti et al., 2009), Illumina (Picornell et al., 2019), Helicos (Jon-
sson et al., 2015), and SOLiD (Callari et al., 2016). In addition, long-read plat-
forms have been established including Oxford Nanopore (de Jong et al., 2017)
and PacBio (Nattestad et al., 2018). However, their utility has been more suited
to applications beyond quantification of transcripts (e.g. RNA-splice variant
analysis (de Jong et al., 2017)). RNA-sequencing data, which is essentially
counts of RNA molecules, requires normalisation to account for gene length
and sequence-depth. Similar to microarray normalisation, several methods
have been developed. Normalisation can be performed using sequence depth
and gene length (e.g. reads per kilobase per million mapped reads (RPKM),
fragments PKM (FPKM) or transcript per million (TPM)) or by distribution of
gene expression (e.g. DEseq, EdgeR) (Evans et al., 2018).
1.4.2 RNAscope
RNAscope® is a novel method of RNA in situ hybridisation (ISH) developed
by Advance Cell Diagnostics (Wang et al., 2012). Previous RNA ISH meth-
ods were limited to highly expressed genes and lack sensitivity and specificity.
RNAscope® overcomes many of these limitations through the implementation
of a novel Z probe (Figure 1.4). Each Z probe is comprised of a 18-25 nt lower
region which is complementary to a target RNA and a 14 nt upper region which
is specific for a pre-amplification molecule. Specificity is improved by the abso-
lute requirement of two individual Z-probes to bind adjacently to one another
to generate a 28-nt binding sequence for the pre-amplification molecule. Fur-
thermore, there is a requirement for multiple Z probe pairs to hybridise to a
single RNA molecule to produce a detectable signal, thus further improving
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specificity.
FIGURE 1.4: RNAscope® Z probe design and hybridisation workflow. Z-probes bind to
target RNA (blue). Pre-amplification molecule associate with Z-probe pairs acting as a
scaffold for amplification molecules. Fluorophores bind to the amplification molecule
to generate a detectable signal.
Signal amplification is generated by several iterations of amplification molecules
binding to a pair of Z probes (Figure 1.4). A pre-amplification molecule firstly
binds to the 28 nt sequence generated by adjacent Z probes. The pre-amplification
molecule acts as a scaffold with 20 binding sites for amplifiers to bind (Wang
et al., 2012). Amplifiers are conjugated to either a fluorophore or an enzyme
(horse radish peroxidase or alkaline phospatase) to produce a detectable signal.
RNA ISH offers the ability to examine RNA abundance in context of tissue his-
tological architecture, similar to immunohistochemistry. As opposed to ‘grind-
and-bind’ approaches, this technology enables researchers the ability to contex-
tualise RNA expression and to account for multiple cell types (Bingham et al.,
2017; Kersigo et al., 2018; Ren et al., 2018). In breast cancer, RNAscope has been
used to determine oestrogen receptor positivity compared to clinical IHC meth-
ods (Yu et al., 2017). RNAscope® and IHC had a 91.7% concordance, however
there were two tumours identified as IHC-positive and RNAscope-negative.
A further four tumours were IHC-negative and RNAscope-positive. Interest-
ingly, upon retesting by IHC, three of the IHC-negative tumours were reclassi-
fied as IHC-positive. Furthermore, both IHC-positive and RNAscope-negative
tumours were reclassified as IHC-negative. RNAscope® therefore displayed
greater specificity and sensitivity over the gold standard IHC. Discrepancy be-
tween IHC and RNAscope®, along with IHC retesting, may be a reflection of
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breast tumour heterogeneity.
Measurement of RNAscope® signals can be performed in a variety of ways to
derive different types of expression information. For example, identifying the
presence/absence of a RNA transcript (Yu et al., 2018), semi-quantification of
RNA intensity, similar to traditional IHC scoring (Yu et al., 2017), and quantifi-
cation of RNA isoforms (Lattimore et al., 2019). A major advantage of RNAscope®
is the ability to specify signals within cell-types or histological regions that aid
in the interpretation of underlying biology. To date, RNAscope® has not been
used to explore gene expression variability, however, observation of tumour
heterogeneity hints at a potential utility for such an analysis (Yu et al., 2017).
1.4.3 Gene Expression Variability
Gene expression is often explored by comparing mean gene expression levels
between multiple biologically relevant groups. This approach is often termed
differential expression analysis and has several distinct methodologies (Habig
et al., 2012; Wang et al., 2019). Additional to changes in mean expression levels,
researchers have explored changes in gene expression variability (Figure 1.5) in
single cell (Elowitz et al., 2002; Blake et al., 2003; Raser and O’Shea, 2004) and
multicellular organisms (Yu et al., 2008; Ecker et al., 2015; Hasegawa et al., 2015;
Bueno and Mar, 2017).
FIGURE 1.5: Illustration of difference in gene expression patterns between two groups.
A gene may have differences in mean (left), variance (middle) or both the mean and
variance (right) between two groups.
Expression variability can arise from intrinsic (stochastic of transcription molecules)
and extrinsic (i.e. cell shape, size and cell cycle stage) factors (Elowitz et al.,
2002). Studies in single cell organisms have illustrated that expression noise
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can be modulated by many mechanisms including: transcription rate, pro-
moter type and frequency of promoter activation (Elowitz et al., 2002; Blake
et al., 2003; Raser and O’Shea, 2004). Elowitz et al. (2002) and Raser and O’Shea
(2004) constructed a dual-reporter model in Escherichia coli and Saccharomyces
cerevisiae, respectively, which relied on two reporter proteins (Cyan fluorescent
and yellow fluorescent proteins) controlled under the same promoter. This re-
porter system allowed the measurement of both intrinsic (fluctuations in only
one fluorescent protein) and extrinsic (fluctuations in both fluorescent proteins)
effects. Gene expression variability in these reporter systems was largely at-
tributed to extrinsic sources (Elowitz et al., 2002; Raser and O’Shea, 2004).
Determining gene expression variability in multi-cellular organisms presents
several challenges, in particular the range of cell types and cell functions in
multi-cellular organisms that produce natural biological variation. Further-
more, common variants in promoter regions can alter gene expression variabil-
ity, adding further complexity (Li et al., 2010). Despite the complex cellularity
and impacts of common variants, gene expression variability has been explored
in human development (Hasegawa et al., 2015) and disease pathology (Yu et al.,
2008; Ecker et al., 2015; Bueno and Mar, 2017).
Hasegawa and colleagues identified gene expression variability during embry-
onic development by single RNA-sequencing at different developmental stages
(Hasegawa et al., 2015). Measuring variability during early development re-
duces the challenges of cellular heterogeneity by limiting the number of cell
types. Furthermore, single cell RNA-sequencing allowed the authors to ex-
plore within and between embryo gene expression variability. Unsurprisingly,
expression variability between individual embryos was greater than within em-
bryos, at all stages of development. By stratifying genes based on expression
levels, invariable genes with essential functions were identified (Hasegawa et
al., 2015).
In tumours, genes essential to tumour survival would likely have little expres-
sion variability, whether the gene is pro- or anti-tumourigenic (Yu et al., 2008).
Bueno and Mar used in silco methods to identify 54 potential synthetic lethal
genes that were invariable in BRCA2 pathogenic variants, suggesting that these
genes are essential to tumour cell survival (Bueno and Mar, 2017). Variable (or
invariable) genes in tumours (Yu et al., 2008) and within tumour types (Ecker et
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al., 2015; Bueno and Mar, 2017) are not associated with change in mean expres-
sion levels. Only 27% and 2% of genes identified by differential variability were
captured by differences in mean gene expression levels in studies that com-
pared normal vs tumours and BRCA2-associated vs sporadic ovarian tumours,
respectively (Yu et al., 2008; Bueno and Mar, 2017). Interestingly, the use of
gene expression variability analysis was able to accurately classify chronic lym-
phocytic leukaemia IgVH mutation status, with the more aggressive subtype of
chronic lymphoctic leukaemia having an increase in gene expression variability
(Ecker et al., 2015). Classifications were equally accurate but more robust than
classifiers developed based on mean expression (Ecker et al., 2015). Another
study showed gene expression variability was increased in schizophrenic indi-
viduals, however, this variability was significantly reduced after treatment with
second generation anti-psychotics (Zhang et al., 2015). Despite the gene expres-
sion measurement were from whole blood, Zhang and colleagues described a
phenotypic change associated with disease state/severity that correlated with
treatment.
1.4.3.1 Measuring Gene Expression Variability
Gene expression variability analysis in single cell organisms typically involves
quantification of reporter system under the same control (Elowitz et al., 2002;
Raser and O’Shea, 2004).
Two broad concepts of gene expression variability are explored in the litera-
ture, one of a whole system change (i.e. the transcriptome displays change in
variability) and one of a gene-specific change. Each of the concepts employs a
range of different statistical approaches.
Whole system (global) changes are typically quantified by comparisons of group
specific standard deviation (SD) or coefficient of variance (CV) (Ecker et al.,
2015; Zhang et al., 2015; Bueno and Mar, 2017). In addition, Alemu et al.,
developed an expression variability measurement in an attempt to reduce de-
pendence on mean expression (Alemu et al., 2014) . Interestingly, this method
correlated highly with the simpler CV measures (Ecker et al., 2015). Once gene-
specific SD (or CV) are calculated for each population these are compared be-
tween populations (Figure 1.6). Change in global gene expression variability
can be observed by a shift in the distributions of SD measurements or a change
in ratios of SD (Ecker et al., 2015; Zhang et al., 2015; Bueno and Mar, 2017).
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FIGURE 1.6: Commonly used approaches to identify system wide gene expression vari-
ability. The distribution of variability (left) between two populations, comparisons of
gene specific variability (middle) and ratios of variability (right).
There is no consensus which measurement of variation is the most robust nor
which has the most utility. CV provides users the ability to compare levels of
variation between genes of different expression levels due to the CV effectively
normalising the SD to the mean level (CV = SD/x). However, at the global
level (i.e. assessing transciptomics), comparisons are made across populations
and not within populations so relative variability is not essential. Furthermore,
CV ratios (CVR) and SD ratios (SDR) effectively present the same data (Figure
1.6). CVs are ratios of SDs and the mean, thus the CVR is a ratio of ratios where
the means effectively cancel out. However, because the the mean is the de-
nominator in the CV equation, the CV is vulnerable to over-representing vari-
ability for genes that are lowly expressed due to near zero-inflation. Multiple
researchers have explored how dependent each statistic is on the mean, with
complete independence being desired (Bueno and Mar, 2017; Hasegawa et al.,
2015). It is assumed that the CV would be more independent due to the mean
being in part of the numerator and denominator of the calculation. However,
empirical evidence has shown that the CV may present a higher correlation
than seen with the SD (Bueno and Mar, 2017).
It is also important to assess individual gene expression variability, similar to
differential expression methods. The aforementioned CV and SD are able to
provide a sense of scale and direction of variability, however, lack the ability to
assess significance of the difference. To this end, several methods for testing for
equality of variance have been described (Bartlett, 1937; Levene, 1960; Brown
and Forsythe, 1974). The F-test and Barlett’s test are both sensitive (increased
type I error rates) to outliers and non-normality (Li et al., 2015). In particular,
the Brown-Forsythe method is consistently described to minimise type I error
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compared to other methods (Li et al., 2015; Wang et al., 2017). Studies of gene
expression variability have used F-test (Cheung et al., 2003; Yu et al., 2008; Ecker
et al., 2015), Bartlett’s test (Bahar et al., 2006) and the Levene’s test (Hasegawa
et al., 2015). The Brown-Forsythe method is a modification to the Levene’s test,
where the mid-point is defined as the group median. The use of the group me-
dian over the mean allows the test to better tolerate outliers, which is important
in small datasets.
1.5 Expression Quantitative Trait Loci
Quantitative trait loci (QTL) is the statistical method in which researchers com-
pare a measurable trait with genetic variations (i.e. differences in genotypes)
(Kearsey, 1998). The development of microarrays and subsequently NGS tech-
nologies has allowed researchers to perform QTL analysis on whole transcrip-
tiome data, whereby gene expression levels are the quantitative trait, termed ex-
pression quantitative trait loci (eQTL) (Jansen and Nap, 2001; Brem et al., 2002).
Additionally, variable expression QTL (veQTL, discussed in Section1.5.1), RNA
splicing QTL (sQTL), protein abundance QTL (pQTL) and epigenetic QTL (e.g.
methylation QTL and histone QTL) have all been developed as method to as-
sociate genetic variation with phenotypic changes (Battle et al., 2015; Grubert
et al., 2015; Li et al., 2016).
In the context of breast cancer, eQTL analysis has identified candidate breast
cancer susceptibility that are associated with common breast cancer risk vari-
ants (Li and Tibshirani, 2013; Michailidou et al., 2017; Guo et al., 2018; Wu et al.,
2018; Ferreira et al., 2019). Expression data obtained from tumour tissues is af-
fected by somatic changes, including somatic mutation, copy number changes
a epigenetic changes making eQTL analysis difficult. A multivariate linear re-
gression model is used to account for somatic copy number and methylation
state of tumour tissue (Li and Tibshirani, 2013; Michailidou et al., 2017; Guo
et al., 2018; Wu et al., 2018). Due to the large amount of data needed to account
for covariates, all breast tumour eQTL analyses have been performed on large
public datasets, specifically The Cancer Genome Atlas (TCGA) and Molecular
Taxonomy of Breast Cancer International Consortium (METABRIC) (Li and Tib-
shirani, 2013; Michailidou et al., 2017; Guo et al., 2018; Wu et al., 2018). More re-
cently, the Genotype-Tissue Expression (GTEx) project has allowed researchers
to explore eQTL in non-diseased breast (Michailidou et al., 2017; Wu et al., 2018)
Chapter 1. Introduction 44
and non-breast tissues (Ferreira et al., 2019). The GTEx project provides gene
expression and genotype data from non-diseased tissues, however it remains
comparatively small compared to public tumour datasets (Aguet et al., 2017).
Whole-genome and transcriptome data provide researches the ability to calcu-
late >1010 gene SNP associations. It is therefore prudent to minimise number
of test preformed, both in terms of minimising false positive rate and minimis-
ing computational time. This can be achieved by limiting genetic variants (e.g.
focus on disease specific variants) or by limiting tests to only those genes that
are close in proximity to the a given variant (termed cis-eQTL). The chromoso-
mal distance between the genetic variant and gene is study specific by typically
ranges between 1-2 mb (Li and Tibshirani, 2013; Michailidou et al., 2017; Guo
et al., 2018; Wu et al., 2018).
1.5.1 Variable Expression Quantitative Trait Loci
Gene expression variability is under genetic regulation and the heritability of
differences has been extensively described (Spielman et al., 2007; Raj et al., 2010;
Zhang et al., 2009; Eraly, 2014). Similar to eQTL analysis, which uses mean gene
expression as the quantitative trait, variable expression QTL (veQTL) can be de-
termined when gene expression variability is used as the trait (Hulse and Cai,
2013; Wang et al., 2014; Brown et al., 2014; Huang et al., 2015). Variable expres-
sion QTL studies are limited and have focused on describing the presence and
the landscape of their existence in multiple organisms (Hulse and Cai, 2013;
Wang et al., 2014; Brown et al., 2014). There have yet to be studies that have
investigated veQTL in the context of breast cancer and breast cancer risk.
1.6 Study Specific Aims
The overall aim of this project was to explore gene expression variability to
identify genes associated with familial breast cancer. The specific aims were:
• To identify BRCA1/2-associated variable genes using large publicly avail-
able microarray datasets.
• Determine mRNA gene expression variability in a cohort of breast tu-
mours using RNA ISH.
• Generate in vitro models of BRCA1-pathogenic carriers and assess gene
expression variability.
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• Investigate common breast cancer risk variants effect on gene expression




Ampicillin sodium salt — Sigma-Aldrich, USA
Antibiotic/antimycotic (100x) — ThermoFisher Scientific, USA
Cholera toxin — Sigma-Aldrich, USA
CyQUANT™ direct cell proliferation assay — ThermoFisher Scientific, USA
DMEM, F-12, HEPES — Gibco, USA
DMEM, high glucose, GlutaMAX™ Supplement — Gibco, USA
Epidermal Growth Factor — PeproTech, Israel
KAPA probe fast universal kit — Kapa biosystems, South Africa
Fetal Bovine Serum — Gibco, USA
Horse Serum — Gibco, USA
Hydrocortisone — Sigma-Aldrich, USA
Insulin from bovine pancreas — Sigma-Aldrich, USA
Lipofectamine™ RNAiMAx transfection reagent — ThermoFisher Scientific,
USA
NucleoSpin® Plasmid Mini Kit — Macherey-Nagel, Germany
Opti-MEM — Gibco, USA
Puromycin — ThermoFisher Scientific, USA
Random hexamers (50 uM) — Invitrogen, USA
RNeasy Mini Kit — Qiagen, Netherlands
RNAGEM™ tissue plus — Zygem, UK
RNase-Free DNase set — Qiagen, Netherlands
RNaseOUT™ recombinant ribonuclease inhibitor — Invitrogen, USA
SuperScript™ III reverse transcriptase — Invitrogen, USA
TAQ-Ti DNA polymerase — Fisher Biotec, Australia
TrypLE™ Express enzyme (1x), phenol red — Gibco, USA
X-tremeGENE™ HP DNA transfection reagent — Sigma-Aldrich, USA
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2.2 Equipment
Accu-Scope 3032 Inverted Microscope — Accu-scope, USA
2200 TapeStation nucleic acids system — Agilent, USA
Countess automated cell counter — Invitrogen, USA
LightCycler® 480 — Roche, USA
Mr Frosty™ — ThermoFisher Scientific, USA
Nanodrop 8000 Spectrometer — ThermoFisher Scientific, USA
Olympus IX81 Microscope — Olympus, Japan
Zeiss Axio Imager.Z1 Microscope — Zeiss, Germany
Shandon Cytospin 2 — ThermoFisher Scientific, USA
2.3 Software
2.3.1 R Packages
R version 3.4.1 was with the following packages:
Package Version Package Version
affy v1.54.0 gridExtra v2.3
Biobase v2.44.0 ggplot2 v2.2.1
biomaRt v2.50.5 hgu133plus2.db v3.2.3
clusterProfiler v3.12.0 illuminaHumanv2.db v.126.0
data.table v1.12.8 knitr v1.2.6
DOSE v3.10.2 lawstat v3.3
DT v0.11 limma v3.32.7
dplyr v1.4.2 preprocessCore v1.38.1
fgsea v1.13.1 reshape2 v1.4.3
genefu v2.8.0 shiny v1.4.0.2
GEOquery v2.42.0 shinydashboard v0.7.1
Novel scripts used throughout this thesis can be found at https://github.com/
wigge206/ThesisCode
Chapter 2. Materials and Methods 48
2.4 Breast Cancer Cohorts
2.4.1 Microarray Studies of Familial Breast Tumours
Gene expression data has been extensively explored in familial breast cancers
and many datasets have been made publicly available (Section 1.2.4, Table 2.1).
To explore BRCA1- and BRCA2-associated gene expression variability, only data-
sets generated by the reproducible oligonucleotide based arrays (i.e. not spot-
ted arrays) that had sufficient sample size and transcriptome coverage were
considered. Sufficient sample size was defined as datasets with greater than 50
tumours, of which at least 25 samples were BRCA1 and/or BRCA2-associated
tumours.
The majority of datasets identified were excluded from analysis in this thesis
due to small sample size (Hedenfalk et al., 2001; van’t Veer et al., 2002; Dudal-
adava et al., 2006; Bane et al., 2009; Fernández-Ramires et al., 2011; Lisowska,
2011), with one additional study excluded as data was generated from the spot-
ted Operon oligo-array (Jönsson et al., 2012). This study included the three
largest published datasets that used near whole-transcriptome coverage on oligo-
nucelotide arrays (Nagel et al., 2012; Larsen et al., 2013, 2014) or Illumina bead-
chip arrays (Waddell et al., 2010a).
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TABLE 2.1: Published microarray studies of BRCA1 and BRCA2 breast tumours.
Study BRCA1 BRCA2 BRCAx Sporadic Total Array platform
Hedenfalk et al.,
2001
7 8 – – 22 cDNA arrays
van’t Veer et al.,
2002




7 – – 7 14 Affymetrix HG
U133 Plus 2.0 Chip




19 30 25 – 75 Illumina Human-
6v.2




13 – 14 22 49 CNIO human cDNA
Oncochip v2
Lisowska, 2011 12 1 8 14 35 Affymetrix HG
U133 Plus 2.0 Chip
Nagel et al., 2012 47 6 102# – 155 Affymetrix HG
U133 Plus 2.0 Chip
Larsen et al., 2013,
2014
33 22 70 128 253 Agilent SurePrint
G3
#26 samples contain a CHEK2 1100delC variant
2.4.1.1 Waddell Dataset
Waddell and collagaues were the first to investigate the gene expression changes
between familial breast cancer of different genotypes and molecular subtypes
(Waddell et al., 2010a). Seventy-five breast cancers cases were selected based
on a multiple breast cancer family history. All samples were tested by full
sequencing and multiplex ligation-dependant probe amplification (MLPA) for
pathogenic variants in BRCA1 (n=19) and BRCA2 (n=30). The RNA was iso-
lated from breast tumours and hybridised on the Illumina Human-6v.2 bead-
chip array. Normalised and raw data was reposited on gene expression om-
nibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/) with the study identifier
GSE19177.
2.4.1.2 Nagel Dataset
Nagel et al., included breast cancer cases based on family history and CHEK2
mutation status (Nagel et al., 2012). Cases were from families with at least two
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relatives (1st or 2nd degree) with breast cancer with one or more cancers diag-
nosed by age 60. A further 16 tumours were included without family history
that had a CHEK2 1100delC variant. In total, 155 tumours (139 selected based
on family history) were tested for mutations in BRCA1 (n=47), BRCA2 (n=6)
and for CHEK21100delC (n=26). There were 76 cases with no pathogenic vari-
ant in either BRCA1 or BRCA2 nor a CHEK2 1100delC variant. Expression was
quantified with the Affymetrix HG U133 plus 2.0 array, and data was reposited
on GEO (GSE27830). For the purpose of this thesis all breast tumours with a
CHEK2 1100delC were excluded.
2.4.1.3 Larsen Dataset
Larsen et al., collected familial breast cancer cases between 1982-2008 that met
one or more of the following criteria (Larsen et al., 2013, 2014): 1) A pathogenic
variant in either BRCA1 (n=33) or BRCA2 (n=22). 2) A family pedigree resem-
bling an autosomal dominant inheritance of breast cancers. 3) Presence of fa-
milial ovarian cancer with the case having breast cancers. 4) Breast cancer at
an age younger than 35 years. Multiple cases from the same family were in-
cluded with 70 non-BRCA1/2 (BRCAx) cases from 58 families. An additional
128 breast cancers were included with unknown family history, including un-
known BRCA1 and BRCA2 genotypes. A two colour array (Agilent SurePrint
G3) was used to measure gene expression for the samples (CY5) and a uni-
versal RNA reference (CY3). Normalised and raw data was resposited in part
(GSE40115) and in full (GSE49481) on GEO for the respective publication.
2.4.2 Breast Cancer Meta-Cohort
A large meta-cohort was provided by Dr. Lance Miller (Wake Forest Univer-
sity) and colleagues which consisted of gene expression data from 2116 breast
tumours (Soon et al., 2011). The meta-cohort was collated from 14 breast can-
cer gene expression studies, all using Affymetrix microarray platforms (HG-
U133A, HG-U133plus2 and HG-U113A2). For consistency, Miller and colleagues
retained only probes found on all array types. Further, each array was RMA
normalised before being combined using comBat normalisation (Alistar et al.,
2014; Miller et al., 2016). Clinical information was also provided, this included,
where possible, ER status, PgR status, PAM50 molecular subtype, grade, treat-
ment and survival information (Table 2.2). Individual RMA normalised datasets
were provided along with the meta-cohort.
Chapter 2. Materials and Methods 51
TABLE 2.2: Clinically relevant features for each dataset
Waddell dataset Nagel dataset Larsen dataset Meta-cohort
n=75 n=155 n=253 n=2116
Germline Mutations
– BRCA1 19 47 33 –
– BRCA2 30 6 22 –
– CHEK2 – 26 – –
– BRCAx 25 76 70 –
Molecular Features
Oestrogen status
– Positive – – 196 1465
– Negative – – 57 436
Progesterone status
– Positive – – 148 700
– Negative – – 105 341
HER2 status
– Positive – – 35 –
– Negative – – 218 –
Grade
– 1 – – 49 253
– 2 – – 94 682
– 3 – – 74 594
2.4.3 Microarray Normalisation
Raw data for each of the publicly available datasets, described above, were ob-
tained either with the R package GEOquery or directly through GEO.
2.4.3.1 Waddell Dataset Normalisation
The raw data from the Waddell dataset (GSE19177) was normalised by the
quantile normalisation method from the preprocessCore package in R and
data was log2 transformed. The normalised dataset consisted of 75 breast tu-
mours, 74 of which were genotyped for BRCA1 and BRCA2 pathogenic vari-
ants. The 75th breast tumour was unknown and was excluded from further
analysis. Probes that mapped to the same transcript identifier were collapsed
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to the probe with the greatest mean expression across all samples. After filter-
ing, 46719 transcripts remained across 74 breast tumours, including 19 BRCA1
and 30 BRCA2-associated tumours.
2.4.3.2 Nagel Dataset Normalisation
Raw data from the Nagel dataset (GSE27830) was normalised by the RMA
method with the affy package in R. The RMA normalisation consists of a
background correction followed by quantile normalisation (Irizarry et al., 2003).
Probes with identical transcript ID (GenBank) were collapsed by selecting the
probe with the greatest mean expression. Lastly, the data was log2 transformed
and tumours with germline CHEK2 1100delC mutation were excluded. After
filtering, the Nagel dataset consisted of 51277 transcripts and 129 familial breast
cancer cases, 47 and 6 were BRCA1- and BRCA2-associated, respectively.
2.4.3.3 Larsen Dataset Normalisation
Raw data from the two-colour Agilent array used in the Larsen dataset (GSE40115
and GSE49481) was normalised by firstly excluding the CY3 intensities. Breast
cancer samples were all measured on the CY5 channel of each respective ar-
ray. CY5 intensities were background corrected and normalised with the limma
package in R. Background-adjusted intensities were normalised by quantile
normalisation and data was log2 transformed. Probes were collapsed based
on systemic names (transcript names) provided by Larsen et al., (2013), in the
case of multiple probes mapping to a systemic name the probe with the greatest
average CY5 intensity was retained. After filtering the expression data, 36599
transcripts remained across 253 breast tumours, including 33 BRCA1 and 22
BRCA2 carriers. In addition, molecular features including ER status, PgR sta-
tus, HER2 overexpression and grade was available (Table 2.2).
As gene expression data for all the BRCAx samples was performed subsequent
to the original GSE40115 dataset (Larsen et al., 2013) batch effect that were intro-
duced were explored. Batch effects were explored by principle component anal-
ysis and by correlating the significant of gene expression variability (Section
2.5.1.1) and differential expression (Section 2.5.2) between overlapping samples
from each repository. There was no obvious batch effects (Figure 2.1C) or ef-
fects on significance of gene expression differences ((Figure 2.1A). Similarly, the
use of only CY5 intensities, and not CY5/CY3 ratios, had only a small effects
on significance of gene expression differences (r = 0.88, Figure 2.1B). Therefore,
I could confidently use the CY5 normalised data from the GSE49481 repository
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FIGURE 2.1: A) Comparison of two available overlapping breast tumour datasets
(GSE40115 and GSE49481) across gene expression analysis. Differential expression
(DE) analysis and differential variability (Dvar) analysis was calculated between
BRCA1-associated and sporadic breast tumours. (B) Comparison of single channel
(CY5) and dual channel ratios (CY5/CY3) across gene expression analysis. C) PCA
analysis of breast tumour sample from the GSE49481 repository which contain original
study cohort (blue) and an additional 70 BRCAx samples (red).DE, differential expres-
sion analysis, Dvar, differential variability analysis
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2.4.4 PAM50 Molecular Subtyping
PAM50 molecular subtypes were provided for the meta-cohort and were avail-
able for the Larsen and Waddell datasets. However, as raw data for both the
Larsen and Waddell datasets were normalised in house, PAM50 subtyping was
performed (Table 2.2). For the Nagel dataset PAM50 predictions was performed
on the complete dataset before excluding those samples with CHEK2 mutations.
PAM50 predictions were done on normalised mircoarray data using the “Pre-
diction Analysis of Microarray” method on PAM50 gene panel (Parker et al.,
2009). Intrinsic subtypes were assigned on samples using the molecular.subtyping
function from genefu package in R (Gendoo et al., 2016).
2.5 Statistical Analysis
2.5.1 Global Gene Expression Variability
To assess changes in global gene expression variability, the standard deviation
(SD, Equation 2.1), coefficient of variance (CV, Equation 2.2) and absolute devi-
ation from the median (MAD, Equation 2.3) were calculated for each transcript.
These, along with the mean, were calculated for: BRCA1 or BRCA2-associated
tumours, BRCAx and sporadic breast tumours. In addition, the SD, CV and
MAD were calculated for each molecular subtypes (basal-like, luminal A, lumi-
nal B, HER2 overexpressing, normal-like) and the combination of all non-basal
tumours. Linear regression was used to model the fit of the comparisons be-
tween two subtypes/genotypes. The size and direction of the effect of global
gene expression variability was measured as the differences between the linear
model and the model of equity (slope =1).







(xi − x̄)2 (2.1)
Where σ is the standard deviation, x is the mean, xi is the observed value for
sample i and N is the number of samples
CV = (σ/x) ∗ 100 (2.2)
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Where σ is the standard deviation and x is the mean.
MAD = median(|xi − x̃|) (2.3)
Where x̃ is the median of the observed values and xi is the observed value for
sample i.
2.5.1.1 Differential Gene Expression Variability
To identify genes that display expression variability,the Brown-Forsythe test
(Equation 2.5) of equality of variances was calculated using the lawstat pack-
age in R. To minimise multiple testing, only probes annotated with gene sym-
bols were tested. Gene expression variability was calculated on 19852, 29127,
39909 and 36599 probes for the meta-cohort, Waddell, Nagel and Larsen datasets,
respectively.
To identify differentially variable genes associated with BRCA1/2 pathogenic
variants, the Brown-Forsythe test was calculated on: 1) Breast tumours with
germline BRCA1 variants compared to BRCAx breast tumours or sporadic breast
tumours; 2) Breast tumours with germline BRCA2 variants compared to BRCAx
breast tumours or sporadic breast tumours; and 3) Breast tumours with either
a germline BRCA1 or BRCA2 variants compared to BRCAx breast tumours or
sporadic breast tumours.
Basal-like tumours were compared to all non-basal tumours (i.e. luminal A, lu-
minal B, HER2 overexpressing and normal-like) independently and as a collec-
tive (non-basal) to identify differentially variable genes associated with molec-
ular subtypes.
2.5.2 Differential Gene Expression
To identify differentially expressed genes, the limma package in R was used
to perform a moderate t-statistic on normalised expression data (Ritchie et al.,
2015). Differentially expressed analysis was calculated on the same sample
comparison as done for differential variability analysis.
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2.5.3 Data Simulation and Random Sampling
Data was simulated for two normally distributed cohorts of equal size with
unequal population variation (SD=1 and SD=5). To estimate effects of sample
size on standard deviation ratios, standard deviation ratios were calculated on
a range of sample sizes (n=5 to n=1000) where the ratios were calculated 1000
times for each sample size with populations re-sampled at each iteration.
Additionally, random sampling was used with the meta-cohort dataset to es-
timate the effects of sample size on the predictions of variability with a linear
model (Section 2.5.1). The linear model was fitted to basal and non-basal groups
over a range of sample sizes (n=10 to n=490) and replicated 1000 times at each
sample size.
In addition to testing sample size effects, the meta-cohort was used to gener-
ate random pseudo-basal and pseudo-non-basal groups. Pseudo groups were
representative in size to those used to calculated basal-associated changes and
were not reflection of subtype (e.g. the psuedo-basal group was 490 breast tu-
mours sampled from the entire meta-cohort). Random sampling was repeated
1000 times. For each iteration the smallest p-value generated by differential ex-
pression analysis (Section 2.5.2) was stored. These p-values were subsequently
compared to the results of the differentially expression analysis to assess the
robustness of the extremely small p-values generated.
2.5.4 Multiple Testing Correction
To decrease the false discovery rate, p-values were adjusted using the Benjamini-
Hochberg (BH) procedure. (Benjamini and Hochberg, 1995). The BH method
controls the Type I error rate by adjusting the calculated p-value based on its
ranked position and number of tests. In addition, the largest p-value remains
unchanged and is set as the upper limited, so that no adjusted p-value is larger.
The adjusted p-value using the BH procedure is calculated as:




Where p.adji is the adjusted p value, pi is the calculated p-value and ri is the
given p-value rank for a give gene (i). N is the number of tests.
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2.6 Variable Expression Quantitative Trait Loci
2.6.1 Data request
Genotype and expression data was acquired through the database of Geno-
types and Phenotypes (dbGaP) and the Genotype-Tissue Expression (GTEx)
Common Fund Project under the project title (#17463) “Identification of vari-
able expression quantitative trait loci that are associated with cancer risk”. The
datasets used for the analyses described in this thesis were obtained through
the dbGaP accession number phs000424.v7.p2.
2.6.2 Genotype Filtering
Table 2.3 describes the workflow used to generate a 012 genotype matrix, where
genotypes were numbered by the minor allele count. Due to the large and
computationally intensive nature of this analysis, the original variant file was
split into each chromosome-specific files. The chromosome-specific variant files
were converted to 012 matrices with the 012 tool within vcftools. The output
from vcftools is an unlabelled 012 matrix with samples as rows. For down-
stream applications each matrix was transposed with a R script, and SNP in-
formation and subject IDs were added. Genotypes were filtered so that only
bi-allelic genotypes of at least 10 subjects with two or more genotypes (AA, Aa,
aa) were retained. Samples with genotype calls were matched to samples from
tissue-specific expression datasets. The subsequent subset of sample matched
genotypes were filtered again to ensure that all genotypes met the criteria.
TABLE 2.3: The workflow of scripts used to generate genotype matrix
Script# Input file Output file Script function




VCF 012 matrix Implements vcftools 012 ma-
trix tool on each VCF
Genotype012_filter.R 012 matrix Genotype filtered 012 matrix Retains genotypes which have
at least 10 subjects across two
or more genotypes.
SubjectMatching.sh 012 matrix Subject filtered 012 matrix Matching tissue expression
subject to genotype subject.
∗Script provided on github https://gist.github.com/obenshaindw/c1afbedb0e317c1483e0
#Scripts are located at https://github.com/wigge206/ThesisCode/tree/master/veQTL/preprocessing
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2.6.3 Gene Expression Filtering
Normalised Reads Per Kilobase of transcript, per Million mapped reads (RPKM)
values for 56203 unique Ensembl (https://www.ensembl.org/) gene identifiers
were split into tissue-specific datasets. For each dataset, only transcripts with
RPKM > 0.1 in at least 10 samples were retained. Subjects with multiple tissue-
specific samples were collapsed by calculating the average RPKM values. Lin-
ear regression models were used to correct expression data for age and sex as
covariates. For the linear model age was dichotomised at age 55.
2.6.4 veQTL Implementation
For each gene, veQTL were mapped by testing for equal variance among indi-
viduals of different genotypes using the Brown-Forsythe method. A custom R
script was used to calculate Brown–Forsythe test-statistics (W , Equation 2.5) on
each genotype and all transcripts. For a response variable y in j groups, trans-
formed to the median absolute deviation Zij = |yij−yj.|where yj . is the median











F (α, k − 1, N − k) (2.6)
Where N is the number of samples, k is the number of different genotypes (2
or 3), Ni is the number of samples in group i, Zi is the mean of the absolute de-
viation from the medians for group i, Z.. is the mean of the absolute deviations
from all samples from their respective group medians andZij is the absolute de-
viation from the median for sample j from group i. The resulting W statistics
follows the F-distribution with degrees of freedom df1 = k−1 and df2 = N−k.
The pf function in R was used to calculate p-values for a given W , k and N .
For improvement in computational speed the test was performed for each geno-
type on all transcripts simultaneously, this was scripted without calling on pre-
defined statistical tests (e.g. levene.test from the lawstat package), pre-
venting unnecessary decisions trees. The Biobase package was used to imple-
ment rowMedians as this improved efficiency of the calculation.
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2.6.5 Breast Cancer Associated Variant veQTLs
Tissue-specific veQTL analysis was performed on 181 known breast cancer risk
variants and all transcripts that passed filtering (Supplementary Table D.1). We
limited proposed breast cancer susceptibility genes to those that had: 1) signif-
icant (p < 5.0x10−8) gene expression variability associated with a breast cancer
risk variants; 2) the significant veQTL association was only observed in breast
tissue and not in kidney, lung or ovary tissue and 3) the gene was only associ-
ated with a change in expression variability (i.e. veQTL) and not a change in
mean expression (i.e. eQTL).
TABLE 2.4: veQTL data for breast cancer associated alleles
Total Breast Ovary Kidney
Genotype 182 152 149 106
Transcript – 33059 29522 25026
2.7 eQTL Analysis
Tissue-specific eQTL analysis was performed in the same four tissue datasets
used for veQTL. The ultra-rapid MatrixEQTL package in R was used to cal-
culate p-values for each gene-variant association. A linear additive model was
used with age (dichotomised at age 55) and sex as co-variates. To maintain effi-
ciency the MatrixEQTL package only returns associations less than a nominal
p-value. For the purpose of this study we returned all associations with p <0.01.
2.8 Pathway Analysis
Gene lists identified throughout this thesis were analysed using over-representation
analysis. Over-representation analysis determines whether gene lists contains
an over-representation (i.e. greater than chance) of genes from a given pathway.
To determine significance, either a hyper-geometric distribution or Fisher’s ex-
act test were performed, where the number of genes in each pathway and total
number of genes tested are necessary. Over-representation analysis was per-
formed using the R packages DOSE and clusterProfiler (Yu et al., 2012,
2015) with the gene ontology (GO) terms as pathways. Total genes were set at
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the number of genes hypothesis testing was performed on (e.g. the total num-
ber of genes that passed filtering).
In addition, gene set enrichment analysis (GSEA) was performed on ranked
gene lists (Subramanian et al., 2005). Gene lists were ranked by the magnitude
and direction of standard deviation ratios (SDR) between two tumour groups.
Associations between gene lists and pathway gene-sets are measured by a run-
ning sum statistic (term enrichment score, ES), which increases when a gene
from a pathway gene-set is met and decreases when the opposite is true. To
calculate significance, 1000 permutations (or a nominal amount set by the user)
are performed and the largest ESs are returned. A p-value for the observed ESs
can then be calculated based on the empirical distribution of ES (Subramanian
et al., 2005).
GSEA analysis was performed only on gene-lists ranked by SDR using the
fgsea package in R using the molecular signatures databases (MSigDB) pro-
vided by GSEA (www.gsea-msigdb.org).
2.9 In vitro Methods
All cell culture work was carried out under aseptic conditions. Cells were
grown at 37◦C with 5% CO2 in flasks, dishes or plates in cell line appropri-
ate growth media (Appendix B). Cells were passaged once they had reached
80-90% confluence by washing cells with phosphate buffered saline (PBS, Ap-
pendix A.5) before incubation with TrypLE™ Express Enzyme (TrypLE) at 37◦C
until cells were detached. Cells were then diluted with complete media. For cell
counting, detached cells in TrypLE we transferred into a 15 mL tube and cen-
trifuged at 500 x g for 5 minutes. The supernatant was decanted and the cell
pellet was resuspended with complete media. A cell aliquot was mixed with
equal volume of trypan blue and counted using the Countess automated cell
counter.
2.9.0.1 Freezing
Once cells were approximately 80% confluent, media was removed and cells
washed with PBS. Cells were incubated at 37◦C in TrypLE until cells were de-
tached, and transferred into a 15 mL tube. Cells were pelleted, supernatant
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was decanted and cells were resuspended in the respective freezing media (Ap-
pendix B). Cryovials were frozen to -80◦C in a Mr Frosty™ container overnight.
Cells were transferred to liquid nitrogen for long term storage.
2.9.0.2 Recovery
Frozen cells were defrosted in a 37◦C water bath before being transferred into a
flask containing pre-warmed complete media. Media was replaced the follow-
ing day to remove toxic DMSO.
2.10 CRISPR-Cas9 Genome Editing of MCF-7 Cells
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 genome
editing was used to: 1) knock-out BRCA1 by the introduction of a frameshift in-
del (insertion, deletion) and 2) knock-in a heterozygous BRCA1 c.2681_2682del
variant. Genome editing was performed in the MCF-7 breast cancer cell line.
2.10.1 Cas9 Plasmid Constructs
Two Cas9 constructs were used (Figure 2.2), the pSpCas9(BB)-2A-PuroR V2.0
(PX459) and pSpCas9(BB)-2A-GFP (PX458) which were kindly donated by the
Centre for Free Radical Research (University of Otago, Christchurch) and the
Cancer Genetics Lab (University of Otago, Dunedin), respectively. The PX459
plasmid, which contained a puromycin resistance gene (PuroR), was used in
all knock-out and knock-in experiments, whereas the PX458 plasmid, which
contained fluorescent EGFP in place of the PuroR gene, was used to establish
transfection conditions (Section 2.10.10). Each plasmid construct was similar in
size (PX458, 9289 bp; PX459 9174 bp) and contained the same S. pyogenes Cas9,
a guide RNA (gRNA) backbone and an ampicillin resistance gene (AmpR).
2.10.2 Guide RNA Design
Guide RNA properties were optimised for each of the knock-out or knock-in
experiments.
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FIGURE 2.2: Plasmid constructs of the two CRISPR plasmid used for genome editing.
Each plasmid contains a gRNA scaffold with BpiI digestion sites for insertion of gRNA,
Cas9 protein coding sequence and ampilicin resistance for selection during transforma-
tion. PX458 (left) contains the EGFP fluorescent protein that was used for optimisation
of transfection efficiency. PX459 (right) contains the PuroR gene used for selection of
transfected colonies.
2.10.2.1 Knock-Out gRNAs
The design of gRNAs for knock out experiments, was done using the Broad
Institutes’s “Design sgRNA for CRISPRko (S. pyogenes and S. aureus)” tool, re-
ferred to as “gRNA designer” from here on. The gRNA designer allows the
assessment of all gRNA with a DNA sequence for S. pyogenes Cas9 (PAM =
NGG). It uses the on-target scoring method described by Doench et al., 2016,
while off-target cutting is evaluated using the cutting frequency determination
score. The algorithm excluded any gRNA within the first 5% of sequence, likely
promoter/non-coding, or any gRNA in the last 65% of sequence. Five gRNAs
were selected based on the combined on and off-target ranks (Table 2.5).
Prospective gRNAs were further examined with Cas-OFFinder (Bae et al., 2014),
an online tool that lists potential off-target binding sites throughout the human
genome for a given gRNA. None of the five gRNAs were predicted to bind to
any off-target region with perfect base pairing. However, BRCA1_gRNA1 was
predicted to bind to CHRDL1 (chrx:110782982) with only one mismatch. A list
of all potential binding sites with a three base pair (bp) mismatch can be found
in Appendix C.
All gRNAs were absent for the BsbI resection enzyme cut sequence (5‘-GAAGAC),
enabling a single digestion ligation step (Section 2.10.5).
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TABLE 2.5: gRNAs for CRISPR-Cas9 direct cleavage
Gudie RNA Sequence (5‘→3‘) On-target score Off-target(<2 mm#)
BRCA1_gRNA1 AGAAACCTACAACTCATGGA 0.64 1
BRCA1_gRNA2 GGCTCAGGGTTACCGAAGAG 0.61 0
BRCA1_gRNA3 GCAGCATTTGAAAACCCCAA 0.74 1
BRCA1_gRNA4 AGGAAACATGTAATGATAGG 0.66 1
BRCA1_gRNA5 GCAGAACTAGGTAGAAACAG 0.66 0
BRCA1_gRNAdel GTTTCTTTAAGGACCCAGAG 0.72 0
#Number of off-targets allowing 2 mismatches (mm)
2.10.2.2 Knock-in gRNA
For the creation of a pathogenic BRCA1 mutation, a single gRNA was designed
to be close to the targeted edit site (c.2681_2682del). The online tool Benchling
(www.benchling.com/crispr/) was used to assess the characteristics any gRNA
nearby the targeted edit site. Similar to the gRNA designer the on-target scor-
ing method described by Doench et al., 2016 was used. However, for off-target
scoring, Benchling used the method described in Hsu et al., 2013. A second
major consideration was whether the protospacer adjacent motif (PAM) could
be silently mutated to prevent Cas9 cleavage post edit.
For the specific BRCA1 c.2681_2682delAA edit, two gRNAs were within 20 bp
of the Cas9 targeted cleavage site, however, only one (BRCA1_gRNAdel, Table
2.5) respective PAM sequence could be silently mutated (c.2661C>T, p.Ala=).
The BRCA1_gRNAdel was predicted to cause a Cas9 mediated cut 15 bp down-
stream of the BRCA1 c.2681_2682del edit site and is complementary to the mi-
nus strand (BRCA1 coding strand). It has a high on-target score (0.72) and
was predicted by Cas-OFFinder to have no matches with a tolerance of 2 bp
mismatch (Appendix C). The PAM sequence TGG (on the plus strand) can be
silently mutated by mutating the coding C on the minus strand to a T (Ala to
Ala). Further, as the gRNA binds to the region overlapping the edit site once
the edit has occurred this will lead to a mismatch for the gRNA and prevent
further gRNA binding and Cas9 cleavage.
2.10.3 Donor Template Design
The donor template, which contains any desired edit(s), was designed in par-
allel with the gRNA as the respective designs are dependent on each other.
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Genome edit efficiencies are influenced by several donor template character-
istics including: size, symmetry, targeted strand and modifications (Section
5.1.1.1)(Richardson et al., 2016; Liang et al., 2017). Therefore, two single-stranded
deoxyoligonucleotides (ssODN) were designed using Benchling and purchased
from Integrated DNA Technologies (IDT). Each ssODN was designed to incor-
porate the same two edits into the genome, a two nucleotide deletion (c.2681_2682del)
and the conversion of C/T (c.2661C>T). Symmetry was measured around the
deletion edit. One ssODN (B1_sym_delAA) was based on the metric in Pires
et al., 2016, which used the same plasmid system as used in this study. The
second ssODN (B1_asym_delAA) was asymmetrical with a 30 nt 3‘ homology
arm (PAM-distal) and a 61 nt 5‘ homology arm (Table 2.6).
TABLE 2.6: ssDNA Donor Template









– indicates the bases that are deleted and absent in the ssODNs
Red bases indicate the edited bases
2.10.4 gRNA Annealing
Top and bottom single stranded DNA (ssDNA) containing the 20 nt target se-
quence (Table C.2) with BsbI overhangs were purchased from IDT (Figure 2.3).
Oligo pairs were annealed together in a 10 µL reaction containing 10 µM of
each oligonucleotide (oligo) and 1 µL of 10x T4 DNA ligase buffer. ssDNA sec-
ondary structure was denatured at 95◦C for 10 minutes and the oligos allowed
to anneal by slowly cooling (5 ◦C/minute) the mixture to room temperature.
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FIGURE 2.3: Schematic of cloning method. Top) Complementary ssDNA oligos were
purchased with BpiI overhangs (nucleotides in red). Middle) ssDNA oligos were an-
nealed. Bottom) BpiI cut sites (red triangles) are located upstream of the gRNA scaffold
(light blue) allowing the ligation of gRNA (top strand) into the BpiI plasmid.
2.10.5 Digestion-Ligation
The PX459 plasmid was designed with two BpiI (isoschizomer of BbsI) binding
site (5‘-GAAGAC in opposite orientation (Figure 2.3)). The significance of the
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design, is the ability to perform single-step digestion-ligation as the BpiI bind-
ing sites are removed from the plasmid. Importantly, all gRNAs were void of
BpiI binding sites (Table 2.5). In a total volume of 20 µL (Table 2.7), 2 µL an-
nealed gRNA (diluted 1 in 200), 100 ng plasmid, 1 µL DTT (1 mM), 1 µL T4
ligation buffer, 1 µL T4 DNA ligase, 2 µL FastDigest buffer and 1 µL BpiI were
mixed and cycled through a six cycle reaction in a thermocycler: 37◦C digestion
for 10 minutes, 23◦C ligation for 10 minutes followed by 20 minutes at 65◦C.
TABLE 2.7: Reaction mix for single-step digestion ligation
Reagent Volume (µl)
PX459 plasmid (100 ng) x
Diluted annealed gRNA∗ 2
DTT (1 mM) 1
T4 Ligation buffer (ATP) 1
T4 DNA ligase 1
FD buffer 2
FastDigest BpiI 1
dH2O up to 20#
∗Annealed oligo’s are diluted 1:200
#Add enough water to make reaction 20 µl
2.10.6 Establishing Competent Bacteria
For clonal work the recA deficient Sbtl3 Escherichia coli (E. coli) cells were used
to prevent plasmid recombination during clonal amplification. The Stbl3 cells
were acquired from the Cancer Genetic Lab (University of Otago, Dunedin) and
were made chemically competent in house.
Frozen Sbtl3 cells were streaked on a lysogeny broth (LB) agar plate and a sin-
gle colony was inoculated in super optimal broth (SOB) growth medium (Ap-
pendix A.2) supplemented with 10 mM MgCl2 and grown overnight at 37◦C.
Three mL of the overnight culture was added to 300 mL of SOB, 10 mM MgCl2
and grown at 37◦C until an 0.4 OD600 was reached. Growth was stopped with
a 15 minute incubation on ice before cells were pelleted by centrifugation at
2,500 x g for 15 minutes at 4◦C. Growth medium was discarded and cells were
resuspended in 90 mL RF1 buffer (Appendix A.6). Cells were incubated for
15 minutes on ice before the centrifugation was repeated, the supernatant was
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removed and cells were resuspended in with RF2 buffer (Appendix A.7). Re-
suspended cells were incubated on ice for 15 minutes before being aliquoted
and stored at -80◦C for future use.
2.10.7 Transformation
Cas9 plasmids post ligation of gRNA were transformed into the chemically
competent Sbtl3 E. coli using an adapted heat-shock method. Ten µL of di-
gestion ligation (see above) reaction was added to 200 µL Sbtl3 competent cells
(7.2x106 cfu/µg) and incubated on ice for 30 minutes. Cells were then heat
shocked for 1 minute at 42◦C and immediately placed on ice for 2 minutes.
Thereafter, 900 µL of LB media was added and incubated at 37◦C for 1 hour
with shaking (200 rpm). After recovery, cells were centrifuged at 3,000 x g for
15 seconds and the supernatant was discarded. Cells were resuspended in the
remaining volume of LB media and streaked on LB agar plates with 100 µg/ml
ampicillin and left to grow overnight at 37◦C. Controls included pUC19 (100
pg) as a positive control and no plasmid as a negative control.
2.10.8 Plasmid Validation
2.10.8.1 Clonal PCR
Individual colonies were selected with a sterile pipette tip and placed directly
into in a tube containing polymerase chain reactions (PCR) mixture (Table 2.11).
The U6 promoter forward primer (Appendix C) was used in combination with
the respective bottom strand oligo as reverse primer (Table C.3). A standard
PCR cycle (Section 2.16) was performed with a 10 minute 95◦C activation step
to lyse cells.
2.10.8.2 Plasmid Extraction and Sequencing
Cells that had the correct size band (Approximately 240 bp) from the colony
PCR were grown overnight in 5 mL LB with 100 µg/ml ampicillin. Glycerol
stocks were created with 500 µL cells and 500 µL of 50% sterile glycerol and
were stored at -80◦C. The remainder of the cells were used for plasmid extrac-
tion using the NucleoSpin plasmid kit. Manufacturer’s instructions were fol-
lowed, with exception of the first centrifugation step which was done at 5,000
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x g for 10 minutes in order to pellet cells. Extracted plasmid DNA was quan-
tified with the Nanodrop 8000 spectrometer and sequencing reactions were set
up using the U6 forward primer (3.2 µM) and 200 ng plasmid DNA. Sanger
sequencing was performed by Genetic Analysis Services, University of Otago
Dunedin. Sequences were manually inspected for the insertion of the target
gRNA sequence.
2.10.9 Transfections of CRISPR-Cas9 Plasmid
Cells were seeded at 2.5x105 cells/well in a 6-well plate and grown overnight.
Once cells were 70-80% confluent complete media was replaced with Opti-
MEM prior to transfection. X-tremeGENE™ HP DNA transfection reagent was
warmed to room temperature and gently mixed. A DNA to transfection reagent
ratio was optimised for each cell-line (Section 2.10.9.1). For all CRISPR-Cas9
transfections 2 µg of respective plasmid was diluted in 200 µL of Opti-MEM
media. A gRNA negative transfection was established with 2 µg of PX459 plas-
mid with no gRNA template inserted. A transfection negative control was set
up with no plasmid DNA.
The optimised amount of X-tremeGENE™ HP DNA transfection reagent was
added to the diluted plasmid DNA. The DNA/transfection reagent mixture
was incubated for 20 minutes before being added dropwise to each respective
well. Cells were incubated for 48 hours before media with transfection reagent
was removed, cells were washed with PBS and incubated with TrypLE to de-
tach cells. Each transfections condition was transferred to three 15 cm dishes
with 15 mL complete media. Cells were allowed to adhere for overnight before
puromycin treatments (Section 2.10.10) .
TABLE 2.8: Seeding densities and puromycin concentrations for CRISPR-Cas9 experi-
ments
Seeding Puromycin
Cell line 6-well 12-well
MCF-7 2.5x105 1.0x105 2 µg/ml
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2.10.9.1 Transfection Optimisation
To established the optimal DNA (µg) to X-tremeGENE™ HP DNA transfection
reagent ratio, cells were seeded at 1.0x105 cells/well in 12-well plates. Four ra-
tios were tested ranging from 1:1 (i.e. 1 µg DNA to 1 µL reagent) to 1:4.
Firstly, 1 µg PX459, EGPF containing, plasmid was diluted in 100 µL Opti-MEM.
A range of transfection reagents was added to each tube and incubated for 20
minutes before being added dropwise to each respective well. Cells were in-
cubated for 48 hours and detached in TrypLE. The cell suspension was placed
in a 96-well plate and sorted using fluorescence-activated cell sorting (FACS)
by Dr Judy Mackenzie (University of Otago, Christchurch). The percentage of
positive GFP cells were measured and the condition with the highest percent-
age was used for future experiments, with consideration for excess cell death.
For MCF-7 cells an optimal ratio of 1:3 (DNA:reagent) was determined.
2.10.10 Puromycin Treatment and Colony Selection
Cells transfected with PX459:gRNA plasmids and transfection controls (no plas-
mid and PX459 only transfections) were seeded into 15 cm dishes and allowed
to adhere overnight. The next day, complete media was replaced with fresh
complete media supplemented with puromycin at a concentration that induced
complete cell death in MCF-7 wild type cells after 48 hours (Supplementary Fig-
ure D.1, Section 2.10.10.1).
Recovery and colony selection of MCF-7 transfected cells was improved through-
out the attempts of genome-editing. The methods described here are those con-
ditions in which CRISPR-Cas9 genome editing was successful, Chapter 5 de-
scribes the different conditions attempted. Treated cells were monitored for
excessive death for 48 hours, only the negative transfection control was ex-
pected to have complete death at this time. After 48 hours of puromycin treat-
ment, the puromycin containing media was removed and replaced with condi-
tioned media (Appendix B.1.2). Cells were maintained in conditioned media,
replaced weekly, until colonies formed. At the formation of colonies, dishes
were washed with PBS twice to remove cell derbies and non-adherent cells.
Single colonies were transferred with a pipette under a microscope to a single
well of a 96-well plate containing 100 µL complete media. Colonies were grown
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to 80% confluency before DNA was extracted from one fifth of the cells. The re-
mainder of the cells were continually bulked for freezing in the parental cell
line’s freeze media (Appendix B).
2.10.10.1 Puromycin Kill Curve
To determine the optimal concentration of puromycin that would kill MCF-7
cells without the PX459 plasmid, a kill curve was established in untransfected
MCF-7 cells. MCF-7 cells were seeded at 5.0x104 cells/well in a 24-well plate,
the equivalent density to that used for transfections. Cells were allowed to ad-
here overnight before media was replaced with complete media. Puromycin
was added to complete media at a range of concentrations (0, 0.25, 0.5, 1, 2, 4
and 5 µg/ml), in duplicate. Plates were gently agitated monitored daily for cell
death by visual inspection. A puromycin concentration that generated com-
plete death after approximately 48 hours was desired. For MCF-7 cells, two
concentrations (1 and 2 µg/ml) resulted in complete cell death at approximately
48 hours. To reduce the chance of wild-type MCF-7 cells surviving, the higher
concentration was selected for future experiments.
2.10.11 BRCA1 edit validation
Sequencing primers were designed adjacent to each of the gRNA predicted cut
sites using primer3 (Supplementary Table C.4). For each colony, DNA was ex-
tracted and primers targeting the predicted edit sites were used to amplify that
region. For all PCR assays the same PCR mastermix was used (Table 2.11) with
only the respective primers differing. All PCR products were visualised on 2%
agarose gels to confirm presence of correct size product before Sanger sequenc-
ing through the genetic analysis services (University of Otago, Dunedin).
2.11 In vitro Gene Expression Variability
To capture gene expression variability two cell models were used. RNA was
purified from cells and sent to the Auckland Genomics Facility (University of
Auckland) for hybridisation to the Clariom™ D Assay.
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2.11.0.1 Isogeneic BRCA1 variants
The pre-malignant breast cell line, MCF-10A and an isogenic cell line with a het-
erozygous BRCA1 pathogenic variant (c.68_69del) were purchased from Hori-
zon and grown in house. To capture variability, RNA from five independent
replicates of each cell line was profiled on the Clariom™ D array. To allow bi-
ological variation, each cell line was maintained in five independent flasks and
expanded under normal cell maintenance conditions for 10 passages (approxi-
mately 30 days). RNA was purified using the Qiagen RNeasy Mini Kit. Purified
RNA was quantified using the Qubit fluorometer and quality was evaluated us-
ing the TapeStation.
2.11.1 siRNA Knock-Down
BRCA1 was knocked down in the ER positive MCF-7 breast cancer cell line. The
siRNA transfection conditions were optimised to achieve a 50% knock-down
of BRCA1 expression in order to mimic heterozygous BRCA1 pathogenic car-
riers (Section 2.11.1.1). Knock-downs were achieved by seeding MCF-7 cells
at 1.0x105 cells/well in a 12-well plate and allowing cells to adhere overnight.
Complete media was replace with 900 µL Opti-MEM. BRCA1 siRNA (Table 2.9)
was diluted with Opti-MEM to a concentration of 0.2 µM (equivalent to 10 nM
final concentration), simultaneously 3 µL RNAiMax Lipofectamine was diluted
in 50 µL Opti-MEM. Finally, 50 µL of each of the diluted mixtures were added
together and incubated for 5 minutes. After which, mixtures were added drop-
wise to the respective wells. Cells were incubated at 37◦C for 48 hours before
being harvested for RNA extraction using either RNAgem or the RNeasy Mini
Kit. For the purpose of capturing gene expression variability, RNA was pu-
rified from five replicates of MCF-7 cells treated with BRCA1 siRNA and five
controls consisting of MCF-7 cells treated with reagent only. Furthermore, to
ensure successful knock-down, BRCA1 expression was quantified by RT-qPCR.
TABLE 2.9: siRNA
Target gene Assay IDs Company
BRCA1 s459 (4390824) ThermoFisher Silencer Select
Negative No. 1 – (4390843) ThermoFisher Silencer Select
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2.11.1.1 Optimisation
MCF-7 cells were seeded at 5.0x104 cells/well density in 24-well plates and al-
lowed to adhere overnight. Complete media was replaced with 450 µL Opti-
MEM and transfection media was prepared. In triplicates, siRNA was diluted
at a range of concentrations to achieve a 10 nM, 20 nM, 40 nM and 80 nM final
concentration (Table 2.10). In addition, 3 µL RNAiMax was diluted in 50 µL
Opti-MEM for each reaction. siRNA and RNAiMax solutions were mixed to-
gether, incubated for 5 minutes and added dropwise to the respective wells.
Cells were incubated at 37◦C for 48 hours being harvested for RNA extrac-
tion using RNAgem. Purified RNA was converted to cDNA (Section 2.15) and
BRCA1 expression was quantified by quantitative PCR (qPCR).
TABLE 2.10: Dilutions for siRNA optimisation experiments
Condition 10µM siRNA (µL ) Opti-MEM Final concentration (µL )∗
Negative siRNA 4 46 40 nM
10 nM 1 49 10 nM
20 nM 2 48 20 nM
40 nM 4 46 40 nM
80 nM 8 42 80 nM
∗ Concentration in 24-well with 500 µL volume
2.11.2 Microarray Expression Analysis
To measure gene expression variability from cell line models, RNA was sent
to the Auckland Genomics Facility (University of Auckland) and hybridised to
the Clariom™ D array. Raw data was normalised by the RMA method with
the affy package in R (Figure 2.4). To assess the normalisation, MA plots were
generate for each array comparing each sample array to a pseudo array, which
was derived as the median probe intensity across all arrays (Figure D.2). Probes
mapping to the same gene were collapsed by retaining the probe with the high-
est mean average across all arrays.
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FIGURE 2.4: Boxplots of probe intensities for each microarray before (left) and after
(right) normalisation.
2.12 DNA Extraction
DNA was extracted from cells with one of two methods:
1) To identify CRISPR-Cas9 edits, colonies in 96-well plates that were near con-
fluent were detached in 25 µL TrypLE. Five µL of cell suspension was placed in
10 µL of 0.5x direct lysis solution (Appendix A.4). Cells in direct lysis solution
were incubated at 65◦C for 30 seconds, 8◦C for 30 seconds, 65◦C for 90 seconds,
97◦C for 3 minutes, 8◦C for 1 minute, 65◦C for 3 minutes, 97◦C for 1 minute,
65◦C for 1 minute, and 80◦C for 10 minutes. Lysates were diluted in 40 µL H2O,
3 µL of diluted lysates were used directly in PCR reaction the remaining DNA
was stored at -20◦C.
2) One third of a confluent T-75 flask was used for DNA extraction using the
salting-out method. Cells were detached from the flask with 1 mL TrypLE,
transferred to 1.7 mL tube and pelleted. The supernatant was discarded and
cells resuspended in 1 mL nuclei lysis solution (Appendix A.3) containing 33
µL 20% SDS and 6.6 µL proteinase K (50 mg/ml). Cell suspensions were incu-
bated for 1 hour at 56◦C with occasional agitation. To precipitate protein, 300 µL
of saturated salt solution (6 M NaCl) was added to cell lysates and tubes were
vigorously shaken for 2 minutes. Lysates were then centrifuged at 20,000 x g
for 15 minutes at 4◦C and the supernatant was transferred to pre-chilled 15 mL
tubes containing 3.75 mL absolute ethanol. Tubes were mixed well and DNA
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was precipitated into a tight knot which was transferred into a 1.7 mL micro-
centrifuge tube containing 70% ethanol. Microcentrifuge tubes containing DNA
were spun for 1 minute at 13,000 x g and supernatant discarded. DNA was al-
lowed to air-dry before pellet was resuspended in H2O. DNA was quantified
using the Nanodrop 8000 spectrometer (Section 2.14.1) and store at -20◦C.
2.13 RNA Extraction
RNA was extracted by two methods, dependent on the downstream applica-
tions. For validation of knock-down and RNA used only for RT-qPCR, the
RNAgem® Tissue Plus Kit was used. For RNA used in microarray based stud-
ies the RNeasy Mini Kit was used.
2.13.1 RNAgem®
Cells were harvested during log-phase growth and pelleted by a 3,000 x g cen-
trifugation for five minutes. The supernatant was discarded and cells were
resuspended in 50 µL extraction reagents containing 1 µL RNAgem® enzyme,
5 µL 10x blue buffer and 44 µL dH2O. These were vigorously mixed, incubated
at 72◦C for 10 minutes and cooled to 4◦C. Lysates were subsequently mixed
with 5 µL 10x DNAse buffer and 2 µL DNAse I and incubated at 37◦C for five
minutes. DNAse I activity was inhibited by heating reactions to 72◦C for 5 min-
utes. Reactions were diluted with 5 µL 10x Tris-EDTA (TE) buffer before use in
RT-qPCR or short term storage at -80◦C.
2.13.2 Qiagen RNAeasy Mini Kit
Cells were harvested during log-phase growth and pelleted by centrifugation
at 3,000 x g for 5 minutes. The supernatant was discarded and the RNeasy
Mini Kit protocol was followed as per manufacturer’s recommendations with
the addition of an on-column DNase treatment using the RNase-free DNase kit
(Qiagen). In brief, cell were resuspended in 350 µL of RLT lysis buffer with
an equal volume of 70% ethanol and mixed thoroughly. The entire content
was transferred to the upper chamber of the Qiagen spin column and was cen-
trifuged at 8,000 x g for 15 seconds. The columns were washed with 350 µL of
RW1 buffer and the centrifugation was repeated. A DNAase and RDD buffer
mixture was prepared by combining 10 µL DNase and 70 µL RDD buffer for
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each reaction in a microcentrifuge tube. Then, 80µL of the DNase/RDD mix-
ture was added directly to the Qiagen spin column membrane and incubated
at room temperature for 15 minutes, immediately after 350 µL RW1 buffer was
washed through the Qiagen spin column at 8,000 x g centrifugation step for 15
seconds. The flow-through was discarded and the membranes were washed
twice with 500 µL RPE buffer and centrifuged at 8,000 x g for 15 seconds. After
the second wash, the columns were centrifuged at 20,000 x g for 1 minute to
dry the membranes. The upper chambers were then transferred to labelled 1.7
mL microcentrifuge tubes. A range of 30-50 µL of RNase-free water was added,
dependent of cell pellet size, to the upper chamber and centrifuged at 8,000 x
g for 1 minute. The eluted solution was added back onto the membrane in the
upper chamber and centrifugation was repeated. The elutant, containing RNA,
was quantified using the Nanodrop 8000 Spectrometer and stored at -80◦C or
used immediately for cDNA synthesis.
2.14 Nucleotide Quantification and Quality Assess-
ment
2.14.1 NanoDrop ND 8000 Spectrophotometer
Total RNA or DNA was quantified on the NanoDrop ND 8000 spectrophotome-
ter (Thermo Fisher Scientific). Briefly, the spectrophotometer was blanked with
RNA or DNA eluant. Subsequently, 1 µL of RNA/DNA was loaded and a
range of absrbances from 220 nm to 350 nm were measured. Nucleotide con-
centration were determined by measuring the 260 nm peak. In addition, purity
of the samples were determined by measuring the absorbance at 280 nm (aro-
matic amino acids have strong absorbance at 280 nm). Furthermore, residual
organic compounds, typically used in extractions, were detected at a 230 nm
absorbance. Only RNA with each of the A260/230 and A260/280 ratios greater
than 1.8 were considered pure and used for downstream applications.
2.14.2 Qubit Fluorometer
For accurate quantification of purified RNA the Qubit RNA high-sensitivity as-
say kit was used, which utilises a molecular dyes that specifically intercalates
with RNA. Briefly, 2 µL of each sample was added to 198 µL of working so-
lution in thin-wall optical-grade 0.5 mL tubes and incubated for 2 minutes at
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room temperature in the dark. Simultaneously, 10 µL of two provided stan-
dards were added to 190 µL working solution in the same manner. Standards
and samples were read with the Qubit fluorometer. The Qubit software gener-
ated a two point standard curve from the standards and sample concentrations
were calculated.
2.14.3 2200 TapeStation
Total RNA quality was assessed using the Agilent RNA ScreenTape system.
The RNA TapeStation system quantifies the abundantly expressed ribosomal
RNA, 18S and 28S by separating RNA on ScreenTape. In brief, 1 µL of RNA
or RNA ladder was mixed with 5 µL of RNA sample buffer and loaded into
the 2200 TapeStation along with ScreenTape. The TapeStation software then
interprets each sample and calculates the RNA integrity score (RIN), average
RNA fragment size and quantity. Only RNA samples with RIN scores greater
than 9.0 were considered for hybridisation with the Clariom™ D array.
2.15 cDNA Synthesis
First strand cDNA synthesis was performed in a 10 µL reaction. Either 500 ng
of total RNA or 5 µL of RNAgem® extracted RNA were mixed with 0.5 µL
random hexamer and 0.5 µL dNTPs (10 mM). To denature secondary structure,
RNA mixtures were heated to 65◦C for 5 minutes and cooled on ice for 1 minute.
To each the denature RNA reactions, 2 µL 5x First-Strand buffer, 0.5 µL 0.1M
DTT and 0.5 µL RNaseOUT™ recombinant RNase inhibitor were added. For
each sample, 0.5 µL of SuperScript™ III RT was added or substituted with 0.5
µL water for the no-RT control. Reactions were mixed and incubated at 25◦C
for 5 minutes, followed by a 30 minutes incubation at 50◦C. Reactions were then
inactivated by heating to 70◦C for 15 minutes. To remove RNA complementary
to cDNA, reactions were treated with 1 µL RNase H and incubated at 37◦C
for 20 minutes. cDNA was stored and -20◦C or diluted 1 in 20 with H2O for
downstream qPCR reactions.
2.16 Polymerase Chain Reaction
For endpoint PCRs, template DNA was amplified with TAQ-Ti DNA poly-
merase. Table 2.11 describes the PCR reactions, where the forward and reverse
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primers are designed to amplify target regions (Appendix C). PCR reactions
were performed on a thermocycler with a 95 ◦C activation step for 10 minutes,
followed by 30 cycles of 95◦C denaturation for 20 seconds, annealing (primer
specific temperatures described in Appendix C) for 30 seconds and a 72◦C ex-
tension step for 45 seconds. Reactions were completed with an extended ex-
tension step at 72◦C for 1 minute. All PCR products were visualised on a 2%
agarose gel.
TABLE 2.11: PCR reaction mixture
Reagent Volume (1x reaction) Final concentration
10x PCR buffer 2.0 µL 1x
25 mM MgCl2 1.6 µL 2 mM
10mM dNTPs 0.2 µL 0.1 mM
10 µM Fwd Primer 0.5 µL 0.25 µM
10 µM Rev Primer 0.5 µL 0.25 µM
TAQ-Ti DNA polymerase 0.3 µL 0.0025 U/µL
DNA (100 ng) x µL –
Distilled H2O y µL make up to 20 µL –
Total 20 µL –
2.16.1 Quantitative Polymerase Chain Reaction
For qPCR diluted cDNA was amplified with the KAPA PROBE FAST universal
mix and florescence was detected with the LightCylcer® 480 (LC480). Primer
and probe mixes were purchased from IDT and resuspended in distilled H2O
at a 20x (25µM primers, 12.5 µM probe) concentration (Supplementary Table
C.5). Pre-designed primer/probes were used when possible. For in house de-
sign, primer3 was used on the target region and primers spanning exon-exon
junctions were desired to decreased DNA binding. Primers were examined for
specificity with NCBI’s Primer BLAST.
In a 10 µL reaction, 0.5 µL of target and reference primer/probe mix were each
added to 5 µL probe mix, 1 µL H2O and 3 µL diluted template cDNA. All reac-
tions were run in triplicate on a 384 well plate in the LC480 under the following
conditions: 95 ◦C for 3 minutes, followed by 40 cycles of 95 ◦C denaturation
for 15 seconds, 60 ◦C annealing for 15 seconds and 72 ◦C extension for 15 sec-
onds. Relative expression was determined by the ∆Ct method (Pfaffl, 2001).
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The LightCylce® software calculates the target/reference ratio which is equiv-
alent to:
2Ct(target)−Ct(reference) (2.7)
Where Ct(target) is the cycle threshold for the target gene and Ct(reference) is the
cycle threshold for the reference genes for a given sample. For the current study
HPRT1 was used as reference gene for all qPCR experiments.
In addition, target/reference ratios were normalised to the control experiments
so that the average relative expression for control samples was equal to 1.
2.17 Preparation of Cyto-Spins
Cyto-spins of MCF-7 BRCA1-/+, MCF-7 CRISPR controls and MCF-10A cells
were prepared by harvesting cells log-phase growth from a T25 flask. Cells
were lifted in 1 mL of TrypLE and diluted in 3 mL of PBS. Cyto-spin chambers
and microscope slides were prepared and washed by placing 100 µL of PBS in
the upper chamber and spun for 5 minutes at 2500 x g with low acceleration in
the Shandon Cytospin 2 centrifuge. Following centrifugation, 200 µL of diluted
cells were placed into the upper chamber and the centrifugation was repeated.
Slides were inspected under a microscope to ensure a monolayer of cells had
been dispersed onto the slides. Cells were fixed by submerging slides in ice-
cold methanol for 5 minutes. Slides were washed immediately twice in ice-cold
PBS. Slides were either stored at -80◦C or immediately used for immunocyto-
chemistry.
2.18 Immunocytochemistry
All immunoflorscence experiments were performed on fixed cell spots gener-
ated by cyto-spins and all antibodies were purchased from Abcam. Fixed cyto-
spins were brought to room temperature and left to dry. Hydrophobic barriers
were drawn around each cell spot, covered with a 1% BSA PBS-T (PBS +0.1%
Tween 20) solution and incubated for 30 minutes at room temperature. An-
tibodies targeting CK5 (ab52635) were diluted 1:100 with a 1% BSA solution,
placed on each cell spot and incubated overnight (approximately 16 hours) at
4◦C. Additionally, a secondary only control was prepared where the cell spot
was incubated with a 1% BSA solution. Slides were washed twice in PBS for 5
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minutes, a 1:1000 dilution of Alexa Fluor® 488 (ab150077) was placed on each
cell spot and slides were incubated for 1 hour at room temperature. Slides were
washed twice in PBS for 5 minutes and DAPI (0.1 µg/µL) was added to each
cell spot for 1 minute. Slides were washed in PBS and coverslipped by adding
a drop of ProLong Diamond Antifade Mountant onto a coverslip and trans-
ferring a slide onto the coverslip. Air bubbles were removed and the mountant
was left to cure for 24 hours at room temperature in the dark before microscopy.
2.19 RNAscope®
RNAscope® probes targeting EN1, PPIB and DapB and the RNAscope® 2.5 BROWN
kit (Cat No: 322310) were all purchased from ACD Bio.
2.19.1 Tissue Microarray Preparation for RNAscope®
Tissue microarrays (TMAs) were acquired from Kathleen Cunnigham for Re-
search into Familial Breast Cancer (KConFab, Peter MacCallum Cancer Cen-
tre). To prepare TMAs forRNAscope®, slides were deparaffinised in Xylene
and 100% ethanol then sections were air dried. Sections were permeabilised by
firstly, covering slides with RNAscope® Hydrogen Peroxide and incubating for
10 minutes at room temperature. Slides were immediately washed repeatedly
with distilled H2O. Secondly, slides were submerged in RNAscope® Target Re-
trieval Reagent at 98◦C-102◦C for 15 minutes and washed with distilled H2O
then rinsed in 100% ethanol and allowed to air dry overnight. A hydrophobic
barrier was created around each TMA section with a hydrophoic pen. Lastly,
sufficient RNAscope® Protease Plus was placed on each section and slides were
placed in the HybEZ™ Slide Rack and incubated at 40◦C for 30 minutes in the
HybEz™ Oven.
2.19.2 Hydridisation of RNAscope® Probes and Amplification
Immediately after incubation of sections with RNAscope® Protease Plus the
slides were washed in distilled H2O. RNAscope® probes were prewarmed in
HybEz™ Oven for at least 10 minutes. To each section sufficient RNAscope®
probe was added to cover the entire section followed by incubated in the Hy-
bEz™ Oven at 40◦C for 2 hours. After hybridisation, slides were washed twice
in 1X Wash Buffer for 2 minutes. The amplification protocol is a series of re-
peating incubations with AMP reagents each followed by two wash steps with
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1x Wash Buffer. In this study the RNAscope® 2.5 BROWN kit was used. Briefly,
AMP1 was incubated for 30 minutes at 40◦C for 30 minutes, AMP2 was in-
cubated at 40◦C for 15 minutes, AMP3 was incubated at 40◦C for 30 minutes,
AMP4 was incubated at 40◦C for 15 minutes, AMP5 was incubated at room
temperature for one hour and AMP6 was incubated at room temperature for 15
minutes.
Signal was produced by mixing equal parts DAB-A and DAB-B in a microcen-
trifuge tube. Sufficient DAB mix was placed onto each section for 10 minutes at
room temperature. Slides were immediately submerged in tap water to remove
DAB reagent.
2.19.3 Counterstaining
All RNAscope® hybridised sections were counterstained with Gills haematoxylin
for one minute at room temperature. Slides were washed through a series of
H2O washes until H2O ran clear. Slide were dipped briefly in 0.02% ammonia
water and transferred to H2O.
Stained sections were dehydrated with incubations in a series of increasing
ethanol concentrations (70%, 95%, 100%) for 2 minutes each. Slides were then
transferred into xylene for 5 minutes. Coverslips had 1-2 drops of DPX moun-
tant added before removing slides from xylene and placing on top of the cover-
slip. Slides were allowed to air-dry before inspection under a microscope.
2.19.4 RNAscope® Scoring
Sections stained with control probes (PPIB and DapB) were scored to assess
quality of RNA. For TMA, each core was scored independently.
A positive signal was assessed as a brown punctuate dot within a cell. Sections
were scored based on the abundance of signals (Table 2.12). A score of zero was
assessed by the absence of any positive signals. A score of ‘0.5’ was assigned
as weak staining where less than 30% of cells had positive signals. A score of
‘1’ was when the majority of cells (>30% cells) had positive signals. A score of
‘2’ was considered moderate with 4-9 positive signals per cell and no clustering
of signals (i.e. signals cluster together so that the number signals can not be
determined). A score of ‘3’ was considered strong with 10 or more positive
signals per cell and only 10% of signals clustering. Lastly, a score of ‘4’ was
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considered intense, with more than 15 signals per cell and frequent clustering.
All scoring was performed at 20x magnification.
TABLE 2.12: RNAscope® scoring criteria
Score Criteria
0 No staining
0.5 0-30% of cells score 1-3 dot(s)/cell
1 1-3 dots/cell
2 4-9 dots/cell. No clusters
3 10-15 dots/cell and <10% clusters
4 >15 dots/cell and >10% clusters
2.19.5 RNA Quantification of Signals
All sections hybridised with EN1 were scanned with the Aperio Scanner, by ei-
ther myself or Amanda Fisher and colleagues at the Histology unit (Dunedin,
University of Otago). LEICA ImageScope software was used in conjunction
with the Aperio RNA ISH (Version 2.0) algorithm to count the presence of pos-
itive signals and number of cells. The RNA ISH algorithm was trained on sev-
eral cores with different levels of signal abundances. The setting from the train-
ing (Table 2.13) was applied to each core and the number of positive signals per
cells was used as estimate of abundance.
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TABLE 2.13: Lecia RNA ISH algorithm settings
Algorithm setting Input
Segmentation Type Individual Cells
Clear Area Intensity 200
Nuclei Detection Method Automatic
Min Nucleus Area (um2) 10
Max Nucleus Area (um2) 200
Nuclear Splitting 0.5
Fill Holes in Nuclei 1
Nuclear Elliptical Conformity 0.1
Nuclear Roundness Conformity 0.1
Nuclear Compactness Conformity 0
Nuclear Elongation Conformity 0.1
Cytoplasmic Distance (um) 0
Signals to Detect Red
Detection Threshold for Signals 0.8
–Signal 1 Min Area (um2) 0
–Signal 1 Max Area (um2) 3
–Signal 1 Lightness 230
–Signal 1 Dark Signal Detection 0.1
–Signal 1 Artefact Reduction 0.1
Identify Signal 1 Clusters No





Gene expression variability in
breast cancers
3.1 Introduction
Gene expression profiles have been extensively used to classify breast tumours
including the prediction of intrinsic subtypes and response to treatments (Sla-
mon et al., 2001; Paik et al., 2004; Parker et al., 2009; Waddell et al., 2010a; Larsen
et al., 2013, 2014). However, despite several attempts, there has been limited
success in identifying gene expression profiles related to BRCA1 and BRCA2
pathogenic variant status (Section 1.2.4). Consensus of genes between studies
has been poor, with little overlap of BRCA1- or BRCA2-associated gene expres-
sion profiles (Table 1.2). These studies have used approaches that focused on
identifying changes in mean gene expression between samples. However, as-
sessment of transcriptome variability has been used in describing disease phe-
notypes in schizophrenia, embryonic development, leukaemia, ovarian cancer
and ageing heart muscle (Bahar et al., 2006; Hasegawa et al., 2015; Zhang et al.,
2015; Ecker et al., 2015; Bueno and Mar, 2017). Additionally, a model of gene
expression variability has been proposed as a mechanism for incomplete pen-
etrance based on a pathogenic variant in a gene that causes a second gene to
become variably expressed (Raj et al., 2010). Cell-fate and disease phenotype
presents only if the variably expressed gene is below a tolerated threshold (Raj
et al., 2010). One study has investigated genes expression variability in BRCA2-
associated ovarian tumours (Bueno and Mar, 2017). On the assumption that
critical genes will be tightly regulated (i.e. have low variability), the authors
sought to identify synthetic lethal candidate genes for BRCA2-associated ovar-
ian tumours. Using a pathway based approach that was focused on BRCA2
functions, 54 candidate synthetic lethal genes were identified for further inves-
tigation.
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The first aim of this study was to use available microarray datasets to iden-
tify BRCA1- and BRCA2-associated gene expression variability phenotypes. As
the largest dataset (meta-cohort) was void of BRCA1/2 variant status, basal-
like PAM50 classification was used as a surrogate for BRCA1 status. Previous
studies have demonstrated the majority of BRCA1-associated tumours are triple
negative and classified as basal-like (Waddell et al., 2010a; Larsen et al., 2013).
The second aim of this study was to use RNA in situ hybridization to assess a
candidate gene at the single cell level for expression variability within tissue
samples.
3.2 Study Design
To identify variable gene(s) and pathways related to BRCA1/2-associated tu-
mours or basal-like tumours, three publicly available datasets (Waddell et al.,
2010a; Nagel et al., 2012; Larsen et al., 2014) and a dataset collated by Dr Lance
Miller and Colleagues (meta-cohort) were prepared (Table 3.1) (Miller et al.,
2016).





Waddell GSE19177 74 (49) Illumina Human 6v.2 Quantile
Nagel GSE27830 129 (53) Affymetrix HG U133
plus 2.0
RMA
Larsen GSE49481 253 (55) Agilent SurePrint G3 Quantile (CY5 only)
Meta-cohort N/A 2116 Affymetrix HG-U133
series†
RMA and comBat
∗Repository IDs are for the GEO database
#Sample numbers after filtering (see Section 2.4.1)
† includes Affymetrix HG-U133A, HG-U133plus2 and HG-U113A2 arrays)
To test gene expression variability, two broad rationales were employed. Firstly,
global changes in gene expression variability were estimated by comparing
gene-level statistics between two populations. Subgroup-specific means, stan-
dard deviations (SD, Equation 2.1), coefficients of variances (CV, Equation 2.2)
and median absolute deviations (MAD, Equation 2.3) were calculated for each
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gene. To quantify changes in gene expression variability the linear regres-
sion was calculated between two tumour groups (e.g. BRCA1-associated tu-
mours and BRCAx tumours), and the beta was compared to model of equity
(f(x) = (x), slope=1) and presented as percentage deviation from equity. Fur-
thermore, SD ratios (SDR) were used to rank genes based on magnitude of dif-
ference in variability and direction for the purpose of gene set enrichment anal-
ysis (GSEA). Gene specific SDRs were calculated as the ratio of SDs between
two tumour groups.
Secondly, to identify candidate genes, the Brown-Forsythe method (Brown and
Forsythe, 1974) was used to test for equality of variances (Equation 2.5). This
method is a robust form of the Levene and the Bartlett tests as it uses population
medians, making it more tolerant to outliers (Li et al., 2015; Wang et al., 2017).
Multiple testing was adjusted for using the Benjamini and Hochberg method to
reduce false discovery rates (Benjamini and Hochberg, 1995).
The last aspect of this chapter, was to use in situ RNA hybridisation (RNAscope®)
to investigate over 500 breast tumours obtained from Kathleen Cunningham for
Research into Familial Breast Cancer (KConFab). The purpose was to measure
differential variability of target genes identified in the microarray analysis in
a cancer cohort with the ability to investigate individual variability. After hy-
bridisation, tissue microarrays were scanned using the Aperio Scanner through
the histology department at the University of Otago Dunedin. The Aperio RNA
ISH algorithm was used to estimate the number of signal and nuclei in each tu-
mour core.
3.3 Results Availability
The results from the analysis of breast tumour microarrays (Section 3.4) are
available through a web application at BCdVar.otago.ac.nz. The web appli-
cation has been built using the R package Shiny and allows users the ability
to search gene expression characteristic between four microarray datasets and
compare tumours by both BRCA1 or BRCA2 genotype and molecular subtype.
The application has been built with the intention to make publicly available
once the results have been published.
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3.4 Results
3.4.1 BRCA1-Associated Breast Tumour Expression Variability
Differences in expression variability were quantified by first assessing global
changes of SD of probes between tumour groups (Section 2.5.1). BRCA1-associated
breast tumours displayed an average 22.8% (95% CI 22.3-23.2) increase in ex-
pression variability compared to BRCAx breast tumours (Table 3.2, Figure 3.1).
The most notable difference in global expression variability was observed be-
tween BRCA1 and BRCAx tumour groups, with an increase in BRCA1-associated
tumour expression variability that ranged from 10.3% (95% CI 9.9-10.7) to 34.4%
(95% CI 33.9-34.8) across the three familial datasets. Similarly, BRCA1-associated
tumours had a 24.0% (95% CI 23.5-24.5) increase in global gene expression vari-
ability compared to sporadic breast tumours.
An increase in BRCA1-associated gene expression variability was also captured
using linear models with gene-level CVs or the more robust MADs (Table 3.2).
Interestingly, the linear models using the MAD suggested a greater increase in
BRCA1-associated gene expression variability compared to both BRCAx (aver-
age deviation 25.0%, 95% CI 24.5-25.6) and sporadic (32.4%, 95% CI 31.9-33.0)
breast tumours (Table 3.2, Figure 3.1). No change in global mean gene expres-
sion was observed for any tumour comparison and there was no observed vari-
ability between BRCAx and sporadic breast tumours in the Larsen dataset (Ta-
ble 3.2).
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TABLE 3.2: Percentage deviation from model of tumour equity


























































































































































































β difference (β diff.) are the absolute differences between β and a model of equity f(x) = x
p-values were calculated from each linear model compared f(x) = x, p-values presented as 0 were < 10−308
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FIGURE 3.1: Expression probe statistics for BRCA1-associated tumours (x-axis) com-
pared to BRCAx or sporadic breast tumours (y-axis) in three datasets: Waddell (first
column), Nagel (second column) and Larsen (third and fourth column). Mean expres-
sion of each probe (first row) between basal and non-basal tumours is similar with
little deviation from the line of equity (red). Statistics used to measure probe vari-
ability, SD (second row), CV (third row) and MAD (fourth row) illustrate an increase in
global variability in tumours from BRCA1-associated tumours. Fitting a polynomial re-
gression (LOESS, orange) and a linear regression (blue, dashed) shows a shift towards
tumours from BRCA1 carriers in all datasets for both metrics of variability.
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3.4.1.1 Pathway Enrichment of BRCA1-Associated Gene Expression Vari-
ability
To determine directionality of variability, gene-wise SDRs were calculated be-
tween BRCA1-associated tumours and BRCAx or sporadic tumours. Genes
were ordered based on SDRs and GSEA was performed on the Hallmark gene
set from Molecular Signatures Database (MSigDB). All three BRCA1 datasets
suggested enrichment in DNA repair, KRAS signalling and WNT β-catenin sig-
nalling pathways when compared to BRCAx tumours (Figure 3.2), with genes
related to these pathways displaying greater variability in BRCA1-related tu-
mours. Furthermore, oxidative phoshorylation was also identified by all three
datasets, however, directionality was not consistent, with the Waddell dataset
suggesting greater variability in BRCAx tumours. In addition, compared to
sporadic breast tumours, both DNA repair and KRAS signalling were identi-
fied as more variable in BRCA1-associated tumours (Figure 3.2D).
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Pathway NES p p.adj
interferon gamma response 2.14 1.6E-04 4.2E-03
interferon alpha response 2.18 1.7E-04 4.2E-03
oxidative phosphorylation 1.46 5.8E-03 9.6E-02
hedgehog signaling 1.59 1.5E-02 1.9E-01
DNA repair 1.39 2.0E-02 1.9E-01
MYC targets v2 1.50 2.5E-02 1.9E-01
KRAS signalling dn 1.34 2.7E-02 1.9E-01
UV response up 1.28 6.4E-02 3.9E-01
hypoxia 1.24 7.0E-02 3.9E-01
WNT beta catenin signalling 1.36 8.9E-02 4.3E-01
G2M checkpoint -0.75 9.8E-01 1.0E+00
bile acid metabolism -1.00 4.5E-01 8.4E-01
pancreas beta cells -1.04 3.8E-01 8.4E-01
spermatogenesis -1.11 2.2E-01 6.0E-01
Pathway NES p p.adj
oxidative phosphorylation 1.73 1.07E-04 2.69E-03
MYC targets v1 1.90 1.08E-04 2.69E-03
KRAS signalling dn 1.54 1.07E-03 1.47E-02
DNA repair 1.42 2.02E-02 1.68E-01
heme metabolism 1.35 2.72E-02 1.94E-01
glycolysis 1.31 4.38E-02 2.49E-01
PI3K AKT mTOR signalling 1.37 4.48E-02 2.49E-01
protein secretion 1.35 5.78E-02 2.89E-01
WNT beta catenin signalling 1.33 1.01E-01 4.20E-01
hedgehog signalling -1.10 3.13E-01 7.83E-01
peroxisome -1.14 1.94E-01 6.94E-01
pancreas beta cells -1.32 9.55E-02 4.20E-01
estrogen response early -2.06 1.47E-03 1.47E-02
estrogen response late -2.18 1.46E-03 1.47E-02
Pathway NES p p.adj
myogenesis 1.43 1.20E-03 6.01E-02
KRAS signalling dn 1.31 1.73E-02 4.33E-01
adipogenesis 1.25 4.23E-02 5.90E-01
hedgehog signalling 1.39 5.25E-02 5.90E-01
mitotic spindle 1.22 5.90E-02 5.90E-01
protein secretion 1.26 8.23E-02 6.86E-01
p53 pathway 1.15 1.46E-01 8.91E-01
pancreas beta cells 1.25 1.48E-01 8.91E-01
WNT beta catenin signalling 1.23 1.65E-01 8.91E-01
DNA repair 1.16 1.78E-01 8.91E-01
apical surface -0.70 9.60E-01 1.00E+00
xenobiotic metabolism -0.80 9.38E-01 1.00E+00
oxidative phosphorylation -0.95 7.65E-01 1.00E+00
estrogen response early -0.96 6.88E-01 1.00E+00
Pathway NES p p.adj
interferon gamma response 2.14 1.51E-04 3.99E-03
interferon alpha response 2.23 1.60E-04 3.99E-03
DNA repair 1.58 2.33E-03 3.88E-02
hypoxia 1.43 9.04E-03 8.36E-02
KRAS signalling dn 1.42 9.80E-03 8.36E-02
myogenesis 1.39 1.36E-02 8.36E-02
hedgehog signalling 1.62 1.40E-02 8.36E-02
apoptosis 1.41 1.46E-02 8.36E-02
oxidative phosphorylation 1.39 1.51E-02 8.36E-02
mTORC1 signalling 1.37 2.05E-02 1.03E-01
mitotic spindle -0.77 9.78E-01 1.00E+00
G2M checkpoint -0.86 8.34E-01 9.83E-01
coagulation -1.12 2.18E-01 3.90E-01





FIGURE 3.2: GSEA analysis on BRCA1-associated gene ranks for the Waddell (A),
Nagel (B) and Larsen (C,D) datasets. Gene ranks for the Larsen dataset were gen-
erated by comparing BRCA1-associated tumours to BRCAx (C) or sporadic tumours
(D). Pathways with gene ranks, normalised enrichment scores (NES) and significance
for the top ranked pathways (Left). Running enrichment score (green line), gene rank
positions (black lines) and pathway ranking metric for each datasets’ most significant
pathway (right). GSEA analysis was performed with fgsea on the Hallmarks annota-
tions from MSigDB, plots were generated by DOSE in R.
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3.4.1.2 Genes Variably Expressed in BRCA1-Associated Breast Tumours
To identify candidate gene(s) associated with BRCA1 pathogenic variant sta-
tus, the Brown-Forsythe test was used to test for equality of gene expression
variance between BRCA1-associated tumours and either BRCAx or sporadic
tumours (hereafter referred collectively to as controls, Section 2.5.1.1). After
p-value adjustment, 345 and 411 genes were differentially variable between
BRCA1-associated and BRCAx breast tumours in the Nagel and Larsen datasets,
respectively. There were 42 genes that were differentially variable in both the
Nagel and Larsen datasets (Figure 3.3A). The directionality of the gene expres-
sion variability was consistent for 86% (36/42) of these genes (Figure 3.3B).
The 36 genes common between datasets were over-represented in pathways
involved in enhancer element binding and peripheral nervous system devel-
opment (Figure 3.3C). No gene reached significance (adjusted p <0.05 ) after
adjusting for multiple testing in the Waddell dataset. A further 989 genes were
differentially variable between BRCA1-associated and sporadic breast tumours
in the Larsen dataset, of these, 33 overlapped the 36 differentially variable genes
between BRCA1-associated and familial BRCAx breast tumours.
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Ontology GO ID Description
Gene 
Ratio p value p adjust
BP GO:0007422
peripheral nervous system 
development 4/28 3.85x10-06 0.0031
CC GO:0033391 chromatoid body 2/32 2.19x10-04 0.017
CC GO:0030057 desmosome 2/32 8.32x10-04 0.032
MF GO:0000980
RNA polymerase II distal 
enhancer sequence-specific 
DNA binding 3/28 3.89x10-04 0.029
MF GO:0001158
enhancer sequence-specific 
DNA binding 3/28 7.12x10-04 0.029
MF GO:0035326 enhancer binding 3/28 1.02x10-03 0.029
A B
C
36 genes in concordance in BRCA1 vs BRCAx analysis
A2ML1 FBN3 LEMD1 SIX3
AFAP1-AS1 GABBR2 LINC00839 SOX6
CLOCK GFRA3 MSLN SOX8
COL22A1 HORMAD1 NDRG1 STAC
CT83 HRCT1 OPRK1 STK24
CYP27C1 IGF2BP3 PCNT TDRD6
CYP39A1 KHDRBS3 PKP1 TTC23
DSC3 KLK6 POU4F1 UBASH3B
ELOVL4 KRT16 RNF150 VGLL1




RNA pol II distal enhancer sequence specific 
DNA binding
Enhancer sequence-specific DNA binding
Enhancer binding





FIGURE 3.3: BRCA1-associated gene expression variability and pathway analysis. A)
Schematic of work-flow to identify statistically significant genes in concordance be-
tween datasets (B). The Waddell dataset (blue) had no significant associated, therefore
comparisons were limited to the Nagel (green) and Larsen analysis (orange). C) Path-
way over-representation analysis for the 36 genes in concordance (B). Bars are shade
based on significance of pathway analysis and represent the number of genes variable
in each pathway. The pathway, GO terms and significance are presented in a table.
Over-representation analysis was performed using the DOSE and clusterProfiler pack-
ages in R.
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3.4.2 Breast Cancer Molecular Subtype Classifications
Intrinsic molecular subtypes were predicted using the PAM50 expression sig-
nature for the three familial breast cancer datasets after normalisation (Table
3.3). Across the three familial breast cancer datasets, the majority of BRCA1-
associated tumours were predicted as basal-like (61-78%). By comparison, a
majority of breast tumours from non-BRCA1 carriers, including BRCA2 carri-
ers, BRCAx and sporadic, were predicted as luminal-like, with tumours from
BRCA2 carriers typically luminal B (53-73%). Only a small portion of sporadic
tumours (8%) and BRCAx tumours (13-22%) were predicted to be basal-like
(Table 3.3).
Subtype predictions for the meta-cohort were provided with the dataset and
showed that only 23% breast tumours were classified as basal-like, with each
of the individual cohorts ranging from 2-45% basal-like (Figure 3.4B). Notably,
the five cohorts comprised of entirely ER positive tumours had few basal-like
tumours (2-7%, Figure 3.4B).
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TABLE 3.3: Distribution of the predicted tumour subtypes within breast tumours
Subtype BRCA1 BRCA2 BRCAx Sporadic
Waddell
–Basal 14 (74%) 5 (17%) 5 (20%) –
–Her2 0 (0%) 1 (3%) 4 (16%) –
–LumA 1 (5%) 8 (27%) 8 (32%) –
–LumB 3 (16%) 16 (53%) 8 (32%) –
–Normal 1 (5%) 0 (0%) 0 (0%) –
Nagel
–Basal 37 (78%) 0 (0%) 17 (22%) –
–Her2 2 (4%) 0 (0%) 3 (4%) –
–LumA 2 (4%) 2 (33%) 39 (51%) –
–LumB 5 (11%) 4 (67%) 16 (21%) –
–Normal 1 (2%) 0 (0%) 1 (1%) –
Larsen
–Basal 20 (61%) 2 (9%) 9 (13%) 10 (8%)
–Her2 2 (6%) 0 (0%) 7 (10%) 14 (11%)
–LumA 1 (3%) 3 (14%) 33 (47%) 55 (43%)
–LumB 9 (27%) 16 (73%) 18 (26%) 48 (38%)
–Normal 1 (3%) 1 (5%) 3 (4%) 1 (<1%)
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FIGURE 3.4: A) Distribution of the RMA normalised data for the 14 individual cohorts
that were collated for the comBat normalised meta-cohort (black). B) Proportions of
clinical (molecular subtype, ER status and grade) features per study, missing data was
termed unknown.
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3.4.3 Basal-like Breast Tumour Expression Variability
To utilise the significantly larger meta-cohort, which had no genotype data
for BRCA1 or BRCA2 genotypes, intrinsic molecular subtypes were compared
within the four datasets. Basal-like tumours displayed consistently greater
global gene expression variability compared to breast tumours of all other sub-
types (non-basal) (Table 3.2, Figure 3.5, Supplementary Figure D.3). The Wad-
dell dataset had a 40.4% (95% CI 39.9-41.0%) increase in basal-like gene expres-
sion variability, the greatest observed change. By comparison, the meta-cohort
had the smallest with a 13.2% (CI 12.6-13.7%) increase in basal-like gene expres-
sion variability (Table 3.2). Each of the 14 individual cohorts showed the same
trend of increased global variability in basal-like tumours (Supplementary Fig-
ure D.4). However, there were five cohorts (Cohort 3, 5, 6, 12 and 13) that had 10
or less basal-like tumours, making the interpretation of these cohorts difficult,
as any outliers will have greater influence in smaller populations (Supplemen-
tary Figure D.5). As with BRCA1-associated tumours, there was no difference
in mean gene expression levels between any tumour subtype independently
(Figure 3.5, Table 3.2).
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FIGURE 3.5: Expression probe statistics for basal-like tumours (x-axis) and non-basal
tumours (y-axis) in four datasets: the meta-cohort (first column) and Waddell (second
column), Nagel (third column) and Larsen datasets (fourth column). Mean expression
levels of each probe (first row) between basal and non-basal tumours are similar with
little deviation from the line of equity (red). Statistics used to measure probe variability,
SD (second row), CV (third row) and MAD (third row) illustrate an increase in global
variability in basal tumours. Fitting a polynomial regression (orange) and a linear re-
gression (blue, dashed) shows a shift towards the basal tumours in all datasets for both
metrics of variability.
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3.4.3.1 Pathway Enrichment of Basal-Like Associated Gene Expression Vari-
ability
All genes were ranked by magnitude and direction of expression variability by
calculating gene-level SDRs. Genes associated as variably expressed in basal-
like tumours were enriched for pathways involving oestrogen response and
WNT β-catenin signalling (Figure 3.6). Additional to oestrogen response, sev-
eral other BRCA1 functional pathways were identified including G2M check-
point and DNA repair. Furthermore, there were similarities with pathways en-
riched in the BRCA1 analysis (Figure 3.2). In particular, KRAS signalling, WNT
β-catenin signalling and oestrogen response pathways were all common to the
results from each analysis.





Pathway NES p p.adj
allograft rejection 2.06 1.02E-04 8.55E-04
G2M checkpoint 1.70 1.02E-04 8.55E-04
MYC targets v1 1.99 1.02E-04 8.55E-04
E2F targets 1.89 1.02E-04 8.55E-04
apical junction 1.70 1.02E-04 8.55E-04
interferon gamma response 1.95 1.03E-04 8.55E-04
interferon alpha response 1.82 2.16E-04 1.55E-03
IL6 JAK STAT3 signalling 1.77 3.22E-04 2.01E-03
inflammatory response 1.56 4.08E-04 2.27E-03
pancreas beta cells -1.50 3.85E-02 8.75E-02
peroxisome -1.46 1.33E-02 4.15E-02
estrogen response late -2.52 5.24E-03 1.87E-02
estrogen response early -2.90 5.24E-03 1.87E-02
Pathway NES p p.adj
myogenesis 1.34 1.03E-02 1.87E-01
KRAS signalling dn 1.33 1.37E-02 1.87E-01
DNA repair 1.29 4.03E-02 3.43E-01
TGF beta signalling 1.38 4.55E-02 3.43E-01
WNT beta catenin signalling 1.41 4.80E-02 3.43E-01
protein secretion 1.26 8.87E-02 4.58E-01
apical junction 1.20 9.03E-02 4.58E-01
unfolded protein response 1.24 9.83E-02 4.58E-01
mitotic spindle 1.19 1.01E-01 4.58E-01
hedgehog signalling -0.98 5.04E-01 9.73E-01
pancreas beta cells -1.03 4.21E-01 9.73E-01
bile acid metabolism -1.04 3.77E-01 9.73E-01
estrogen response late -1.94 1.49E-02 1.87E-01
estrogen response early -2.10 1.45E-02 1.87E-01
Pathway NES p p.adj
MYC targets v1 1.63 2.19E-04 1.10E-02
KRAS signalling dn 1.59 8.76E-04 1.30E-02
WNT beta catenin signalling 1.78 1.55E-03 1.30E-02
IL6 JAK STAT3 signalling 1.68 1.56E-03 1.30E-02
IL2 STAT5 signalling 1.49 3.82E-03 2.73E-02
oxidative phosphorylation 1.46 6.67E-03 3.95E-02
interferon gamma response 1.45 7.11E-03 3.95E-02
TNFa signalling via NF-kB 1.38 1.96E-02 9.78E-02
allograft rejection 1.35 2.68E-02 1.22E-01
apoptosis 1.31 4.99E-02 1.81E-01
pancreas beta cells 1.41 5.30E-02 1.81E-01
peroxisome -0.89 7.71E-01 8.76E-01
estrogen response early -0.98 5.24E-01 6.39E-01
estrogen response late -1.12 2.25E-01 4.03E-01
Pathway NES p p.adj
interferon gamma response 2.06 1.19E-04 2.18E-03
allograft rejection 1.80 1.20E-04 2.18E-03
interferon alpha response 2.00 1.31E-04 2.18E-03
IL6 JAK STAT3 signalling 1.72 6.59E-04 6.59E-03
inflammatory response 1.54 1.19E-03 8.85E-03
apical junction 1.54 1.43E-03 8.95E-03
KRAS signalling dn 1.38 1.77E-02 8.05E-02
DNA repair 1.40 2.08E-02 8.55E-02
WNT beta catenin signalling 1.53 2.22E-02 8.55E-02
g2m checkpoint -1.02 3.86E-01 5.68E-01
myogenesis -1.27 3.39E-02 1.13E-01
peroxisome -1.47 1.36E-02 6.80E-02
estrogen response early -1.48 1.24E-03 8.85E-03
estrogen response late -1.56 6.20E-04 6.59E-03
FIGURE 3.6: GSEA analysis on basal-like gene variability ranks for the meta-cohort
(A), Waddell (B), Nagel (C) and Larsen (D) datasets. Pathways with gene ranks, nor-
malised enrichment scores (NES) and significance for the top ranked pathways (Left).
Running enrichment score (green line), gene rank positions (black lines) and pathway
ranking metric for each datasets most significant pathway (right). GSEA analysis was
performed with fgsea on the Hallmarks annotations from MSigDB, plots were gener-
ated by DOSE in R.
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3.4.3.2 Genes Variably Expressed in Basal-Like Breast Tumours
There were 7754, 725, 3130 and 4218 significantly (adjusted p < 0.05) variable
genes that differed between basal-like and non-basal breast tumours in each of
the meta-cohort, Waddell, Nagel and Larsen datasets, respectively. A total of
190 genes were differentially variable in all datasets, with 188/190 genes con-
sistent in direction across all datasets. These 188 genes were over-epresented
for genes involved in different pathways, including epidermal development,
stem cell differentiation and transcription activation (Figure 3.7).
188 gene concordant 
between all studies
Ontology ID Description Gene Ratio p value p adjust
BP GO:0008544 epidermis development 20/175 1.90x10-08 4.80x10-05
BP GO:0070268 cornification 10/175 1.47x10-07 1.86x10-04
BP GO:0043588 skin development 17/175 6.26x10-07 5.28x10-04
MF GO:0001228 DNA-binding transcription 
activator activity, RNA pol II-
specific
15/174 1.22x10-05 4.80x10-03
BP GO:0001655 urogenital system 
development
13/175 1.86x10-05 0.010
BP GO:0048863 stem cell differentiation 11/175 2.20x10-05 0.010
BP GO:0061564 axon development 15/175 2.71x10-05 0.010
BP GO:0043062 extracellular structure 
organization
14/175 2.78x10-05 0.010
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FIGURE 3.7: Basal-like gene expression variability and pathway analysis. A) Basal-like
variable genes in concordance between the meta-cohort (purple), Waddell (blue), Nagel
(green) and Larsen (orange) datasets. B) The 188 genes in concordance, directionally
and identified by all datasets, were assessed for over-representation. Bars are shaded
based on significance of pathway analysis and the bar-length represents the number
of genes variable in each pathway. The pathway, GO terms and significance are pre-
sented in the table. Over-representation analysis was performed using the DOSE and
clusterProfiler packages in R.
The meta-cohort, which had the largest sample size (n=2116), contained 54%
of probes that were significantly variable and 76% of probes that were signifi-
cantly differentially expressed. Furthermore, many of the probes reported ex-
tremely significant p-values, with 199 differentially expressed and 9 differen-
tially variable probes reporting adjusted p-values smaller than 1x10-100 (Table
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3.4). To gain confidence that significance was true and not a symptom of sam-
ple size or underlying biases in one of the 14-individual cohorts, cohorts were
individually interrogated. In addition, random sampling was performed on the
entire cohort to establish whether sample size alone was driving these observa-
tions.
TABLE 3.4: The ten most variably expressed genes between basal-like and non-basal
breast tumours for each dataset
Meta-cohort Waddell
Affy ID Symbol t p p adjust IlluminaID Symbol t p p
209644_x_at CDKN2A 833.9 7.9E-155 1.6E-150 ILMN_1693218 ART3 137.7 3.4E-18 5.6E-14
215729_s_at VGLL1 815.3 6.4E-152 6.4E-148 ILMN_1657749 CYP27C1 136.9 3.9E-18 5.6E-14
220559_at EN1 792.8 2.2E-148 1.5E-144 ILMN_1703765 GPR12 116.4 1.6E-16 1.5E-12
207039_at CDKN2A 583.7 4.5E-114 2.2E-110 ILMN_1719755 FBN3 104.4 1.6E-15 1.2E-11
213260_at FOXC1 543.5 3.6E-107 1.4E-103 ILMN_1685569 TTYH1 100.7 3.5E-15 2.0E-11
209800_at KRT16 490.9 5.7E-98 1.9E-94 ILMN_1688205 KLK10 99.2 4.7E-15 2.3E-11
203439_s_at STC2 483.1 1.3E-96 3.8E-93 ILMN_1662886 KLHL34 96.0 9.5E-15 3.9E-11
205044_at GABRP 437.8 1.7E-88 4.3E-85 ILMN_1789244 SOX8 94.3 1.3E-14 4.9E-11
209842_at SOX10 427.8 1.1E-86 2.4E-83 ILMN_1679168 LOC653110 90.6 3.0E-14 1.0E-10
205030_at FABP7 394.2 1.4E-80 2.8E-77 ILMN_1782937 LOC652358 88.6 4.6E-14 1.3E-10
Nagel Larsen
Affy ID Symbol t p p adjust Agilent ID Symbol t p p
209990_s_at GABBR2 164.0 1.7E-24 6.7E-20 A_23_P110276 AFAP1-AS1 303.0 6.2E-45 2.3E-40
204885_s_at MSLN 157.9 6.4E-24 1.3E-19 A_33_P3383561 POLR2F 222.6 2.1E-36 3.9E-32
1560527_at NFE4 137.0 8.1E-22 1.1E-17 A_33_P3723448 ART3 219.7 4.6E-36 5.7E-32
223861_at HORMAD1 133.2 2.0E-21 2.0E-17 A_33_P3286923 TMPRSS5 209.3 7.8E-35 7.1E-31
1552848_a_at PTCHD1 130.1 4.3E-21 3.2E-17 A_32_P517715 RAD51B 208.2 1.1E-34 7.7E-31
214079_at DHRS2 129.7 4.8E-21 3.2E-17 A_23_P212042 MELTF 193.1 6.8E-33 4.1E-29
228873_at COL22A1 126.3 1.1E-20 6.3E-17 A_23_P161458 OLAH 186.5 4.6E-32 2.4E-28
224146_s_at ABCC11 120.3 5.1E-20 2.5E-16 A_24_P696761 LEMD1 185.8 5.5E-32 2.5E-28
235496_at HRCT1 111.4 5.2E-19 2.3E-15 A_23_P129133 OCA2 171.1 4.1E-30 1.7E-26
208305_at PGR 108.8 1.0E-18 4.1E-15 A_23_P401472 CHRM3 166.2 1.8E-29 6.5E-26
Meta-Cohort Analysis
The ten most differentially expressed probes between basal and non-basal tu-
mours were examined in each cohort (Supplementary Table D.2). Cohort 7 did
generate extremely small p-values (p-value = 6.7x1063), although this was sig-
nificantly larger than observed in the meta-cohort analysis (2.6x10-264). Cohort
7 was the largest individual cohort (n=344) and accounted for 28% (138/490)
of all basal tumours in the meta-cohort. Due to limited basal samples in sev-
eral cohorts (3, 5, 6, 12 and 13) it was difficult to test the bias of basal versus
non-basal samples. Additionally, cohort 5 had a left-shifted distributed den-
sity of expression compared to all other datasets (Figure 3.4A). PCA analysis of
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the 2,500 most variable genes between basal and non-basal better differentiated
samples based on subtype rather than cohort (Supplementary Figure D.6).
To ensure p-values were likely driven by differences between subtypes, samples
were randomly sampled into either a pseudo-basal group (n=490) or a pseudo-
non-basal group (n=1626), reflecting the true sizes of each respective group (Ta-
ble 2.2). Due to the superior computational speed of the differential expression
analysis, differential expression was tested on 1000 randomly assigned samples
groups. It would be expected that if differences in subtype were driving signifi-
cant changes, randomly selected subgroups would have larger p-values. Across
the 1000 simulations the smallest p-value (unadjusted) was 3.6x10-9, which was
substantially larger than 2.6x10-264, the smallest differentially expressed p-value
between basal and non-basal tumours (Supplementary Figure D.7).
3.4.4 BRCA2-Associated Breast Tumour Expression Variability
Conflicting observations were observed when comparing BRCA2-associated tu-
mours to familial BRCAx tumours across the three familial breast cancer datasets.
There was no change in global gene expression variability in the Waddell dataset,
whereas both the Larsen and Nagel datasets showed an increase in global gene
expression variability in BRCA2-associated tumours (Figure 3.8, Table3.2). The
Nagel dataset displayed the greatest increase in gene expression variability for
BRCA2-associated tumours (26.39%, 95% CI 25.9-26.9). However, due to the
few BRCA2 samples (n=6), interpretation should made cautiously as variability
is likely over-inflated with small sample sizes (Supplementary Figure D.5). In
the Larsen dataset there was a 11.1% (95% CI 10.6-11.6) and 11.6% (95% CI 10.7-
11.7) increase in gene expression variability compared to BRCAx and sporadic
breast tumours, respectively.
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FIGURE 3.8: Expression probe statistics for BRCA2-associated tumours (x-axis) com-
pared to BRCAx or sporadic breast tumours (y-axis) in three datasets: Waddell (first
column), Nagel (second column) and Larsen (third and fourth columns). Mean expres-
sion of each probe (first row) between BRCA2 and BRCAx or sporadic tumours are
similar with little deviation from the line of equity (red). Statistics used to measure
probe variability, SD (second row), CV (third row) and MAD (third row), have little
agreement between studies. Fitting a polynomial regression (orange) and a linear re-
gression (blue, dashed) shows a shift towards the BRCA2-associated tumours in the
Nagel dataset, but little/no change in the Larsen and Waddell datasets.
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3.4.4.1 Pathway Enrichment of BRCA2-Associated Gene Expression Vari-
ability
GSEA analysis was performed on SDR ranked genes between BRCA2-associated
and either BRCAx (Figure 3.9A-C) or sporadic breast tumours (Figure 3.9D). In-
terestingly, ten pathways were significantly enriched in the Nagel datatset (Sup-
plementary Figure 3.9). However, the Nagel dataset had unequal populations
with only six BRCA2-associated tumours compared to 76 BRCAx tumours. Al-
though over-inflation of SDRs likely arose (Supplementary Figure D.5), GSEA
utilises genes ranks and therefore the robustness of gene rank order is essen-
tial. SDs derived from six individuals would be vulnerable to inflation by any
outlier consequently altering the SDR ranks and making GSEA of the Nagel
dataset unreliable. GSEA of the Wadell and Larsen datasets only identified
significant enrichment of genes involved in the interferon-α response pathway
(Figure 3.9A). Genes associated with BRCA2 varaibility when compared to spo-
radic tumours, were involved in MYC targets, unfolded protein response and
myogenesis pathways (Figure 3.9D).
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Pathway NES p p.adj
unfolded protein response 1.26 5.14E-02 3.56E-01
myogenesis 1.19 5.36E-02 3.56E-01
oxidative phosphorylation 1.20 5.69E-02 3.56E-01
MYC targets v1 1.17 7.91E-02 4.40E-01
MYC targets v2 0.74 9.36E-01 1.00E+00
interferon alpha response 0.66 9.95E-01 1.00E+00
WNT beta catenin signalling -1.18 2.44E-01 8.74E-01
angiogenesis -1.22 2.06E-01 8.58E-01
E2F targets -1.14 2.02E-01 8.58E-01
androgen response -1.34 4.86E-02 3.56E-01
apical junction -1.30 3.24E-02 3.56E-01
pancreas beta cells -1.60 1.06E-02 1.77E-01
spermatogenesis -1.49 3.20E-03 8.01E-02





Pathway NES p p.adj
interferon alpha response 2.16 7.61E-04 3.81E-02
interferon gamma response 1.28 2.38E-02 2.97E-01
hedgehog signalling 1.37 7.65E-02 6.31E-01
pancreas beta cells 1.31 1.06E-01 6.31E-01
MYC targets v2 0.91 6.25E-01 8.22E-01
cholesterol homeostasis 0.90 6.97E-01 8.51E-01
angiogenesis 0.76 8.60E-01 9.47E-01
KRAS signalling dn -1.13 2.25E-01 7.35E-01
androgen response -1.20 1.75E-01 7.27E-01
peroxisome -1.25 1.18E-01 6.31E-01
apical junction -1.22 1.12E-01 6.31E-01
wnt beta catenin signaling -1.32 1.08E-01 6.31E-01
PI3K AKT mTOR signalling -1.44 1.87E-02 2.97E-01
oxidative phosphorylation -1.46 5.95E-03 1.49E-01
Pathway NES p p.adj
interferon gamma response -1.31 4.90E-03 2.45E-02
androgen response -1.44 3.21E-03 1.78E-02
KRAS signalling up -1.34 2.70E-03 1.69E-02
TGF beta signalling -1.56 2.33E-03 1.67E-02
apical junction -1.36 1.60E-03 1.33E-02
IL6 JAK STAT3 signalling -1.48 1.30E-03 1.30E-02
TNFa signalling via NF-kB -1.42 4.00E-04 5.00E-03
allograft rejection -1.55 1.00E-04 1.67E-03
IL2 STAT5 signalling -1.46 1.00E-04 1.67E-03
inflammatory response -1.50 1.00E-04 1.67E-03
Pathway NES p p.adj
MYC targets v1 1.52 5.30E-03 8.20E-02
unfolded protein response 1.45 5.60E-03 8.20E-02
myogenesis 2.02 6.50E-03 8.20E-02
oxidative phoshorylation 1.13 1.20E-01 1.00E+00
interferon alpha response 1.01 4.80E-01 1.00E+00
reactive oxygen species 
pathway 0.87 7.30E-01 1.00E+00
G2M checkpoint -1.16 1.70E-01 7.10E-01
E2F targets -1.17 1.50E-01 7.10E-01
KRAS signalling up -1.2 1.10E-01 6.60E-01
coagulation -1.28 7.10E-02 5.00E-01
pancreas beta cells -1.39 6.70E-02 5.00E-01
bile acid metabolsim -1.33 5.20E-02 5.00E-01
spermatogenesis -1.5 3.80E-03 8.20E-02
FIGURE 3.9: GSEA analysis on BRCA2-associated gene ranks for the Waddell (A),
Nagel (B) and Larsen (C,D) datasets. Gene ranks for the Larsen dataset were gener-
ated by comparing BRCA2-associated tumours to BRCAx (C) or sporadic tumours (D).
Pathways with gene ranks, NES and significance for the top ranked pathways (Left).
Running enrichment score (green line), gene rank positions (black lines) and pathway
ranking metric for each datasets most significant pathway (right). GSEA analysis was
performed with fgsea on the Hallmarks annotations from MSigDB, plots were gener-
ated by DOSE in R.
Chapter 3. Gene expression variability in breast cancers 106
3.4.4.2 Genes Variably Expressed in BRCA2-Associated Breast Tumours
Fifteen genes and one gene (TEX19) were differentially variable between BRCA2-
associated and BRCAx breast tumours in the Nagel and Larsen datasets, re-
spectively. A further gene (IL19) was differentially variable between BRCA2-
associated and sporadic breast tumours. Neither TEX19 nor IL19 were found
to be variable in the Nagel dataset. Similar to the analysis of BRCA1-associated
tumours, no gene was variably expressed between BRCA2-associated and BR-
CAx tumours in the Waddell dataset. Due to the small number, pathway over-
representation analysis could not be performed on BRCA2-associated variable
genes.
3.4.5 Evaluation of BRCA1-Associated Candidate Genes
To identify gene(s) that reflect a possible BRCA1-associated tumours pheno-
type, the top 1.5% most variable genes from the genotype and subtype specific
analyses were compared (Figure 3.10). Twelve genes were in the top 1.5% most
variable genes for all datasets comparing BRCA1-associated to BRCAx or spo-
radic breast tumours. Furthermore, 24 genes were in the top 1.5% most variable
genes for all dataset comparing basal-like to non-basal tumours. Three genes
(DSC3, EN1 and IGF2BP3) intersected both the subtype and genotype analyses
(Figure 3.10A,B). For RNA ISH, a single candidate gene was selected due to
cost of probe design. Therefore, public gene expression datasets and the bio-
logical context were evaluated for each candidate gene. Previous experiences
with RNAscope® had highlighted difficulties in quantifying poorly expressed
genes. Therefore, the GTEx (www.gtexportal.org) dataset and METABRIC (Ac-
cessed through www.cbioportal.org) were used to quantify gene expression in
normal and breast tumour tissue, respectively. EN1 was selected for further
analysis using RNA ISH based on the following rationales: Firstly, EN1 was
well expressed in normal breast, whereby mean expression was in the 57th per-
centile amongst genes expressed in breast tissue from the GTEx dataset (Figure
3.10C). Secondly, The METABRIC dataset independently observed a significant
increase in EN1 expression variability in both ER negative (p = 2.2x10−106)
and basal-like breast tumours (p = 3.7x10−146, Figure 3.10D,E). Thirdly, EN1
expression variability was independent of gene dosage (Supplementary Fig-
ure D.8). Excluding EN1 copy number amplification, which included only 4
samples, SDs for each gene dosage were within 0.7 SDs of the entire tumour
cohort. Fourthly, EN1expression had been observed as increased in basal-like
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breast tumours (Beltran et al., 2014). Additionally, Figure 1a of Beltran and col-
leagues paper, presented boxplots of EN1 expression stratified by breast tumour
subtypes, where basal-like tumour displayed greater variability, although not
tested, compared to other subtypes (Beltran et al., 2014).
Similar to EN1, IGF2BP3 had increased expression variability in ER negative
(p = 2.9x10−87) and basal-like breast tumours (p = 5.5x10−80, Figure 3.10D,E),
and IGF2BP3 expression variability was independent of gene dosage (Supple-
mentary Figure D.8). Furthermore, IGF2BP3 and encoded protein (IMP3) have
previously been observed to be expressed in basal-like and ER negative tu-
mours (Walter et al., 2009; Won et al., 2013; Su et al., 2014). However, IGF2BP3
was lowly expressed in breast tissue, with expression levels in the 13th per-
centile. In contrast, DSC3 was well expressed with mean expression in the 65th
percentile amongst genes expressed in normal breast tissue. However, DSC3
has been reported to be down-regulated in breast, prostate and colorectal can-
cers as well as breast cancer cell lines (Klus et al., 2001; Oshiro et al., 2005; Cui
et al., 2011; Pan et al., 2014). Furthermore, there was no expression data for
DSC3 in the METABRIC dataset.
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3 219
BRCA1 carriers vs control
Waddell (n=19 vs n=25)
Nagel (n=47 vs n=76)
Larsen - (n=33 vs n=70)a
- (n=33 vs n=128)b
Basal vs non-basal
Waddell (n=25 vs n=49)
Nagel (n=54 vs n=75)
Larsen (n=41 vs n=212) 
Meta-cohort (n=490 vs n=1,626)




DSC3 1.9x10-4 4.0x10-4 5.4x10-5 6.9x10-5
EN1 3.6x10-3 5.5x10-4 1.6x10-8 4.3x10-6
IGF2BP3 1.8x10-2 5.0x10-7 4.1x10-5 6.9x10-5
A
B
BRCA1-associated differential expression variability (p)
C
D
p = 2.89x10-87p = 2.19x10-106
p = 3.7x10-146 p =  5.5x10-80




















FIGURE 3.10: Rationale for candidate gene(s) selection for BRCA1-associated tumour
phenotype. A) Intersection between the consensus BRCA1-associated variable genes
(green) and basal-like associated variable genes (orange). B) Significances of differ-
ential variability genes that intersected both analyses from A. C) Gene expression (Z-
scores, calculated across all samples) of candidate genes (B) in normal breast epithe-
lium. D) EN1 (left) and IGF2BP3 (right) expression represented as Z-scores in the
METABRIC dataset stratified by intrinsic subtype. p-values were calculated by the
Brown-Forsythe test comparing basal-like tumours to all others. E) Correlation of EN1
(left) and IGF2BP3 with ESR1 expression and ER status (insert). All p-values were esti-
mated using the Brown-Forsythe test. Each samples is represented as a dot.
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3.4.6 EN1 in situ RNA Hybridsation in Breast Tumours
Breast tumours from 503 patients were acquired from Kathleen Cunningham
for Research into Familial Breast Cancer (KConFab) across seven tissue microar-
rays (TMAs, Table 3.5). These included 151 BRCA1-associated and 124 BRCA2-
associated breast tumours.
TABLE 3.5: Clinicopathological data for tumours
TMA8 TMA9 TMA10 TMA11 TMA12 TMA16 TMA17
Sample 60 60 60 57 24 121 121
BRCA pathogenic variants
– BRCA1 60 - 60 - 24 4 3
– BRCA2 - 60 - 57 - 3 4
ER status
– Positive 12 30 7 25 1 60 51
– Negative 34 7 34 11 10 19 23
– Unknown 14 23 19 21 13 42 47
PR status
– Positive 11 25 8 23 2 56 43
– Negative 34 23 30 10 4 18 20
– Unknown 15 12 22 24 18 47 58
HER2
– Positive 4 5 3 4 1 7 13
– Negative 19 12 14 3 1 14 20
– Unknown 37 43 43 50 22 100 88
CK5
– Positive 31 8 27 5 13 10 8
– Negative 25 48 26 41 9 94 88
– Unknown 4 4 7 11 2 17 25
Chapter 3. Gene expression variability in breast cancers 110
Each tumour core was assessed for RNA quality and specificity by measur-
ing the abundantly expressed gene PPIB and a negative control targeting the
bacterial gene dapB. Tumours stained for PPIB mRNA were scored based on
the number of signals (mRNA molecules) per cells (Table 2.12). Tumour cores
with a score of greater than 2 (>4 RNA molecule signals per cell, Figure 3.11C)
and lacking signal for dapB mRNA were considered to have high quality RNA.
No PPIB signal was detected for tumours on TMA9 and TMA16 and therefore
these were excluded from further analysis. Tumours from the remaining five
arrays ranged in abundance of PPIB (Figure 3.11G). Two-hundred-and-thirteen
tumours had positive PPIB mRNA signals with 141/213 tumours being scored
2 or greater for PPIB staining. No tumours had any positive dapB expression
detected.






FIGURE 3.11: Representative images of breast tumours scored 0 (A), 0.5 (B), 1 (C), 2
(D), 3 (E) and 4 (F) for PPIB. G) Percentage of cores assigned to each score for each of
the tissue microarrays with positive cores. Unknown cores were those with insufficient
epithelial or tumour tissue to determine positive signals.
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To estimate EN1 mRNA expression variability between tumour groups, slides
were scanned with the Aperio Scanner and RNA abundance was quantified
with the Aperio RNA ISH Algorithm. The percentage of cells with a posi-
tive signal for EN1 mRNA was determined for each tumour. Similar to the
tumour microarray analysis (Section 3.4.1), RNA in situ hybridisation captured
an increase in EN1 expression variability in BRCA1-associated breast tumours
(p = 6.3x10−04, Figure 3.12). The outputs generated from the Aperio RNA ISH
Algorithm did not have the ability to estimate inter-tumoural variability.
A
B
BRCA1-associated tumour BRCA2-associated tumour BRCAx-associated tumour
FIGURE 3.12: EN1 RNAscope® of breast tumour cores. A) Representative images of
BRCA1, BRCA2 and non-BRCA1/2 associated breast tumours stained for EN1. B)
Percentage of EN1 positive tumour cells in each familial tumour type. A significant
difference (Brown-Forsythe test) in EN1 expression variability was observed between
BRCA1-associated and BRCAx tumours.
3.5 Discussion
BRCA1-associated and basal-like breast tumours exhibited increased global gene
expression variability compared to BRCAx and non-basal tumours, respectively
(Figure 3.1, 3.5). These trends were captured across all datasets and with three
commonly used metrics of variability (SD, CV and MAD, Table 3.2). In contrast,
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no change in mean global gene expression was observed between tumour sub-
type or genotypes (Figure 3.1, 3.5). The CV has previously been used for similar
studies as it allows the comparison of variability amongst gene expression lev-
els (Bahar et al., 2006; Yu et al., 2008; Li et al., 2010; Ecker et al., 2015). However,
as the CV is a ratio of the SD and mean, it is prone to over-inflation of lowly ex-
pressed genes. Furthermore, the SD has been described as more dependent on
the mean expression level compared to the CV, although this was not observed
in our analysis (Hasegawa et al., 2015; Bueno and Mar, 2017) (Supplementary
Figure D.9).
Transcriptome variability has been used to described diseases and phenotypes
in humans (Cheung et al., 2003; Bahar et al., 2006; Yu et al., 2008; Ecker et al.,
2015; Bueno and Mar, 2017; Zhang et al., 2015). Gene expression variability be-
tween healthy individuals is likely driven by genetic polymorphisms (Cheung
et al., 2003; Wang et al., 2014). Germline BRCA1 pathogenic variants may alter
gene expression variability through both direct (e.g. transcriptional regulation)
and indirect (e.g. impaired DNA repair) functions. Interestingly, tumours that
have acquired somatic variations, have similarly global gene expression vari-
ability compared to normal tissue (Yu et al., 2008). Therefore, BRCA1-associated
breast tumour gene expression variability may reflect the expression variabil-
ity state of non-diseased tissue. Conversely, BRCA1-associated breast tumour
gene expression variability may arise through an increase in sub-clonal pop-
ulations and increased genomic instability attributed to BRCA1-associated tu-
mours (Kwei et al., 2010). Furthermore, basal-like and BRCA1-associated tu-
mours are often more aggressive (Yehiely et al., 2006). In leukaemia, tumour
gene expression variability correlated with tumour aggressiveness (Ecker et al.,
2015).
In contrast to BRCA2-associated breast tumours (Figure 3.8), BRCA2-associated
ovarian tumours exhibited greater variability of genes involved in BRCA2 re-
lated pathways (Bueno and Mar, 2017). Furthermore, Bueno and Mar identified
potential BRCA2 synthetic lethal interactions by identifying genes associated
with low variability in BRCA2-associated tumours.
Genes variably expressed associated with BRCA1 pathogenic variants were en-
riched for BRCA1 and EN1 related pathways (Figure 3.2). EN1, which encodes
the transcription factor Engrailed Homeobox 1 (EN1), was observed to be more
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variable in BRCA1 and basal-like tumours (Figure 3.10B). EN1 is essential for
embryonic development and important in neurological development, where
EN1 expression is dependent on WNT signalling and vice versa (McMahon et
al., 1992; Alves dos Santos and Smidt, 2011). Additionally, Peluffo and col-
leagues identified genes involved in WNT signalling pathways that were sig-
nificantly altered after EN1 knock-down in a panel of basal-like breast cancer
cell lines (Peluffo et al., 2019). EN1 has been consistently observed to be over-
expressed in basal-like and triple-negative breast tumours (Beltran et al., 2014;
Kim et al., 2018; Peluffo et al., 2019). Tumours with high EN1 expression have
poorer overall survival and greater probability of brain metastases (Beltran et
al., 2014; Kim et al., 2018; Peluffo et al., 2019). The interpretation of IHC staining
of EN1 was more complex. Kim et al., reported poorer survival outcomes asso-
ciated with basal-like and triple negative breast tumours that were negative for
cytoplasmic EN1. However, no difference was observed in tumours based on
EN1 nuclear staining. Further complexity was observed in TNBCs that were de-
void of either CK5/6 or EGFR basal markers (termed quintuple-negative breast
cancers), as quintuple-negative breast cancers positive for EN1 expression had
poorer survival outcomes. These conclusions were based on a small number
of cytoplasmic negative EN1 tumours with 16, 11, and 5 TNBCs, basal-like and
quintuple-negative breast cancers, respectively (Kim et al., 2018). Furthermore,
high levels of EN1 expression in tumour tissues was associated with poorer out-
comes, which was in contrast to IHC results but in agreement with other studies
(Beltran et al., 2014; Peluffo et al., 2019). RNAscope® analysis of 500 breast tu-
mours performed in this study showed further evidence for BRCA1-associated
EN1 expression variability. Additionally, EN1 expression was up-regulated in
BRCA1-associated tumours. The lack of patient outcome data prevented an
analysis of EN1 expression levels with survival outcome. Furthermore, the Le-
cia RNA ISH algorithm used was unable to attribute signals to individual cells
and therefore intratumoral variability could not be assessed.
3.6 Conclusion
Gene expression variability was increased in BRCA1-associated, but not BRCA2-
associated breast tumours. Additionally, three genes were identified that were
variably expressed in BRCA1-associated and basal-like breast tumours. RNA
ISH analysis of EN1 in breast tumours cores replicated the gene expression
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variability observed in the microarray datasets. Furthermore, pathway anal-
ysis revealed pathways related to BRCA1 and EN1 functions that were variable
in BRCA1-associated and basal-like tumours.
Chapter 4
In Vitro Gene Expression Variability
4.1 Introduction
Results from Chapter 3 demonstrated that BRCA1-associated breast tumours
had greater global gene expression variability compared to sporadic and BR-
CAx breast tumours (Figure 3.1). In addition, basal-like breast tumours, which
are enriched for BRCA1-associated tumours, also had greater global gene ex-
pression variability compared to all other subtypes (Figure 3.5). A total of 12
BRCA1-associated and 24 basal-like associated genes were identified as differ-
entially variable. To replicate these results in vitro, two cell models were estab-
lished.
4.1.1 Human Breast Cell Lines
To investigate the effects of reduced BRCA1 expression levels and a loss of func-
tion BRCA1 variant, two breast cell lines were used. Firstly, the pre-malignant
MCF-10A breast cell line was purchased from Horizon Discovery Ltd (Cam-
bridge, UK), along with an isogenic MCF-10A cell line that contained a mono-
allelic BRCA1 185delAG (BRCA1 c.68_69del) mutation (MCF-10A BRCA1mut/+).
The MCF-10A cell line is an immortal breast epithelial cell line derived from
non-tumourgenic tissue (Soule et al., 1990). To study the effects of pathogenic
BRCA1 variants, Konishi et al., established an isogenic MCF-10A cell line har-
bouring a heterozygous BRCA1 185 delAG mutation (Konishi et al., 2011). The
introduction of the BRCA1 185 delAG mutation led to impaired DNA damage
response and increased the sensitivity of MCF-10A cells to cytotoxic damage
from doxorubicin or γ-irradiation (Konishi et al., 2011; Savage et al., 2014). The
isogenic MCF-10A and MCF-10A BRCA1mut/+ cell lines have been used to ex-
plore response to oestrogen, chromatin looping and metabolism (Savage et al.,
2014; Cuyàs et al., 2016; Zhang et al., 2019).
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Secondly, the MCF-7 breast cancer cell line was used to explore reduced BRCA1
expression in a human breast cancer model. MCF-7 cells were derived from
a breast tumour metastasis in the pleural fusion of a 69-year-old Caucasian
women (Soule et al., 1973; Lee et al., 2015). The generation of the MCF-7 cell line
involved a heterogeneous populations of tumour epithelium. Early isolates had
a large range of chromosome numbers (70-144). Long term culture reduced the
range of chromosome number to 77-99 chromosomes (Soule et al., 1973). The
range has remained relatively stable with the current ATCC (www.atcc.org, ac-
cessed Jan 2020) batch reporting a range of 66-87 chromosomes 50 years after
the original culture .
4.2 Study Design
To capture variability in cell line models, RNA was extracted from two experi-
mental models in the MCF-10A and MCF-7 cell lines, respectively (Figure 4.1).
Firstly, 5 replicates of MCF-10A and MCF-10A BRCA1mut/+ were independently
expanded under normal growth conditions after which RNA was harvested.
Secondly, 5 replicates of MCF-7 breast cancer cells were treated with either a
siRNA that targeted BRCA1 or a negative siRNA that was not complementary
to any human RNAs. Forty-eight hours post transfection RNA was harvested
(Figure 4.1).
High quality RNA (RIN > 9.0) was sent to Auckland Genomics (University
of Auckland, NZ) for whole-transcriptome analysis on the ClariomTM D ar-
ray (ThermoFisher Scientific, USA) for quantification. The ClariomTM array has
greater than 6.75 million probes that target approximately 134,000 RefSeq genes.
Raw probe intensity values were obtained and normalised by the RMA method
(Irizarry et al., 2003). The Brown-Forsythe method (Brown and Forsythe, 1974)
to test for the equality of variance was used, as per Chapter 3, to identify genes
statistically variable between experimental conditions (Section 2.5.1.1).
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FIGURE 4.1: Schematic of experimental design to capture in vitro gene expression vari-
ability in MCF-7 and MCF-10A cell lines.
4.3 Results
4.3.1 Transfection of MCF-7 with Different Concentrations of
siRNA
To mimic heterozygous BRCA1 pathogenic variant carriers, a range of siRNA
concentrations were used to knock-down 50% of BRCA1 expression as mea-
sured by RT-qPCR (Section 2.11.1.1). To optimise transfection conditions, MCF-
7 cells were treated with a range of BRCA1 siRNA concentrations (10 nM, 20
nM, 40 nM and 80 nM) for 48 hours. Interestingly, all concentrations of siRNA
tested achieved an approximately 50% reduction of BRCA1 gene expression
(Figure 4.2). Furthermore, visual inspection of transfected cells showed no ob-
servable difference in cell death or morphology compared to untreated cells.
For the remainder of knock-down experiments the lowest concentration that
achieved 50% reduction in BRCA1 expression (10 nM) was used.
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FIGURE 4.2: BRCA1 expression in MCF-7 cells after transfection of siRNA targeting
BRCA1. BRCA1 expression was measured by RT-qPCR post transfection and nor-
malised to siRNA negative control (siRNA Ctrl). MCF-7 cells grown with no trans-
fection media and with transfection reagent only were also quantified. Four concen-
trations (10 nM, 20 nM, 40 nM and 80 nM) of siRNA were tested. A 50% reduction
(red dashed line) of BRCA1 expression was was achieved by all siRNA concentrations.
Error bars represent +/- S.E.M of triplicate experiments.
4.3.2 RNA Quality Control
RNA extracted from both MCF-7 and MCF-10A cell lines was assessed for qual-
ity on the TapeStation (Agilent, USA) by comparing the abundance of riboso-
mal RNA (28S and 18S). RNA from all conditions and cell lines was of high
quality with a mean RIN of 9.88 (range 9.6-10, Figure 4.3).
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FIGURE 4.3: Representative gel electrophoresis (left) performed on the Aligent TapeS-
tation system. The first lane represents the ladder, the subsequent 15 are RNA from
cell lines. The RIN values for respective samples are below and range from 9.6-10. The
intensity trace of one sample is depicted on the right, highlighted are the two rRNA
18S and 28S and a marker RNA loaded into the sample.
4.3.2.1 BRCA1 Expression
To validate BRCA1 knock-down by siRNA, BRCA1 expression was quantified
by RT-qPCR and subsequently confirmed with microarray analysis (Figure 4.4).
BRCA1 expression was reduced by greater than 50% (2-fold) in all samples
treated with siRNA targeting BRCA1. BRCA1 expression was reduced 3.6-fold
(p = 1.5x10−3, 95% CI 2.6-4.5) and 5.0-fold (p = 1.8x10−8, 95% CI 3.7-6.8) as mea-
sured by RT-qPCR and microarray analysis, respectively.
The introduction of a mono-allelic BRCA1 del185AG variant in the MCF-10A
cell line, led to a modest 1.4-fold (p = 7.9x10−8, 95% CI 1.2-1.7) decrease in
BRCA1 expression (Figure 4.4). A similar difference in BRCA1 expression was
observed between MCF-7 and MCF-10A cell lines, where the MCF-10A cells
exhibited 2.5- fold (p = 2.5x10−4, 95% CI 1.5-4.3 ) greater BRCA1 expression.
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FIGURE 4.4: BRCA1 expression quantified by microarray analysis (left) and RT-qPCR
(right). siRNA targeting BRCA1 in five independent replicates successfully reduced the
BRCA1 abundance. RT-qPCR (right) results are normalised mean BRCA1 expression
levels +/- normalised Cp error ratios, n=1. KD, knock-down.
4.3.3 Global Gene Expression Variability in BRCA1 in vitro Mod-
els
To measure changes in global gene expression variability, SDRs were calcu-
lated within each cell type (e.g. sdMut/sdWT ), whereby SDR=1 represents no
difference. Although the SDR is vulnerable to inflation at low sample size, the
relative size of the inflation compared to the linear model is smaller (Supple-
mentary Figure D.5). In contrast to global gene expression analysis of BRCA1-
associated tumours (Chapter 3), there was a decrease (SDR = 0.87) in global
gene expression variability associated with BRCA1 mutations in the MCF-10A
cell line. Knock-down of BRCA1 in MCF-7 cells had little effect (SDR = 1.04)
on global gene expression variability.
4.3.3.1 Variably Expressed Genes in BRCA1 in vitro Models
Gene expression variability was estimated within cell types (e.g. MCF-7 or
MCF-10A) that had either a BRCA1 mutation or BRCA1 expression was knocked-
down. A total of 858 and 1333 genes showed (unadjusted p < 0.05) gene ex-
pression variability associated with BRCA1 status in the MCF-7 and MCF-10A
cell models, respectively. However, no gene was significantly variable after
adjusting for multiple testing in either cell line. Furthermore, only 38 genes
were suggestive of BRCA1-associated variability in both cell lines. The size
of the intersect between cell lines is expected by chance (hypergeometric test,
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p = 0.88). Pathway analysis of the 38 intersecting genes displayed an enrich-
ment for several pathways involved in mRNA processes (Figure 4.5). Individ-
ually, the MCF-10A cell models indicated an over-representation of genes in-
volved in RNA metabolism and cell cycle processes. For the MCF-7 cell line
model, genes were enriched for pathways involved in regulation of cell prolif-
eration and differentiation (Figure 4.5).
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FIGURE 4.5: The top eight biological pathways over-represented from genes variable
in both MCF-7 and MCF-10A BRCA1 cells models (A) and in either MCF-7 cell models
(B) or MCF10-A (C) models alone. Pathways were identified from biological pathway
annotations from GO terminology. Bar length represent the number of genes variable in
each pathway and are coloured based on significance of over-representation. Pathway
analysis was performed using the R package DOSE and clusterProfiler.
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4.3.3.2 Analysis of Genes Variably Expressed in Breast Tumours
In Chapter 3 three candidate genes (DSC3, EN1 and IGF2BP3) were identi-
fied that were variably expressed in basal-like and BRCA1-associated breast
tumours (Figure 3.10). None of the three candidate genes identified in tumour
analysis were significantly variable in the different BRCA1 cell line models (Ta-
ble 4.1, Figure 4.6). DSC3 (p = 4.5x10−17) and IGF2BP3 (p = 4.3x10−23) had sig-
nificantly greater expression in the ER negative MCF-10A cell lines compared
to the ER positive MCF-7 cell line. Similar to the analysis of the METABRIC
dataset in Chapter 3 (Figure 3.10), there was a negative correlation of ESR1
expression with IGF2BP3 expression across cell lines (r = −0.97, Figure 4.7).
Additionally, in vitro analysis identified a negative correlation between ESR1
expression with DSC3 expression (r = −0.98, Figure 4.7). No correlation was
observed between EN1 and ESR1. Furthermore, only one BRCA1-associated
gene (OPRK1, p = 0.038) from the tumour analysis (Section 3.4.1.2) was vari-
ably expressed in the BRCA1 cell line models (Table 4.1). Variable expression
of OPRK1 was not consistent between cell line models, with significant results
only found for the MCF-7 BRCA1 knock-down cell line. Analysis of the MCF-
10A cell models suggested equivocal variability (p = 0.18) between wild type
and BRCA1 mutated cells.
FIGURE 4.6: In vitro expression of candidate genes (DSC3, EN1 and IGF2BP3) from
tumour analysis in the MCF-7 and MCF-10A cell models. Boxplots represent the nor-
malised expression of five replicates measured by ClariomTM D microarray and are
plotted as the inter-quantile range, with the median marked as black line. The whiskers
extend +/- 1.5 times the inter-range or to the lowest point.
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TABLE 4.1: In vitro differential variability analysis of BRCA1-associated candidate
genes from tumour analysis
MCF-7 BRCA1-KD MCF-10A BRCA1mut/+ Tumour∗
W p W p W p
EN1 0.56 0.48 0.66 0.45 37.91 1.59x10−08
CT83 0.27 0.62 2.73 0.15 29.01 4.87x10−07
KLHL34 2.27 0.18 0.05 0.84 23.54 4.56x10−06
A2ML1 1.26 0.3 0.03 0.86 23.39 4.85x10−06
FBN3 0.01 0.93 0.8 0.4 22.94 5.86x10−06
IGF2BP3 1.45 0.27 0.85 0.39 18.46 4.06x10−05
DSC3 2.66 0.15 0.03 0.86 17.8 5.44x10−05
VGLL1 0.03 0.88 0.6 0.47 17.19 7.15x10−05
LMF1 0.15 0.72 0.01 0.91 16.88 8.21x10−05
SOX8 3.86 0.1 0.23 0.65 16.28 1.07x10−04
OPRK1 7.03 0.04 2.33 0.18 14.99 1.94x10−04
GFRA3 0.03 0.88 0.79 0.41 14.54 2.39x10−04
CYP39A1 0.85 0.39 0.01 0.91 13.86 3.28x10−04
HORMAD1 0 .001 0.97 5.87 0.05 13.78 3.40x10−04
∗Data from the analysis of BRCA1-associated tumours compared to BRCAx tu-
mours in Larsen dataset (Chapter 3)
W , Brown-forsythe test statisitic
FIGURE 4.7: Correlation between BRCA1-associated candidate genes (DSC3, EN1 and
IGF2BP3) identified from the analysis of breast tumours (Chapter 3) with ESR1 in the
MCF-7 and MCF-10A cell models.
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4.3.4 Cellular Subtyping in BRCA1 Cell Models
Intrinsic molecular subtypes were predicted for each cell lines using the PAM50
method (Parker et al., 2009). The MCF-10A and the isogenic MCF-10A BRCA1mut/+
cells were both predicted as basal-like. Similarly, the knock-down of BRCA1 ex-
pression in MCF-7 cells after 48 hours had no effect on subtype predictions.
All MCF-7 replicates were predicted as luminal A. To further investigate any
subtle changes in markers associated with basal or luminal tumours in MCF-7
cells after 48 hours of BRCA1 knock-down, the gene expression of nine basal
and luminal markers were explored (Figure 4.8). Interestingly, all five luminal
markers (ESR1, PGR, KRT18, KRT8 and KRT19) showed a trend towards de-
creased expression in MCF-7 cells after BRCA1 knock-down. However, only
the progesterone receptor (p = 0.005), cytokeratin 18 (p = 0.004) and cytoker-
atin 8 (p = 0.043) were significantly down-regulated (Figure 4.8). By compari-
son, two of the four basal markers showed increased expression in MCF-7 cells
after BRCA1 knock-down.
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FIGURE 4.8: The effect of BRCA1 knock-down on the expression of basal (Top) and lu-
minal (bottom) markers in MCF-7 cells . Boxplots represent the normalised expression
of five replicates measured by ClariomTM D microarrasy. Comparison of gene expres-
sion was performed by the Student T-test. ns: p > 0.05, *: p < 0.05, **: p < 0.01, ***: p <=
0.001, ****: p <= 0.0001
4.3.5 Differentially Variable Gene Expression Between Cell In-
trinsic Subtypes
To investigate genes variably expressed in cell line BRCA1 models, cells pre-
dicted as basal and luminal A were compared. A total of 665 genes were sig-
nificantly variable (adjusted p < 0.05) between cellular subtypes predicted
by PAM50. Pathway analysis of variably expressed genes identified between
basal-like and luminal cell lines showed that these genes were enriched in mRNA
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processes, including mRNA splicing (Figure 4.9). Furthermore, gene expres-
sion variability analysis between molecular subtypes in the tumour microar-
rays identified 190 genes significantly variable, 22 of which were variable be-
tween cells predicted as basal and luminal A (Table 4.2). These results suggest a
low level of agreement between genes variable in the tumour subtype analysis
(Section 3.4.3.2) and in vitro subtype analysis.
FIGURE 4.9: The top eight biological pathways over-represented from genes variable
between basal and luminal A cells. Pathways are identified from the biological path-
way annotations from GO terminology. x-axis and bar colours are the -log(10) p-value
(Hyper-geometric distribution).
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TABLE 4.2: In vitro differential variability analysis of basal candidate genes from tu-
mour analysis
in vitro Tumour∗
W p W p
UGT8 10.51 5.11x10−03 389.53 1.03x10−79
MSLN 13.30 2.17x10−03 299.12 8.82x10−63
GFRA1 4.56 4.86x10−02 258.48 5.87x10−55
WWTR1 6.28 2.34x10−02 213.94 3.20x10−46
GJB3 4.52 4.95x10−02 198.81 3.26x10−43
PLOD3 5.77 2.88x10−02 182.71 5.43x10−40
CHRM3 6.77 1.92x10−02 172.44 6.35x10−38
ADCY1 6.09 2.53x10−02 171.65 9.20x10−38
CAPN6 23.37 1.83x10−04 168.20 4.57x10−37
DSG3 7.97 1.22x10−02 167.24 7.16x10−37
NOVA1 28.03 7.27x10−05 162.01 8.21x10−36
CCL20 39.70 1.05x10−05 135.81 1.84x10−30
MAMLD1 6.25 2.37x10−02 122.78 8.94x10−28
TSPAN1 105.74 1.86x1008 118.82 5.90x10−27
SLC6A15 7.41 1.51x10−02 116.82 1.53x10−26
TFF1 38.39 1.28x10−05 113.82 6.44x10−26
ODAM 5.67 3.00x10−02 112.20 1.40x10−25
NUDT11 54.40 1.57x1006 98.22 1.16x10−22
PCP4 8.69 9.44x10−03 82.63 2.22x10−19
FAIM 30.72 4.46x10−05 52.79 5.21x10−13
KRT9 4.67 4.61x10−02 43.64 4.98x10−11
HR 9.11 8.16x10−03 25.43 4.99x10−07
∗Data from the analysis of basal-like tumours compared to non-basal tumours in
Meta-cohort dataset (Chapter 3)
W , Brown-forsythe test statisitic
4.4 Discussion
Two in vitro models demonstrating the potential effects of BRCA1 pathogenic
variants were established in breast cell lines (MCF-7 and MCF-10A) to measure
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BRCA1-associated gene expression variability. In MCF-7 cells, BRCA1 knock-
down was optimised to mimic heterozygous BRCA1 pathogenic variants car-
riers, correlating mutation burden and expression (e.g. 50% of the alleles mu-
tated correlating to 50% reduced expression). Genes variably expressed by both
cell line models were over-represented in BRCA1 related pathways including
cell cycle control, RNA processes and interactions with protein kinase B (AKT)
(Fabbro et al., 2004; Bae et al., 2005; Xiang et al., 2008; Baek et al., 2018). The
introduction of a BRCA1 pathogenic variant in the MCF-10A cell line led to a
greater number of variably expressed genes compared to the MCF-7 BRCA1
knock-down models, including genes involved in cell cycle regulation (Figure
4.5C). The variability of these genes suggests that MCF-10A BRCA1mut/+ cells
exhibited a varied response to the regulation of these pathways. It is plausi-
ble that accumulation of DNA damage may be heterogeneous amongst MCF-
10A BRCA1mut/+ cells and cells are appropriately stalled at respective cell cycle
checkpoints. Equally, the cell cycle checkpoint response could be impaired in
a sub-population of cells, as BRCA1 has functions in both DNA repair and cell
cycle control (Scully et al., 1997; Xu et al., 2001; Yu and Chen, 2004; Fabbro et al.,
2004).
Pathway analysis also identified non-sense mediated decay (NMD) in the MCF-
10A cell line model (Figure 4.5C). The pathogenic variant BRCA1 c.68_89del
introduces a 2 bp frameshift and leads to a premature stop codon (Buisson
et al., 2006). Consistent with observations that truncated BRCA1 transcripts
are known to undergo NMD (Buisson et al., 2006; Chen et al., 2008), variable
gene expression analysis indicates that NMD may be occurring in cells carrying
pathogenic variants. However, unlike other BRCA1 truncating variants, there
is no evidence of allelic imbalance or NMD for the BRCA1 c.68_69del variant
(Perrin-Vidoz, 2002), despite decreased BRCA1 expression in blood tissue and
breast cancer cell lines (Elstrodt et al., 2006; Chehade et al., 2016). Instead of
undergoing NMD, it has been proposed that re-initiation of translation occurs,
whereby a downstream methionine acts as a new start codon, effectively sub-
verting the frameshift variant (Buisson et al., 2006; Drost et al., 2016). In mice,
a truncated functional Brca1-RING domain-less protein is produced which is
essential for tumour development and Brca1 function (Drost et al., 2016). Simi-
larly, in the human BRCA1 c.68_89del mutant SUM1315MO2 cell line truncated
protein is expressed, however, compared to the mouse model the protein trun-
cation is more severe (Elstrodt et al., 2006; Drost et al., 2016). It is unclear
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whether the truncated BRCA1 protein generated from the BRCA1 c.68_89del
variant still exhibits function or whether the truncated protein is produced in
human tissues. The enrichment of variable genes involved in NMD suggests
a difference in requirements for NMD activity in MCF-10A BRCA1mut/+ cells.
These differences in requirements may arise due to the increased DNA dam-
age and genomic instability observed in MCF-10A BRCA1mut/+ cells (Savage
et al., 2014). These cells may acquire somatic truncating mutations through-
out the transcriptome that, once transcribed, are degraded through NMD. The
somatic mutation profile is likely cell or sub-clone specific, generating cell pop-
ulations with differential requirements for NMD. Additionally, the difference in
NMD activity may be a direct result of transcription of the BRCA1 variant allele,
whereby higher levels of expression result in transcripts either being degraded
(through NMD) or retained (through initiation at down-stream methionine).
By comparison, only subtle changes were observed in gene expression vari-
ability in MCF-7 cells after BRCA1 knock-down (Figure 4.5). However, path-
way analysis was consistent with previous BRCA1 deficient cell models, where
genes involved in the AKT signalling pathway have been associated with re-
duced BRCA1 expression (Xiang et al., 2008; Baek et al., 2018). BRCA1 is a
negative regulator of AKT and BRCA1 deficiency leads to the accumulation
of activated AKT and increased G1/S progression (Xiang et al., 2008; Baek et
al., 2018). Genes involved in cell cycle transitions were not enriched in MCF-7
cells, however, extended exposure of BRCA1 siRNA may have led to disruption
in these pathways. Analysis of basal and luminal markers showed a subtle shift
in MCF-7 subtype not detected by the PAM50 method (Figure 4.8). Increased
time of BRCA1 siRNA exposure may result in MCF-7 cells transiting to a basal-
like subtype.
The BRCA1 deficient breast cell line models failed to replicate BRCA1-associated
gene expression variability observed in breast tumours (Chapter 3). In partic-
ular, there was an absence of BRCA1-associated candidate genes (DSC3, EN1
and IGF2BP3) that were differentially variable between tumour type (Table 4.1).
Only OPRK1 displayed a trend of BRCA1-associated gene expression variabil-
ity (p = 0.04) in the MCF-7 cell model. In addition, in vitro analysis of basal-like
gene expression variability also lacked consistency with tumour analysis, with
Chapter 4. In Vitro Gene Expression Variability 132
only 12% (22/190 genes) suggestive of variability from the in vitro analysis (Ta-
ble 4.2). Furthermore, in contrast to tumour analysis, BRCA1-associated MCF-
10A cells exhibited less gene expression variability, and knock-down of BRCA1
had no effect on global variability in MCF-7 cells.
Despite the contrasting results between the analyses of cell lines and breast tu-
mours, in vitro models may still have potential when assessing the disruption
of particular variants. Furthermore, knock-down models may be further de-
veloped to assess prolonged exposure to decreased BRCA1 expression. The ob-
servations of decreased luminal and increased basal markers in MCF-7 BRCA1
knock-downs indicate a potential early transition towards a basal-like subtype
(Figure 4.8). Interestingly, only luminal markers were significantly different
compared to controls, suggesting that loss of luminal markers may be an ear-
lier events in basal-like BRCA1-associated tumours. Furthermore, the knock-
down of the WT allele in MCF-10A BRCA1mut/+ may generate expression pro-
files more similar to tumours, and additionally exploring gene expression vari-
ability in asymptomatic breast tissue may replicate observations from MCF-10A
models.
This study aimed to reduce BRCA1 expression to mimic a heterozygous protein
truncating variant, where the truncated mRNA is expected to undergo NMD
(Chen et al., 2006; Chehade et al., 2016). In contrast to this study, MCF-7 cells
have been extensively used as a model of BRCA1 loss using interfering RNAs
with the aim to maximise the reduction of BRCA1 expression with only consid-
erations for cytotoxicity (Bae et al., 2005; Chabalier et al., 2006; Promkan et al.,
2009; Gong et al., 2016; Baek et al., 2018; Koobotse et al., 2018). There are limita-
tions to the rationale used in this study, largely due to the assumption that re-
duced levels of BRCA1 underlies breast cancer risk and tumourigenesis. Several
protein truncating variants do not show allelic imbalance or decreased BRCA1
expression levels (Buisson et al., 2006; Findlay et al., 2018). Additionally, of
the 23 studies identified in this thesis that have investigated BRCA1-associated
gene expression signatures (Section 1.2.4), only two reported BRCA1 expression
to be correlated to pathogenic variant status (Jönsson et al., 2012; Zahavi et al.,
2018). Therefore, without further knowledge it was difficult to determine the
appropriate knock-down model to mimic a heterozygous pathogenic variant.
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Similarly, the pre-malignant BRCA1-pathogenic model was set up by the ex-
pansion of sub-clones of MCF-10A and MCF-10A BRCA1mut/+. To allow diver-
gence, and to capture different expression variability, sub-clones were cultured
independently in complete growth media for approximately 20 days. To my
knowledge, there is no evidence on the divergence of gene expression levels
within sub-clones nor methods to easily and cost effectively quantify gene ex-
pression changes. Therefore, it remains challenging to predict or optimise ex-
perimental conditions that allow gene expression variability to naturally arise.
Intriguingly, MCF-7 cells transfected with a range of BRCA1 siRNA concentra-
tions did not display a dose-dependent reduction in expression (Figure 4.2), nor
did any concentration exhibit noticeable cellular death. Additionally, BRCA1
expression was reduced by approximately 70% when performing knock-downs
on cells for microarray analysis (Figure 4.4), which was greater than all con-
centrations observed during optimisation experiments. Improvements in the
knock-down efficiency are unexplained, however, they may correlate with the
use of an earlier MCF-7 lineage, differences in RNA extraction or better sam-
ple handling. Knock-down efficiencies were optimised in MCF-7 at a later
passage compared to the knock-downs used for microarray analysis. In ad-
dition, two different RNA extraction methods were used. For the optimisation
of knock-down conditions, RNAGEM TissuePlus was used due to the low cost
and speed in isolating RNA. RNA extracted with RNAGEM TissuePlus is not
suitable for microarray or sequencing methods but was suitable for PCR based
experiments (e.g. RT-qPCR). For the microarray analysis, RNA was extracted
and purified using the Qiagen RNeasy kit. Importantly, both methods required
DNase treatment to degrade DNA and as the efficiency of DNA digestion is
unknown it is a potential source for the perceived differences in knock-down.
The pre-designed IDT qPCR assay for BRCA1 (Hs.PT.56a.27724517.g) did not
span exon-exon junctions and would potentially amplify DNA. To address this
issue future qPCR assays should be designed to span exon-exon junctions.
4.5 Conclusion
The reduction of BRCA1 expression in normal breast and breast cancer cell lines
led to subtle changes in gene expression profiles that resulted in genes involved
in AKT signalling being more variable. Additionally, gene expression profiles
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of basal and luminal markers were suggestive of a trend towards a basal-like
subtype. The MCF-10A BRCA1mut/+ cells exhibited gene expression variability
in genes involved in cell cycle transitions and NMD. The enrichment of genes
involved in NMD provides evidence of degradation of BRCA1 c.68_89del trun-
cated transcripts for the first time. The MCF-10A and MCF-7 BRCA1 models
were both unable to capture the observations of increased gene expression vari-
ability found in BRCA1-associated breast tumours (Chapter 3).
Chapter 5
Development of an In Vitro BRCA1
Model in MCF-7 Cells
5.1 Introduction
The results from the study of published gene expression data of familial breast
tumours (Chapter 3) showed that BRCA1-associated tumours had greater global
expression variability compared to BRCAx tumours. In addition, three genes
(EN1, DSC3 and IGF2BP3) were identified as differentially variable in BRCA1-
associated and basal-like breast tumours. In contrast, MCF-10A cells had greater
gene expression variability compared to an isogeneic MCF-10A BRCA1mut/+ cell
line (Section 4.3.3). Additionally, BRCA1 knock-down in MCF-7 breast cancer
cells had no effect on global gene expression variability. The discrepancy be-
tween gene expression variability results form analyses of tumours and cell
lines may be due to key differences between the sample types, such as biologi-
cal heterogeneity (e.g. tumour heterogeneity and cellularity) and small sample
size. In Chapter 4, results demonstrated that decreased BRCA1 expression in
MCF-7 cells was associated with decreased luminal and increased basal mark-
ers, suggesting that the cells may have begun a luminal to basal transition.
However, these changes resulted after 48 hours exposure to BRCA1 siRNA
and it is unclear what would have resulted from prolonged exposure to re-
duced BRCA1. MCF-7 cells have been shown to be able to transition towards a
basal-like phenotype under genetic disruption (Bernardo et al., 2013; Su et al.,
2015), including the overexpression of EN1 (Su et al., 2015), a BRCA1-associated
variable gene (Figure 3.10). In this study, stable MCF-7 BRCA1 knock-out cell
lines were developed using genome engineering to assess long-term exposure
to BRCA1 pathogenic mutations and to investigate the luminal-basal transition.
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5.1.1 CRISPR-Cas Genome Editing
CRISPR-Cas genome editing is derived from an adaptive immunity response
observed in bacteria (Barrangou et al., 2007; Barrangou and Marraffini, 2014).
The first step, adaptation, is the incorporation of invading genetic material into
a CRISPR array sequence within the bacterial genome. The CRISPR-array is
transcribed and processed to generate several CRISPR RNAs (crRNA) that bind
to specific foreign DNA targets and form a complex with Cas proteins. The
Cas-crRNA complexes are able to target foreign DNA and digest it using Cas
endonuclease activity.
Jinek et al., first described the utility of CRISPR-Cas as a tool to site-specifically
cleave DNA (Jinek et al., 2012). Importantly, Jinek et al., utilised a chimeric
guide RNA (gRNA) rather than the natural trans-activating (tracrRNA) and tar-
geting RNA (crRNA), simplifying experimental design. The utility of CRISPR-
Cas was highlighted by two studies which edited the genomes of several mam-
malian cell lines (Cong et al., 2013; Mali et al., 2013). Target sites for genome
editing are limited to the presence of a Cas specific protospacer adjacent motif
(PAM) immediately adjacent to the gRNA target sequence (Figure 5.1). The first
examples of CRISPR-Cas guided genome editing used Streptococcus pyogenes
Cas9 (spCas9), which recognises a NGG PAM sequence (Jinek et al., 2012; Cong
et al., 2013; Mali et al., 2013). Subsequently, Cas proteins that recognise other
PAM sequences have also been identified (Table 5.1), allowing the targeting of
virtually any genomic loci. Furthermore, Cas proteins have been modified to
generate variants that offer greater specificity (Jinek et al., 2012; Kleinstiver et
al., 2016). spCas9 D10A (also known as Cas9 nickase) is engineered so that one
nuclease domain is inactivated, providing increased specificity by the require-
ment of two gRNAs, each targeted to a given strand with cut sites near one
another, to generate a DSB (Jinek et al., 2012).
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TABLE 5.1: Summary of nuclease proteins used in genome editing
CRISPR Nucleases Species PAM Sequence (5’ to 3’)
SpCas9 Streptococcus pyogenes NGG
SaCas9 Staphylococcus aureus NGRRT or NGRRN
NmeCas9 Neisseria meningitidis NNNNGATT
CjCas9 Campylobacter jejuni NNNNRYAC
StCas9 Streptococcus thermophilus NNAGAAW
LbCpf1 Lachnospiraceae bacterium TTTV
AsCpf1 Acidaminococcus sp. TTTV
N, any nucleotide; R, A or G; V, A or C or G; W, A or T; Y, C or T
DSBs induced by Cas-cleavage are resolved through either non-homologous
end joining (NHEJ) or homologous recombination repair (HRR). Genome edit-
ing can exploit both these mechanisms to generate site specific knock-outs or
knock-ins (Figure 5.1). NHEJ is an imperfect repair mechanism which can ran-
domly lead to small insertions and deletions (indels). The inclusion of indels
in a gene can lead to a protein coding frameshift, and early stop codon, a pre-
mature termination or such changes can lead to nonsense mediated decay of
the RNA transcript (Buisson et al., 2006; Chen et al., 2008; Brogna and Wen,
2009), thus effectively knocking out the targeted genes. However, as indels are
introduced in a random manner, this editing process is not suitable if a specific
DNA sequence is desired (e.g. to mimic known disease causing variant). Al-
ternatively, HRR can be exploited to insert a desired mutation at the specific
target site (Yang et al., 2013; Richardson et al., 2016; Pires et al., 2016; Liang
et al., 2017). The knock-in method requires the co-transfection of a DNA donor
template along with the CRISPR components. The donor template, containing
the desired edit, acts in place of the invading sister chromatin where the DSB is
repaired by base-pair chemistry utilising the donor template sequence.
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FIGURE 5.1: Schematic of CRISPR induced DNA double stranded break.
5.1.1.1 Donor Template Optimisation
HRR requires the invasion of DNA, naturally the sister chromatin, at the site
of resected DNA. CRISPR-Cas genome editing can exploit HRR by providing a
donor template to act in place of the sister chromatin. For small genomic edits
the use of small (<200 bp), affordable, single-stranded oligodeoxynucleotides
(ssODN) have been used (Yang et al., 2013). The minimum requirement for a
donor template is a sufficient region of homology flanking either side of the
genomic breakpoint, termed the 5’ and 3’ homology arms. Edit efficiencies are
influenced by several donor template characteristics including: size, symmetry,
targeted strand and modifications (Richardson et al., 2016; Liang et al., 2017)
(Table 5.2). Edit efficiencies have been greatly influenced by ssODN length,
with those greater than 130 bp showing significant decrease in efficiency (Yang
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et al., 2013). Edit efficiencies are greatest for ssODNs approximately 80-90 bp
long (Yang et al., 2013; Liang et al., 2017), although ssODNs as small as 25 bp
have been successful in introducing single base pair mutations (Igoucheva et
al., 2001). Additionally, insights into Cas9 kinetics have implicated greater effi-
ciency with asymmetrical ssODNs (i.e. larger 3’/5’ homology arms) (Richard-
son et al., 2016; Liang et al., 2017). Furthermore, donor templates complemen-
tary to gRNA (and target-strand) have shown improved efficiency (Yang et al.,
2013; Richardson et al., 2016). However, Liang et al., described that both target
and non-target strand were resected simultaneously and that donor template
complementary to either strand was able to achieve similarly high edit efficien-
cies (Liang et al., 2017).
TABLE 5.2: Reported optimal ssODN design
Study Size (bp) Complementary strand Symmetry (bp)
Yang et al., 2013 70 Non-target Not tested
Richardson et al., 2016 127 Non-target 91- 5’-arm, 36-3’-arm
Pires et al., 2016∗ 120 Not described Symmetry
Liang et al., 2017 97 No preference 67 5’-arm, 30 3’-arm
∗Used the PX459 plasmid system
5.2 Study Design
The CRISPR-Cas9 genome editing system was used to knock-out BRCA1 and
knock-in a BRCA1 c.2681_2682del variant in the MCF-7 cell line. Briefly, the
PX458 plasmid (Figure 2.2), which contained a gRNA scaffold, spCas9, AmpR
gene and eGFP, was used to optimise transfection conditions (Section 2.10.9.1).
The PX459 was used for all knock-out and knock-in experiments and contained
the same elements as PX458 with the exception of the eGFP gene which was
replaced with a PuroR gene (Figure 2.2). Transfected cells were selected by
puromycin treatment at a concentration that achieved complete MCF-7 cell
death after 48 hours (Section 2.10.10). Single-cell colonies were allowed to ex-
pand in conditioned media (Appendix B.1.2) until sizeable colony formation, at
which time colonies were transferred to an individual well in a 96 well plate.
Near confluent colonies were continually expanded and an aliquot of cells was
used for genotyping by Sanger Sequencing (Section 2.10.11).
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MCF-7 cells with stable BRCA1 knock-outs and knock-ins were tested for basal
and luminal marker expression. Expression of the basal marker CK5/6 was
quantified by immunocytochemistry (ICC) on MCF-7 and MCF-7 mutated cells
over approximately 25 days of continual growth. In addition, expression of the
luminal marker, ESR1, and BRCA1 were quantified by RT-qPCR. Lastly, to ex-
plore BRCA1-associated gene expression variability observed in tumour tissue
(Chapter 3), the expression of EN1 was quantified by RT-qPCR.
5.3 Results
5.3.1 Generation of gRNA-CRISPR-Cas9 Plasmids
5.3.1.1 Guide RNA Characteristics
Six gRNAs were designed for guided CRISPR-Cas9 DNA cleavage (Figure 5.2).
All gRNAs targeted regions of exon 11 and were predicted to disrupt between
82.3% and 35.4% of mRNA sequence, assuming imperfect repair resulting in a
frameshift. All five gRNAs used for knock-out experiments targeted the minus
strand (BRCA1 coded strand). The BRCA1_gRNAdel gRNA used to introduce
a BRCA1 c.2681_2682del mutation targeted the plus strand (BRCA1 anti-sense
strand). Additionally, both ssODN donor templates (Table 2.6) were comple-
mentary to the BRCA1_gRNAdel gRNA non-target strand. On-target scores
generated by either gRNA designer or benchling were strong (mean=0.66, range=0.61-
0.74) for all gRNAs.
FIGURE 5.2: Target binding sites for gRNAs used in genome editing of BRCA1. Chro-
mosomal location of BRCA1 is depicted as a red line on an ideogram of chromosome
17. All gRNA target regions of exon 11 are marked in the insert. gRNAs in blue target
the BRCA1 coding strand, the one in red targets the anti-sense strand.
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5.3.1.2 Plasmid Production
PX459 plasmids containing gRNA (Table 2.5) targeting BRCA1 (PX459:BRCA1_gRNA)
were purified from E.coli Stbl. Clonal PCR with primers targeting the U6 pro-
moter and gRNA were used to identify colonies for expansion and plasmid
purification (Figure 5.3). Purified plasmid was sequenced to ensure the correct
gRNA was inserted immediately upstream of the gRNA template (Figure 5.3).
FIGURE 5.3: Clonal PCR and Sanger sequencing of ligated PX459 plasmid and gR-
NAs. Left) Gel electrophoresis of clonal PCR for 10 colonies transformed with
PX459:gRNA_BRCA1 in Stbl3 E.coli. PCR amplicons were generated using primers tar-
geting the U6 promoter and ligated gRNA. The KAPA universal ladder was run in the
first lanes of top and bottom segments. In lane 2 uncut PX459 plasmid and a negative
PCR (no plasmid) was run in the top and bottom segments of the gel, respectively. The
right panel shows representative chromatograms of Sanger sequences of PX49 plas-
mid (top) and PX459 plasmid contacting the BRCA1_gRNA3 (bottom). Sequences were
generated using the U6 forward primer. The BpiI cut sites are represented by inverted
triangles and the BRCA1_gRNA3 sequence is encased by a black box (bottom chro-
matogram).
5.3.2 Optimisation of DNA:Transfection Reagent Ratios
To optimise transfection of plasmid DNA, the GFP containing PX458 plasmid
was used with a range of DNA:transfection reagent ratios and the percentage of
GFP positive cells was measured by FACS analysis. Negative GFP expressing
cells were defined by a gate of 4.6% GFP signal based on the negative control
transfections (no plasmid). Cells appeared viable and no noticeable cell death
was observed by visual inspection between transfection conditions. However,
all conditions had increased cell death compared to untreated cells, as observed
by the increased number of rounded or detached cells. There was little differ-
ence in transfection efficiency when adjusting DNA:transfection reagent ratios
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above a 1:2 ratio (Figure 5.4). The ratio of 1:3 (DNA:transfection reagent) pro-
duced the greatest percentage of GFP-positive cells ( 49.0%, Figure 5.4) and was
















FIGURE 5.4: Optimisation of CRISPR plasmid transfection in MCF-7 cells. PX458 was
transfected into cells and FAC sorting was used to determine the presence of GFP sig-
nal. A) Negative cells were defined by a gate of 4.6% GFP signal as measured in the
MCF-7 negative controls, respectively. B) DNA:transfection reagent ratios were defined
by 1 µg plasmid DNA to a range of X-tremeGENE HP (1 - 4µl). Live cell images (below)
were capture at 20x objective before FAC sorting.
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5.3.3 Isolation of Monoclonal Transfected Cells
Transfection of MCF-7 cells with PX459:BRCA1_gRNAs was attempted on a
total of five occasions. Across these attempts several conditions were altered
before successfully edited cells were obtained. The major challenges were sur-
vival of single cells and edit efficiency. To improve survival of cells post-puromycin
treatment, transfection conditions and supplemented media were independently
tested. Firstly, transfection conditions were reduced to 24 hours, thus limiting
cells contact with toxic XtremeGENE-HP. However, no improvement in cell sur-
vival was observed and no BRCA1 edited cells were captured, therefore 48 hour
transfections were conducted for the remainder of this study. Conditioned me-
dia was used to improve cell survival at low seeding densities, whereby media
from log-phase growth MCF-7 cells was mixed at a 1:1 ratio with complete me-
dia (Appendix B.1.2). Under these conditions, there was an increase in colony
formation and a total of 124 colonies were isolated across six transfections with
plasmids, PX459:gRNA_BRCA1 1-5 and PX459:gRNA_BRCA1 delAA. Interest-
ingly, no colonies formed for three of the gRNAs (BRCA1_gRNA 1, 2 and 5).
Clones were sequenced in batches until successful MCF-7 BRCA1 mutant cells
were identified. In total, 40 clones were sequenced, of which 12 clones had in-
troduced a BRCA1 mutation (Table 5.3). Edits were confirmed by re-sequencing
in both directions after expanded growth, and all 12 clones were generated
by random indels around the BRCA1_gRNA3 guided Cas9 cleavage site. No
BRCA1 c.2681_2682del knock-in clones were captured. To track cell age in cul-
ture, cells were arbitrarily labelled as passage one at confirmation of mutation.
Additionally, three clones transfected with empty PX459 plasmid were selected
and expanded under the same conditions to be used as controls.
5.3.3.1 Characterisation of MCF-7 BRCA1 Mutations
Five clones had bi-allelic mutations that exhibited different mutations on each
allele (Table 5.3). Two of these compound heterozygous clones exhibited the
same mutations, an in-frame six base pair deletion and an out-frame one base
pair deletion. A further three clones had a mono-allelic mutation, of which two
clones contained the same mutation (BRCA1 c.2432del). The remaining four se-
quenced clones revealed chromatograms consistent with allele sequences that
could not be resolved. This was likely due to mixed populations of edited and
WT MCF-7 cells. The clones with unknown BRCA1 sequences were stored in
liquid nitrogen for future analyses. These cells can be seeded at low density to
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allow single-cell colony formation for resolving mixed populations.
TABLE 5.3: Allelic mutations introduced in MCF-7 cells
Clone name Allele 1 Allele 2
Heterozygous 1 Wild type BRCA1 c.2433del
Heterozygous 2 Wild type BRCA1 c.2432_2433del
Heterozygous 3 Wild type BRCA1 c.2432_2433del
Compound het 1 BRCA1 c.2433del BRCA1 c.2427_2432del
Compound het 2 BRCA1 c.2433del BRCA1 c.2429_2431del
Compound het 3 BRCA1 c.2433del BRCA1 c.2427_2432del
Compound het 4 BRCA1 c.2427_2433del BRCA1 c.2429_2437del +
c.2440_2442CTA>ATT
Compound het 5 BRCA1 c.2432del BRCA1 c.2433C>A
het, heterozygous
MCF-7 BRCA1 mutations were assessed by Dr Vanessa Lattimore (University
of Otago) using the Evidence-based Network for Interpretations of Germline
Mutant Alleles (ENIGMA) classification guidelines (v2.5.1). All eight clones in
which allele sequences could be resolved contained a predicted pathogenic al-
lele (Table 5.4). In addition, none of the five compound heterozygous clones
contained a second pathogenic variant. The second allele for four of the com-
pound heterozygous clones were in-frame mutations of unknown significance
and the remainder mutation was a synonymous missense mutation predicted
to be likely benign. The BRCA1 c.2427_2432del in-frame mutation found in
the Compound heterozygous 1 and Compound heterozygous 3 altered three
codons resulting in deletion of glutamic acid, asparagine and proline, and an
insertion of an aspartic acid at BRCA1 p.809_811. The BRCA1 c.2429_2431del
in-frame mutation found in the Compound heterozygous 2 altered two codons
translating to the deletion of asparagine and proline (p.810_811) and the in-
sertion of threonine. The complex second allele of Compound heterozygous 4
(Table 5.3) resulted in a deletion of four amino acids (asparagine, proline, ly-
sine, and glycine) at BRCA1 p.810_813 and the insertion of an arginine and the
substitution of leucine for isoleucine at BRCA1 p.814.
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TABLE 5.4: Classification of BRCA1 mutation introduced in MCF-7 cells
BRCA1 Mutation Type Class∗ Rationale
c.2427_2432del Inframe Class 3 Insufficient evidence to determine
clinical significance.
c.2427_2433del Frameshift Class 5 Variant predicted to encode a PTC
and has a low bioinformatic likeli-




Inframe Class 3 Insufficient evidence to determine
clinical significance.
c.2429_2431del Inframe Class 3 Insufficient evidence to determine
clinical significance.
c.2432_2433del Frameshift Class 5 Variant predicted to encode a PTC
and has a low bioinformatic likeli-
hood to result in a splicing aberra-
tion.
c.2432del Frameshift Class 5 Variant predicted to encode a PTC
and has a low bioinformatic likeli-
hood to result in a splicing aberra-
tion.
c.2433C>A Synonymous Class 2 Synonymous substitution variant
with a low bioinformatic likeli-
hood of disrupting splicing.
c.2433del Frameshift Class 5 Variant predicted to encode a PTC
and has a low bioinformatic likeli-
hood to result in a splicing aberra-
tion.
∗Classification based on the ENIGMA classification guideline (v2.5.1).
PTC, Premature termination codon.
5.3.4 MCF-7 BRCA1 Mutations on Cell Proliferation and Mor-
phology
MCF-7 control and MCF-7 BRCA1 mutant cells were inspected under a bright-
field microscope to assess any changes in cell morphology (Figure 5.5). No mor-
phological changes in MCF-7 cells were observed and all clones exhibited nor-
mal epithelial cobblestone morphology associated with MCF-7 cells. However,
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there was an increased number of rounded cells associated with Compound
heterozygous 4 at both earlier passage and after several weeks in culture (Fig-
ure 5.5). DNA content was measured to estimate cellular proliferation in a selec-
tion of CRISPR-clones that were used in additional experiments in this chapter.
This limited the handling of multiple clones and minimised maintenance and
experimental reagents needed. Interestingly, only the MCF-7 Compound het-
erozygous 2 cells exhibited a greater growth-rate compared to parental MCF-7
and MCF-7 control cells. There was no measurable difference in growth rate be-






































































Passage 3 Passage 3Passage 10 Passage 10
FIGURE 5.5: Sub-confluent images of MCF-7 CRISPR-edited and controls cell lines.
Images were captured under bright field at 10x objective.
Chapter 5. Development of an In Vitro BRCA1 Model in MCF-7 Cells 147
FIGURE 5.6: Proliferation of MCF-7 CRISPR clones. DNA content relative to the 24
hour (T24) time point was calculated for each cell line at four time points. Points repre-
sent the mean normalised DNA content for three biological replicates, each biological
replicate had three technical replicates. Error bars represent +/- SEM across biological
replicates.
5.3.5 Subtype Markers in MCF-7 BRCA1 Mutant Cells
To examine whether the introduction of likely pathogenic BRCA1-mutation is
sufficient to differentiate MCF-7 cells towards a basal-like phenotype, the ex-
pression of the basal marker CK5/6 and the luminal marker ESR1 were mea-
sured. There was no detectable CK5 expression after approximately 25 days of
culture in any MCF-7 cell line tested, irrespective of mutation status or time in
culture (Figure 5.7). There was, however, a significant decrease in ESR1 expres-
sion in all the MCF-7 BRCA1 mutated clones expect for Compound heterozy-
gous 1 (Figure 5.8). There was an average of 17.5% (range 5.3-24.6%) decrease in
ESR1 expression across the MCF-7 BRCA1 mutated clones (Figure 5.8). In con-
trast, MCF-7 control clones expressed equivalent or greater ESR1, with a 19.7%
increase in ESR1 expression for the MCF-7 Ctrl 2 sub-clone (Figure 5.8).









P4 P5 P6 P7 P8
CK5 Positive control Secondary Only
FIGURE 5.7: ICC for CK5 expression (green) in MCF-7 and MCF-7 BRCA1 cell lines.
MCF-7 cell lines were grown over several passages (P) to capture any changes in CK5
expression associated with likely pathogenic BRCA1 mutations. CK5/6+ MCF-10A
cells (top) were used as ICC controls. ICC was performed on cell spots generated by
cyto-spins of cells during log-phase growth. Two samples failed to generate cell spots
and are depicted as ’No Data’. All MCF-7 cell lines were devoid of positive CK5/6
expression, irrespective of BRCA1 mutations. Nuclei were stained with DAPI (blue)
and images were captured at 20x objective on a Zeiss Axio Imager.Z1 Microscope.
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FIGURE 5.8: ESR1 expression in MCF-7 and MCF-7 BRCA1 mutant cells. Bars represent
normalised mean expression for 3 biological replicates compared to WT expression.
Error bars represent SEM. Comparison of gene expression was performed by a one-
sample T-test comparing all groups to mean of one. *: p < 0.05, **: p < 0.01, ***: p <=
0.001, ****: p <= 0.0001
5.3.6 BRCA1 Expression in MCF-7 and MCF-7 BRCA1 Mutant
Cells
To measure correlation of BRCA1 mutation and expression, RNA from MCF-7
BRCA1 mutants cells in log-phase growth were quantified. There was no con-
sistent correlation in BRCA1 expression and BRCA1 mutation status. Further-
more, the MCF-7 control clones also showed deviations for the parental MCF-7
cells. MCF-7 Ctrl 1 cells had a significant 24.5% decrease in BRCA1 expression.
A similar decrease was observed in the Compound heterozygous 2 (26.5%),
Compound heterozygous 4 (24.4%) and Heterozygous 5 (21.0 %) clones. Inter-
estingly, the Compound heterozygous 1 clone had a 39.1% increase in BRCA1
compared to parental MCF-7 cells.
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FIGURE 5.9: BRCA1 expression in MCF-7 and MCF-7 BRCA1 mutant cells. Bars rep-
resent normalised mean expression for 3 biological replicates compared to WT expres-
sion. Error bars represent SEM. Comparison of gene expression was performed by a
one-sample T-test comparing all groups to mean of one. *: p < 0.05, **: p < 0.01, ***: p
<= 0.001, ****: p <= 0.0001
5.3.7 EN1 Expression in MCF-7 and MCF-7 BRCA1 Mutant Cells
EN1 had variable expression associated with basal and BRCA1 breast tumours
(Figure 3.10). However, this observation was not captured in the transcriptome
profiles of either pre-malignant MCF-10A or MCF-7 cells with altered BRCA1
(Figure 4.6). In Chapter 4, BRCA1 was transiently knocked-down for 48 hours
before gene expression was quantified. The CRISPR derived MCF-7 BRCA1 sta-
ble mutants were therefore used to determine if longer term exposure to altered
BRCA1 may alter EN1 expression in MCF-7 cells. No MCF-7 clone produced
EN1 gene expression that was detectable by RT-qPCR. To compare this result
with publicly available data, the Cancer Cell Line Encyclopaedia dataset was
interrogated through the cbioportal (www.cbioportal.org). Consistent with re-
sults in this chapter, MCF-7 cells showed no expression of EN1. Interestingly,
the cell lines that exhibited the greatest EN1 expression tended to carry a muta-
tion in BRCA1 or BRCA2 (Figure 5.10).
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FIGURE 5.10: EN1 expression in breast cancer cell lines from the Cancer Cell Line Ency-
clopedia. A) Cell lines with BRCA1 or BRCA2 mutation are coloured blue, MCF-7 cells
are highlighted in orange, other cells with wild type BRCA1 and BRCA2 are in grey
crosses and dots. Breast cancer cells available in house are labelled. B) Comparison of
EN1 expression in cell lines containing BRCA1 and BRCA2 mutant or not (wild type).
Significance was determined by Student T-test. *: p < 0.05
5.4 Discussion
This chapter described the development of the first stable MCF-7 BRCA1 mu-
tant cell lines using CRISPR-Cas9 genome editing technology. Eight MCF-7 cell
lines were developed that carried a likely pathogenic BRCA1 mutation. Ad-
ditionally, five of the eight cell lines carried a second, likely benign, mutation
(Table 5.4). In addition to the cells developed in this study, there are several iso-
genic BRCA1 mutated cell lines reported, these include the MCF-10A cells used
in Chapter 4 and one developed in the leukaemia HAP1 cell line (Konishi et al.,
2011; Findlay et al., 2018; Kweon et al., 2020). The HAP1 cell line is developed
from a male with chronic myelogenous leukaemia, thus the utility of these cell
lines as a BRCA1-associated breast cancer model may be limited. With the use
of high-throughput methods and deep sequencing of mixed clonal populations,
the HAP1 cell lines have been able to accurately predict variants status based on
the relative abundance of mutated cells over time (Findlay et al., 2018; Kweon
et al., 2020). These methods, however, do not isolate HAP1 BRCA1 mutant
cells, therefore, the MCF-10A and MCF-7 BRCA1 mutant breast cell lines may
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be better suited to investigating BRCA1-associated tumour phenotypes, includ-
ing treatment response, biomarkers of BRCA1 status and modifiers of BRCA1
risk.
The introduction of a BRCA1 mutation into an established MCF-7 breast can-
cer cell line had minimal effect on cell morphology and proliferation (Figure
5.5, 5.6). Of the MCF-7 BRCA1 mutant cell lines tested, only the BRCA1 Com-
pound heterozygous 2 cells had increased proliferation compared to MCF-7
cells (Figure 5.6). Additionally, BRCA1 Compound heterozygous 4 cells exhib-
ited more cell rounding, which may be an indicator of greater cell death. Future
cell proliferation and cell viability assays need to be performed to better under-
stand the consequence of BRCA1 mutations to MCF-7 cells growth and death
rate. However, these phenotypes, may not be indicative of BRCA1 mutations
or pathogenicity of a BRCA1 variant.
The knock-down of BRCA1 expression in MCF-7 cells appeared to subtly al-
ter the expression of basal and luminal markers (Figure 4.8). In this chapter,
CK5/6 and ESR1 were measured to examine whether longer exposure to loss
of BRCA1 function may result in a luminal to basal transition (Figure 5.7,5.8).
Similar to the results in Chapter 4 (Figure 4.8) , there was a significant decrease
in the ESR1 luminal marker (Figure 5.8). However, after the expansion of MCF-
7 cells for approximately 25 days there was no detectable CK5/6 expression in
any of the MCF-7 cell lines (Figure 5.7). The decrease in ESR1 expression is
consistent with previous BRCA1 knock-down in ER positive MCF-7 and T47D
cell lines (Hosey et al., 2007). The complex interplay between oestrogen and
BRCA1 function may be independent of expression profiles associated with lu-
minal and basal subtypes. Additionally, breast cancer subtype fate may be an
early tumourgenic event which is not able to be recapitulated by the luminal
MCF-7 cell model. However, a previous study in mice has demonstrated that
luminal cancer models can be shifted towards a basal phenotype, which in-
cludes the loss of ER expression, by the addition of a Brca1 germline mutation
(Bai et al., 2013, 2014).
Consistent with previous expression studies (Table 1.2), BRCA1 expression does
not accurately predicted the presence of a BRCA1 variant and is not able to be
used to assess pathogenic potential of unknown BRCA1 variants (Buisson et al.,
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2006). Interestingly, the BRCA1 Compound heterozygous 1 cells exhibited sig-
nificantly greater BRCA1 expression and the BRCA1 Compound heterozygous
3 cells had significantly less expression compared to parental MCF-7 cells, de-
spite containing identical mutations (Figure 5.9). The remaining BRCA1 mutant
clones all exhibited significantly lower expression compared to parental MCF-7
cells. The varied BRCA1 expression across MCF-7 control and mutant clones il-
lustrates the difficulties in identifying appropriate BRCA1 expression levels for
knock-down based studies. These results are supported by observations that
seemingly identical MCF-7 cells can have altered oestradiol response, differ-
ences in total chromosomes, and gene expression profiles (Nugoli et al., 2003;
Kleensang et al., 2016; Ben-David et al., 2018). These findings reinforce the im-
portance of establishing single cell colony controls for heterogeneous cell pop-
ulations. Furthermore, as there remained variation amongst the control clones
in this study, there is a need to compare several control clones to genome edited
cells to ensure observed effects are not a symptoms of sub-clonal isolated but
rather the introduction of the genome edit. These control cells are likely iso-
lates of different sub-clonal MCF-7 cells, however, there remains the possibility
that there was non-specific Cas9 cleavage. One approach to generate a more
isogenic MCF-7 control and mutant cell line would be to generate a single cell
colony first, depleting the sub-clonal population before performing CRISPR-
Cas genome editing.
Chapter 3 demonstrated greater gene expression variability in BRCA1-associated
tumours. Additionally, EN1 was shown to be variably expressed in BRCA1-
associated breast tumours in the microarray analysis and with RNA ISH (Fig-
ure 3.12). By comparison, breast cell models in Chapter 4 did not capture EN1
expression variability in either MCF-7 or MCF-10A models (Figure 4.6) and RT-
qPCR was unable to detect any expression of EN1 in any of the CRISPR-Cas
modified MCF-7 cell lines used in this study. Consistent with these results,
the CCLE database further indicated extremely low or no expression of EN1 in
MCF-7 cells (Figure 5.10A) . CCLE data does illustrate a presence of increased
EN1 expression in cell lines that harboured BRCA1 or BRCA2 variants (Figure
5.10B). However, this study suggests that a CRISPR-Cas introduced BRCA1 mu-
tations in MCF-7 cells may be insufficient to alter EN1 expression.
To understand the utility of these cell lines as a BRCA1-associated breast cancer
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model, the impact of the variants on BRCA1 function needs to be further inves-
tigated. Such investigations may include response to DNA damage (Ransburgh
et al., 2010), transcriptional activity (Woods et al., 2016) and ubquitin ligase
function (Carvalho et al., 2007; Starita et al., 2015). Additionally, characterising
each cell line by assessing tumour related phenotypes would better contextu-
alise the relevance to BRCA1-associated tumours. Furthermore, a comprehen-
sive panel of luminal and basal subtype markers should be assessed, including
clinical ICC markers (e.g. ER, PgR and HER2), as the assessment in this study is
not definitive. Due to the length of time taken to establish the CRISPR modified
MCF-7 clones, transcriptome analysis in Chapter 4 had already been performed
and producing data assesd in this thesis. However, transcriptome analysis of
CRISPR modified MCF-7 cells remains a point of interest and such experiments
would be further enhanced by establishing clonal MCF-7 populations to ac-
count for the heterogeneous cell populations. Additionally, these studies would
benefit by optimising in vitro conditions to mimic BRCA1-associated tumours
as discussed in Chapter 4.
5.5 Conclusion
MCF-7 cells containing BRCA1 mutations were successfully developed using
CRISPR-Cas genome editing technologies. Although MCF-7 cells with BRCA1
mutations had reduced expression of the luminal marker ESR1, there was no
evidence of increased expression of the basal marker CK5/6. Similar to BRCA1
knock-down, the introduction of pathogenic BRCA1 mutations did not lead to
a luminal to basal transition in MCF-7 cells. These MCF-7 BRCA1 mutant cells
are a potential resource as a BRCA1-associated breast cancer model, however,




Trait Loci Analysis of Breast Cancer
Risk Variants
The work throughout this chapter has been published in a pre-print on bioRχiv
(https://doi.org/10.1101/2020.03.23.004366)
6.1 Introduction
Genome wide association studies (GWAS) in breast cancer have identified more
than 180 common risk variants (Michailidou et al., 2015, 2017; Milne et al.,
2017), however, the causal genes and biological mechanisms that confer dis-
ease susceptibility remain largely unknown. Risk variants are often located in
non-coding regions making it difficult to determine pathogenic pathways. Ap-
proximately 700 potential gene targets of breast cancer risk variants have been
identified using analytical methods that employ genomic data from chromatin
interactions, enhancer–promoter correlations, transcription binding, topologi-
cally associated domains and gene expression (Michailidou et al., 2015, 2017).
Gene expression traits are under genetic regulation and the heritability of dif-
ferences in genotypes have been extensively described (Petretto et al., 2006).
For example, identification of expression quantitative trait loci (eQTL) has been
a key approach for investigating tissue-specific effects of breast cancer risk vari-
ants under the hypothesis that non-breast tissue may be involved in breast can-
cer risk (Ferreira et al., 2019). Gene expression patterns are often explored as-
suming genetic control of mean expression level, however, the variability of
gene expression is also genetically controlled (Blake et al., 2003; Raser and
O’Shea, 2004; Spielman et al., 2007; Hulse and Cai, 2013). Just as differences
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in expression means have been associated with genotypes, so can differences in
expression variability be associated with genotype.
Gene expression variability has been described in a wide range of organisms
including prokaryotes (Elowitz et al., 2002), yeast (Blake et al., 2003; Raser
and O’Shea, 2004) and complex multicellular organisms (Ecker et al., 2015;
Hasegawa et al., 2015; Bueno and Mar, 2017). Furthermore, gene expression
variability has been shown to be important in early human development (Hasegawa
et al., 2015), schizophrenia (Zhang et al., 2015) and cancer subtypes (Bueno and
Mar, 2017; Ecker et al., 2015). The effects of genetic variation on gene expression
variability have been recently described in human derived lymphoblastoid cell
lines from HapMap individuals (Hulse and Cai, 2013) and in the TwinsUK co-
hort (Brown et al., 2014; Wang et al., 2014).
Breast cancer risk variants associated with eQTL, based on mean gene expres-
sion, have been investigated in both breast tissue (tumour and normal), and
non-breast tissue (Li and Tibshirani, 2013; Guo et al., 2018; Ferreira et al., 2019).
However, the mechanisms underlying breast cancer risk for the majority of
variants remains to be uncovered. Here, variable expression quantitative trait
loci (veQTL) has been demonstrated as a method for testing the association of
variants with gene expression variability. We performed veQTL analysis on 181
variants that have been previously associated with breast cancer risk and iden-
tified 60 new candidate genes and pathways associated with 27 breast cancer
risk variants.
6.1.1 Study Design
Genotype and expression data were acquired through the database of Geno-
types and Phenotypes (dbGaP) and the Genotype-Tissue Expression (GTEx)
Common Fund Project (release version phs000424.v7.p2.). Genotype data was
filtered (Section 2.6.3) to remove any genotype with less than 10 individuals.
RPKM data for 56,203 unique Ensembl transcripts (https://www.ensembl.org/)
were split into tissue-specific datasets and lowly expressed transcripts were re-
moved (Section 2.6.2).
Tissue-specific veQTL (Section 2.6.4) and eQTL (Section 2.7) analysis was per-
formed on breast cancer associated genotypes (Supplementary Table D.1) and
all transcripts that passed filtering with sex and age (dichotomised at age 55)
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as covariates. Tissue-specific analysis was performed on four tissues (breast,
kidney, lung and ovary) and proposed breast cancer susceptibility genes were
limited to those that had: i) significant (p < 5.0x10−8) gene expression vari-
ability associated with a breast cancer risk variants, ii) the significant veQTL
association was only observed in breast tissue and iii) the gene was only asso-
ciated with a change in expression variability (i.e. veQTL) and not a change in
mean expression (i.e. eQTL) (Figure 6.1). Pathway over-representation analysis
(Section 2.8) was performed on candidate breast susceptibility genes using GO
terms.
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GTEx dataset (phs000424.v7.p2)
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FIGURE 6.1: Workflow for the identification of candidate breast cancer susceptibility
genes by veQTL and eQTL analyses.
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6.2 Results
6.2.1 Identification of veQTLs and eQTLs
The GTEx dataset comprises 635 genotyped samples, of which tissue samples
from normal breast (n=255), lung (n=387), kidney (n=41) and ovary (n=123)
were used. A significant proportion of breast cancer risk variants are predicted
to alter expression of cancer susceptibility gene(s) in breast tissue. To identify
veQTL that specifically increase cancer risk in breast tissue veQTL associations
were excluded if identified in other tissue types. These assumptions would,
however, exclude any breast cancer susceptibility genes whose expression vari-
ability is tolerated in other tissues but not breast. RNA-sequencing and geno-
type data were split into tissue-specific datasets and filtered to remove low fre-
quency genotypes and genes with low expression. After pre-processing 33059,
29522, 25026 and 35137 transcripts were retained for the breast, ovary, kidney
and lung, respectively. Large GWAS have identified variants associated with
breast cancer risk or subtype specific breast cancer risk. In total, 181 breast can-
cer risk variants were identified in the literature (Supplementary Table D.1), of
which 152, 148, 106 and 152 breast cancer risk variants were retained after filter-
ing out non-biallelic and genotypes with few minor alleles (Section 2.6) for the
breast, ovary, kidney and lung datasets, respectively (Figure 6.1, Supplemen-
tary Table D.1).
Associations between breast cancer risk variants and gene expression variabil-
ity were tested, correcting for sex and age, in four tissues. The risk variants
were significantly (p < 5x10−8) associated with veQTL in the breast (70), ovary
(9) and lung (109) (Table 6.1, 6.2 Supplementary Table D.3, D.4). No significant
associations were observed in the kidney analysis. By comparison, the numbers
of observed eQTL in breast (155), ovary (19) and lung (123) were greater, and
similarly there were no significant kidney eQTL. The majority of veQTL and
eQTL associations were trans and acted over distances greater than 1 Mb or
between chromosomes. Only 2/70, 5/109 and 2/9 significant association were
cis-veQTL (+/- 1 Mb) in the breast, lung and ovary, respectively. A greater pro-
portion of eQTL were observed in cis compared to veQTL, with approximately
5% of veQTL and 13% eQTL acting in cis.
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TABLE 6.1: Significant veQTL and eQTL breast cancer variants and associated genes
for each tissue
veQTL eQTL
Variants Genes veQTL (cis) Variants Genes veQTL (cis)
Breast 27 60 70 (2) 16 139 155 (18)
Kidney 0 0 0 0 0 0
Lung 28 81 109 (5) 24 101 123 (17)
Ovary 5 9 9 (2) 7 19 19 (4)
TABLE 6.2: Significant veQTL association in breast tissue
rsNumber ensembl ID Gene Symbol W p-value
rs11814448 ENSG00000228549.2 50.50 3.80E-19
rs11814448 ENSG00000225972.1 MTND1P23 42.18 1.65E-16
rs11814448 ENSG00000237973.1 MTCO1P12 31.00 9.38E-13
rs11814448 ENSG00000259187.1 30.05 2.01E-12
rs6569648 ENSG00000198945.3 L3MBTL3 29.63 2.77E-12
rs11814448 ENSG00000233421.3 LINC01783 29.60 2.91E-12
rs4577244 ENSG00000265550.1 29.42 3.32E-12
rs11814448 ENSG00000132967.9 HMGB1P5 28.99 4.77E-12
rs11814448 ENSG00000232177.1 MTND4P24 28.18 9.22E-12
rs2594714 ENSG00000225972.1 MTND1P23 27.62 1.43E-11
rs2290203 ENSG00000233870.1 26.43 3.81E-11
rs3817198 ENSG00000204936.5 CD177 25.95 5.65E-11
rs11814448 ENSG00000270773.1 24.49 1.93E-10
rs1011970 ENSG00000137440.3 FGFBP1 24.44 2.00E-10
rs34005590 ENSG00000167748.6 KLK1 42.08 4.60E-10
rs1011970 ENSG00000267409.1 22.98 6.84E-10
rs11075995 ENSG00000147465.7 STAR 22.89 7.32E-10
rs13329835 ENSG00000223715.1 LINC01208 22.73 8.41E-10
rs2594714 ENSG00000172799.5 ZBTB8OSP2 22.70 8.65E-10
rs2594714 ENSG00000196656.6 22.65 9.01E-10
rs11814448 ENSG00000204666.3 22.63 9.29E-10
rs11075995 ENSG00000148795.5 CYP17A1 22.58 9.54E-10
rs117618124 ENSG00000256609.1 39.73 1.29E-09
rs71557345 ENSG00000106333.8 PCOLCE 39.31 1.61E-09
rs11814448 ENSG00000237533.1 21.95 1.64E-09
rs6828523 ENSG00000236055.1 39.24 1.66E-09
rs11814448 ENSG00000241717.1 VWFP1 21.88 1.75E-09
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rs71557345 ENSG00000198796.6 ALPK2 39.11 1.76E-09
rs2594714 ENSG00000232177.1 MTND4P24 21.81 1.83E-09
rs6815814 ENSG00000204666.3 21.58 2.23E-09
rs45631563 ENSG00000166923.6 GREM1 38.32 2.42E-09
rs11814448 ENSG00000225093.1 RPL3P7 21.24 3.02E-09
rs4442975 ENSG00000196355.2 20.88 4.06E-09
rs11075995 ENSG00000203859.5 HSD3B2 20.79 4.38E-09
rs3817198 ENSG00000163221.7 S100A12 20.78 4.45E-09
rs71557345 ENSG00000182759.3 MAFA 36.77 4.98E-09
rs13365225 ENSG00000233845.1 20.23 7.11E-09
rs11814448 ENSG00000172799.5 ZBTB8OSP2 20.15 7.70E-09
rs4849887 ENSG00000270388.1 MTCO3P22 35.66 8.23E-09
rs117618124 ENSG00000075886.10 TUBA3D 35.36 9.12E-09
rs2594714 ENSG00000228549.2 19.78 1.05E-08
rs11814448 ENSG00000259781.1 HMGB1P6 19.73 1.11E-08
rs12479355 ENSG00000227135.1 19.58 1.24E-08
rs11075995 ENSG00000160882.7 CYP11B1 19.44 1.41E-08
rs10816625 ENSG00000207574.1 MIR661 34.39 1.43E-08
rs10069690 ENSG00000237973.1 MTCO1P12 19.39 1.48E-08
rs2594714 ENSG00000132967.9 HMGB1P5 19.34 1.53E-08
rs4808801 ENSG00000206192.7 ANKRD20A9P 18.97 2.11E-08
rs13365225 ENSG00000183628.8 DGCR6 18.95 2.16E-08
rs11814448 ENSG00000198868.3 MTND4LP30 18.93 2.21E-08
rs2594714 ENSG00000270773.1 18.88 2.29E-08
rs1011970 ENSG00000259342.1 18.82 2.42E-08
rs2594714 ENSG00000250133.2 HOXC-AS2 18.79 2.48E-08
rs2594714 ENSG00000233421.3 LINC01783 18.76 2.54E-08
rs11814448 ENSG00000232573.1 RPL3P4 18.68 2.74E-08
rs13329835 ENSG00000230202.1 18.65 2.79E-08
rs13329835 ENSG00000254052.1 IGHVIII-67-4 18.64 2.82E-08
rs71557345 ENSG00000269657.1 32.79 2.98E-08
rs6122906 ENSG00000213959.2 18.62 2.99E-08
rs6596100 ENSG00000222040.3 18.56 3.03E-08
rs7297051 ENSG00000253631.1 IGLV7-35 18.41 3.44E-08
rs132390 ENSG00000273179.1 32.34 3.58E-08
rs9348512 ENSG00000242163.1 18.30 3.79E-08
rs6596100 ENSG00000199480.1 RNA5SP389 18.24 4.01E-08
rs71557345 ENSG00000164692.13 COL1A2 32.07 4.13E-08
rs13329835 ENSG00000196656.6 18.19 4.17E-08
rs117618124 ENSG00000130202.5 NECTIN2 31.88 4.41E-08
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rs71557345 ENSG00000174429.3 ABRA 31.88 4.52E-08
rs71557345 ENSG00000104369.4 JPH1 31.79 4.70E-08
rs117618124 ENSG00000152086.7 TUBA3E 31.74 4.70E-08
W , Brown-Forsythe test statistic
6.2.2 Classes of veQTLs
By assessing expression values associated with each genotype across the four
different tissues, I observed three classes of veQTL (Figure 6.2). Class I resem-
bled a homozygous recessive phenotype, where the presence of two minor al-
leles was associated with altered gene expression variability. Class II showed
a dominant phenotype where the dosage of the minor allele correlated with
the change in expression variability. Class III resembled a heterozygous phe-
notype where the presence of two different alleles altered gene expression vari-
ability. Significant breast veQTL were largely Class I homozygous recessive
(56%), (Figure 6.2), while the majority (9/11) of Class II veQTL were also eQTL.
In total, 21 veQTL (30%) were also eQTL. Seven breast cancer variants with
significant veQTL had no samples homozygous for the minor allele and were
unable to be classified. However, all seven variants had more gene expression
variability in heterozygous samples, thus ruling out a Class I veQTL.
Class I II III
Homozygous recessive Dosage Heterozygous
Breast veQTL only 30 2 10
Breast veQTL & eQTL 9 9 3
Total breast veQTL 39 11 13
RP13-6852P2 – rs2594714 VWFP1 – rs11814448 MIR4461 – rs11814448
FIGURE 6.2: Characteristics of gene expression variability in veQTL. Three classes of
veQTL were observed with respect to the minor allele. Significant breast veQTL were
represented in all three classes with the majority (39/70) class I
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6.2.3 Comparison of veQTL and eQTL
To estimate biases in dataset-specific veQTL analysis, quantile-quantile plots
(q-q plots) were generated and genomic factors estimated for each tissue (Fig-
ure 6.3). No substantial genomic inflation (λ < 1.1) was observed for the veQTL
analysis in the breast, lung or ovary (λ ranged 1.00-1.05). However, a larger ge-
nomic inflation factor of 1.15 was observed for kidney tissue, implying a small
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FIGURE 6.3: Tissue specific q-q plots and genomic inflation factors (λ) for the asso-
ciations of breast cancer risk variants and gene expression variability, with observed
p-values plotted as a function of expected p-values under the null hypothesis of no
association; the red lines indicates the a null distribution of p-values.
Tissue specific p-values distributions were similar between veQTL and eQTL
analyses (Figure 6.4A). Three tissues (breast, lung and ovary) displayed an anti-
conservative distribution with a greater number of p-values tending towards
zero. For the larger lung and breast datasets, there was a greater number of
p-values near zero compared to ovary tissue, suggesting a greater number of
tests that reject the null hypothesis of no difference in expression variability
between groups. Examination of the kidney dataset demonstrated a uniform
distribution of p-values, highlighting the limited effect for the selected variants
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for both veQTL and eQTL analysis. Variant-gene pairs were ranked according
to eQTL significance and the rank correlation of p-values between eQTL and
veQTL analysis were calculated for each tissue specific dataset. Correlations
ranged from 0.052 in the kidney to 0.183 in the lung, suggesting the variant-
gene ranks between veQTL and eQTL analysis are different and veQTL analysis
identified a novel set of genes associated with risk variants (Figure 6.4B).
Chapter 6. veQTL Analysis of Breast Cancer Risk Variants 165
FIGURE 6.4: Tissue-specific performance of veQTL and eQTL analysis. A) Tissue spe-
cific p-value distribution for BC variants eQTLs (red) and veQTLs (blue). B) Tissue
specific correlations of –log10(p) for eQTL (x-axis) and veQTL (y-axis).
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6.2.4 Identification of Candidate Target Genes of Breast Cancer
Risk Variants
The majority of breast cancer variants have no known associations with other
traits, however, 25 variants have previously been associated with a phenotype
other than breast cancer risk (www.gwascentral.org). Two variants (rs11571833
and rs17879961) have been previously associated with lung cancer, while rs10069690
and rs74911261 have been associated with ovarian and kidney cancers, respec-
tively. Interestingly, none of these variants were significantly associated with
differential variability in any genes in these tissues. However, rs10069690 had
a significant association with differential variability in gene expression in each
of the lung and breast analysis. As the majority of the variants confer breast
cancer risk only, we eliminated any veQTL that was observed in a non-breast
tissue (Figure 6.5). Fifty-five of the 70 significant breast veQTL were observed
in breast tissue only. Pathway enrichment analysis of the candidate genes as-
sociated with these breast-specific veQTL revealed hormonal biosynthetic pro-
cesses and collagen fibril organisation pathways that were enriched (Figure 6.5).
The enrichment of the hormonal pathways listed in Figure 6.5 were driven by
four genes (CYP11B1, CYP17A1, HSD3B2 and STAR), all of which were associ-
ated with the risk variant rs11075995. By comparison, the 88 veQTL that were
significant in lung tissue were not significantly enriched for any pathway using
pathway analysis (data not shown).
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Glucocorticoid metabolic process
Hormone biosynthetic process























































FIGURE 6.5: Pathway enrichment of candidate breast cancer risk genes identified
through veQTL analysis. Fifty-five gene SNP pairs were observed only in breast tis-
sues, 47 of these were veQTL but not eQTL associations. The candidate genes identi-
fied by these 47 genes were enriched for pathways involved in C21-steroid hormone
metabolic process. Pathway analysis was performed in R using GO terms and using
the DOSE and ClusterProfiler packages.
6.2.5 rs11075995 Alters Expression of Genes Involved in C21
Steroid Synthesis
The minor allele (A) of rs11075995, which is associated with ER negative breast
cancer risk, was found to be associated with increased variability in expression
of four genes by veQTL analysis (Figure 6.6). To connect the signals of veQTL
analysis with the association of breast cancer risk, GWAS statistics generated by
Michailidou and colleagues on the largest meta-analysis of breast cancer risk to
date (Michailidou et al., 2017) were compared to the veQTL signals generated
using the GTEx data. Regional plots at the rs11075995 locus for ER negative
breast cancer risk associations or trans-veQTL with candidate genes were vi-
sually examined to determine likely casual variants (Figure 6.6). Two signals
identified were associated with ER negative breast cancer risk, one of which
was the lead variant rs11075995 (Figure 6.6A). The same variants (rs11075995)
produced the strongest signal for variable expression of all four candidate genes
involved in the C21-steroidal pathway (Figure 6.6B).
Chapter 6. veQTL Analysis of Breast Cancer Risk Variants 168
ER negative breast cancer risk 
B
A
FIGURE 6.6: Co-localisation of ER negative breast cancer GWAS and trans-veQTL sig-
nals. A) Regional association plots for ER negative breast cancer risk for rs11075995
from Michailidou et al (2017). B) Regional association plots for trans-veQTL at
rs11075995. Points indicate individual SNPs at their chromosomal location and sig-
nificance (-log10(p-value)) for either GWAS (A) or trans-veQTL (B). The blue line rep-
resents the recombination rate and the colour of the points indicates the strength of the
LD with rs10075995 measured as r2 in the EUR population from 1000 genomes (hg19).
All plots were generated using LocusZoom.
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The candidate genes (CYP11B1, CYP17A1, HSD3B2 and STAR) associated with
rs11075995 are all involved in the conversion of cholesterol to hormones via
the C21 steroidal biosynthesis pathway (Figure 6.7). STAR is involved in the
transportation of free cholesterol into the mitochondria where it is converted
to pregnenolone. The remaining three candidate genes all code for enzymes
that catalyse the conversion of multiple molecules and act in several pathways
which produce different hormones (Figure 6.7).
FIGURE 6.7: Schematic of part of the C21-steroid biosynthesis pathway. Genes shown
in red were associated with a significant increase in variability in individuals homozy-
gous for the rs1105995 risk allele (A) in breast tissue (i.e. 4 of the 70 breast-derived
genes from Figure 6.5). Dashed arrow, transport. Solid arrow, enzymatic activity.
The rs11075995 SNP is located in the second intron of the FTO gene (Figure
6.8)., a Fe2+/2-oxoglutarate-dependent oxidative RNA demethylases impor-
tant in the demethylation of RNA methyladenosine (m6A) (Han et al., 2010).
Variants in this locus are associated with increased body mass index (BMI), the
mechanism of action has been linked to expression changes of the neighbour-
ing gene IRX3 in the human brain and in particular the hypothalamus (Frayling
et al., 2007; Smemo et al., 2014). Furthermore, there is conflicting evidence
of rs11075995 association with breast cancer risk. Recent studies identified a
loss of breast cancer risk association after adjusting for BMI (Kang et al., 2017).
However, Garcia-Closas and colleagues tested the association with ER nega-
tive breast cancer risk after adjusting for BMI and observed no change (Garcia-
Closas et al., 2013). We therefore explored the effects of the rs11075995 on the
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expression of both FTO and IRX3 in breast tissue. Neither FTO nor IRX3 had
significant breast eQTL or veQTL associations with rs11075995. However, FTO
(p = 0.05), and not IRX3 (p =0.29), had decreased expression in the homozygous
minor allele individuals in breast tissue (Figure 6.8B, Supplementary Figure
D.10).
FIGURE 6.8: cis-effects of rs11075995 minor allele and FTO expression. A) Ideogram
and chromosomal location of the rs11075995 (red box) variant within an intron FTO
gene. Exons are depicted by orange box, lines are introns. B) Tissue-specific expression
of FTO stratified by genotypes at the rs11075995 locus. T/T homozygous major allele
(Green), A/T heterozygous (Orange), A/A homozygous minor allele (Blue).
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6.3 Discussion
Tissue-specific veQTL datasets were generated for breast cancer variants in four
normal tissue datasets acquired from GTEx. To predict candidate genes in-
volved in breast cancer risk, significant (p < 5x10−8) veQTL unique to breast
tissue were considered. This approach identified 60 candidate genes that were
associated with 27 variants. The majority of significant veQTL were class I and
displayed a homozygous recessive like phenotype (Figure 6.2). Furthermore,
veQTL analysis identified distinctly different genes compared to eQTL analysis
(Figure 6.4). However, 30% of class II breast veQTL were also eQTL, highlight-
ing a small subset of genes that had both changes in mean expression and vari-
ability associated with minor allele dosage.
Pathway analysis of the 60 candidate genes found several hormonal biosyn-
thetic pathways enriched along with monocyte chemotaxis and collagen fib-
ril organisation (Figure 6.5). The enrichment of the C21-hormonal biosynthetic
pathway was driven by the presence of four genes (CYP11B1, CYP17A1, HSD3B2
and STAR), all of which were variable in association with the risk allele of
rs11075995. Furthermore, rs11075995 produced the strongest signal for variable
expression for all four candidate genes and was the most likely casual variant
(Figure 6.6).
Breast cancer development has been associated with exposure to steroid hor-
mones (Key et al., 2001). These hormones are typically synthesised in non-
breast tissues (e.g. ovary and adrenal gland) and are secreted into the cir-
culation to act on distant tissues (e.g. breast). The activation of local hor-
mone biosynthesis, associated with the risk allele of rs11075995, through the
metabolism of cholesterol to pregnenlone may lead to greater exposure and/or
hormone imbalance in breast tissues, which may drive tumourigenesis. Lo-
cal steroidogenesis and ultimately production of androgens has been observed
in androgen independent advanced prostate cancers (Dillard et al., 2008). In
prostate cancer, the local production of androgens may explain the develop-
ment of hormonal treatment resistance in late-stage disease.
Summary statistics of GWAS signals obtained through GWAS central identified
significant associations of rs11075995 with overall and ER negative breast can-
cer risk and with BMI. No other trait was reported to be associated at p < 0.001
with rs11075995. BMI is a known dose-dependent risk factor for developing
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breast cancer in post-menopausal women (Liu et al., 2018). Interestingly, breast
cancer risk association studies that have adjusted for BMI have demonstrated
a dependence for variants at the rs11075995 locus on BMI status (Kang et al.,
2017). However, an independent relationship was described for ER negative
breast cancer risk and BMI for rs11075995 (Garcia-Closas et al., 2013), suggest-
ing that variants in the same locus may have disease-specific risk profiles.
The variant rs11075995 is located in intron 2 of the FTO gene (Figure 6.8A).
Interestingly, we observed a marginally significant decrease in FTO (p = 0.05)
expression in breast tissue associated with individuals homozygous for the
rs11075995 risk allele (Figure 6.5). FTO is involved in demethylation of RNA
adenosine (m6A). Methylated adenosines are post-transcriptional modifications
that signal RNAs for further processing, including degradation and splicing
(Mauer et al., 2019). The four genes associated with rs11075995 all have the
m6A target site (GGACU). RNA variability may occur due to dysregulation
of these pathways (mRNA degradation and splicing) in response to decreased
FTO expression.
Variants in intron 1 and 2 of FTO have been strongly associated with obesity and
changes in BMI (Frayling et al., 2007; Wood et al., 2016), however, these vari-
ants act on the expression of the neighbouring gene Iroquois homeobox protein
3 (IRX3) in the hypothalamus region of the brain (Smemo et al., 2014). IRX3 is
a highly conserved transcription factor typically expressed during neural de-
velopment (Cohen et al., 2000). The role of IRX3 in obesity is yet to be fully
elucidated, with conflicting reports of body mass associated to deficient Irx3.
Smemo et al., described a 30% increase in body weight of Irx3-deficient mice
(Smemo et al., 2014), while in contrast the partial depletion of Irx3 through
a lentiviral system resulted in mice with greater body mass (de Araujo et al.,
2019).
Intriguingly, both IRX3 and FTO are highly expressed in the hypothalamus,
a region of the brain important to hormonal regulation (de Araujo et al., 2019;
Smemo et al., 2014). It is unknown whether risk variants for either BMI or breast
cancer, directly disrupt the regulation of hormonal control in the hypothalamus.
Furthermore, it is unclear what effect IRX3 expression would have on breast
cancer risk and whether any effect would be independent of the risk attributed
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to obesity alone. A better understanding of the downstream transcriptional tar-
gets of IRX3 may identify pro-tumourgeneic pathways.
The results in this study are consistent with the hypothesis that different vari-
ants in the FTO locus may be associated with tissue-specific hormonal control
and subsequently different pathologies. Consequently, we would expect dif-
ferences in the regulation of C21 hormones in breast tissue for the different
rs11075995 genotypes. Furthermore, candidate genes identified through veQTL
analysis require functional validation. A major challenge with assessment of
intra-sample gene expression variability is the limitation of single-point ‘grind
and bind’ approaches. However, approaches such as RNA ISH and single cell
RNA-sequencing provide the ability to detect intratumural expression variabil-
ity. It is of further importance to derive the mechanism of variability, which
may be driven by interactions of genotypes with exposures or epistasis.
6.4 Conclusion
Breast cancer risk variants are associated with variable expression of candidate
breast cancer susceptibility genes. These included genes involved in hormonal
biosynthetic pathways that are associated with a single variant (rs11075995). To
our knowledge, this is the first time gene expression variability has been used
to identify candidate cancer susceptibility genes.
Chapter 7
Discussion
The principle aim of this thesis was to investigate gene expression variability
to identify genes associated with familial breast cancer. In addition to assess-
ing breast tumours from women carrying rare high risk variants in BRCA1 and
BRCA2, I sought to use gene expression variability to identify candidate breast
cancer susceptibility genes that are associated with common breast cancer risk
variants. These studies have revealed several key outcomes including; the iden-
tification of variably expressed genes in BRCA1- and BRCA2-associated breast
tumours (Chapter 3), the identification of global gene expression variability in
basal-like/BRCA1-associated tumours (Chapter 3), the creation of a web appli-
cation that can be used to interrogate gene expression variability results (Chap-
ter 3), validation of gene expression variability using RNAscope® in an inde-
pendent cohort of breast tumours (Chapter 3), generation of methods to assess
gene expression variability in vitro (Chapter 4), assessment of the impacts of
BRCA1 alterations on a luminal breast cancer cell line (Chapter 4, 5), the es-
tablishment of CRISPR-Cas genome engineering in our laboratory (Chapter 5),
and the development of veQTL analysis as a method to associate breast cancer
risk variants with candidate genes (Chapter 6).
7.1 Breast Tumour Gene Expression Variability
In tumours, gene expression variability has been used to identify a pan can-
cers essential gene set (Yu et al., 2008), tumour subtype phenotypes (Ecker et
al., 2015) and candidate synthetic lethal genes in BRCA2-associated ovarian tu-
mours (Bueno and Mar, 2017). In this thesis, gene expression variability analy-
ses successfully characterised basal-like, BRCA1- and BRCA2-associated breast
tumours for the first time (Chapter 3). BRCA1-associated and basal-like breast
tumours both exhibited greater global variability compared to BRCAx and non-
basal tumours, respectively (Figure 3.1). The increase in BRCA1-associated gene
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expression variability is likely a contributing factor to the poor replicability of
published ‘BRCA1 signatures’ (Table 1.2). Gene expression variability was used
to identify 36 candidate genes that were differentially variable between BRCA1-
associated and BRCAx breast tumours (Figure 3.10). Three genes (DSC3, EN1
and IGF2BP3) of the 36 BRCA1-associated genes were also identified as vari-
ably expressed between basal-like and non-basal tumours. To validate these
observations, RNAscope® was used to investigate EN1 expression in an inde-
pendent cohort of breast tumours, the results of which were consistent with
BRCA1-associated tumours demonstrating greater EN1 expression variability
(Figure 3.12).
7.1.1 Gene Expression Variability: A Symptom of Tumour Het-
erogeneity
BRCA1 and basal-like breast tumours exhibited consistently greater gene ex-
pression variability compared to BRCAx and non-basal tumours, respectively
(Figure 3.1,3.5). BRCA1-associated breast tumours are commonly characterised
as basal-like, with 72% of BRCA1-associated tumours in this study predicted
as basal-like tumours (Table 3.3). These tumours typically present younger in
age, are higher in histological-grade, more aggressive, and are more likely triple
negative compared to non-basal breast tumours (Sørlie et al., 2003; Yehiely et
al., 2006; Wang et al., 2018). Additionally, these tumours are associated with in-
creased genomic instability and tumour-infiltrating lymphocytes (TILs) (Kwei
et al., 2010; Sedic et al., 2015; de Boo et al., 2020), which may be a source of
gene expression variability. However, high levels of TILs are also observed
in HER2 over-expressing breast tumours (Loi et al., 2014; de Boo et al., 2020),
which compared to basal-like tumours had less gene expression variability and
were similar to other non-basal subtypes (Luminal A, Luminal B and normal)
(Supplementary Figure D.3). Additionally, there was little evidence of immune
function from the results of pathway analysis performed on either BRCA1-
associated or basal-like variable gene sets. These results suggest that basal-like,
and likely BRCA1-associated, tumours have greater gene expression variability
irrespective of the increased presence of TILs.
The increased genomic instability and mutation burden observed in BRCA1-
associated tumours (Kwei et al., 2010) along with tumourigenesis occurring
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during an early cell state (Lim et al., 2009; Nolan et al., 2016), may drive gene ex-
pression variability observed in these tumours (Figure 7.1A). BRCA1-associated
and basal-like tumour development initiates in luminal progenitor cells (Lim et
al., 2009; Nolan et al., 2016), which have greater differentiation potential com-
pared to luminal tumours that develop from mature mammary epithelium (Ri-
som et al., 2018)(Figure 7.1A). Furthermore, genes involved in stem cell devel-
opment were over-represented in basal-like tumours (Figure 3.7). The ability
of the developing tumour to differentiate, along with greater genomic instabil-
ity can lead to greater frequency of sub-clonal populations (Figure 7.1A). Inter-
and intra-tumoural gene expression variability between basal and luminal tu-
mours can be captured for a given gene, or globally, based on tumour sampling
(Figure 7.1B). Therefore, inter-tumoural gene expression variability may pre-
dict heterogeneous expression for a given tumour type. In contrast, tumour
tissue has been shown to exhibit similar gene expression variability compared
to normal-matched tissues, suggesting that the acquisition of somatic muta-
tions has little impact on variability (Yu et al., 2008). However, as I observed
that BRCA1-associated and basal-like tumours exhibited significantly greater
variability compared to BRCAx, BRCA2-associated and non-basal tumours, it
is possible that these tumours have a phenotype of global changes not captured
in other tumour types.
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FIGURE 7.1: A model of breast tumour development and the arise of gene expres-
sion variability. A) Schematic of mammary epithelial cell differentiation and subtype-
specific breast tumour development. BRCA1-associated and basal-like tumours initia-
tion at the luminal progenitor cells state and have the capacity to further differentiation.
Subsequent tumour cells can express any combinations of the luminal (Cytokeratin
19, CK19), basal (Cytokeratin 14, CK14), and mesenchymal (Vitmentin, VIM) mark-
ers. In contrast, luminal tumours initiate from well differentiated ductal epithelium
and exclusively express CK19. Additionally, BRCA1-associated and basal-like tumours
are subjected to greater genomic instability and subsequently greater mutational bur-
den, which can contribute to greater sub-clonal populations (reflected as differently
coloured tumours cells). B) Intra-tumour gene expression variability can be a symp-
tom of tumour heterogeneity. Sub-clonal cell populations can have distinct expression
levels for any given gene, and the proportion of cellularity in the tumour bulk can ef-
fect sampling that will alter the sample mean expression. Sampling, either within a
tumour or across a population will lead to greater variability in basal-like tumours (B,
far right).
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7.1.2 Impact of Loss of BRCA1 Functions on Gene Expression
Variability
In addition to impaired DNA damage and cell cycle control, BRCA1 may di-
rectly influence gene expression variability by altering the epigenetic landscape.
BRCA1 interacts with histone deactylases (Yarden and Brody, 1999; Chai et
al., 1999), can ubiqunate histones through association with BARD1 (Xia et al.,
2003; Zhu et al., 2011) and can indirectly alter DNA methylation (Suijkerbuijk
et al., 2008; Shukla et al., 2010). BRCA1 deficiency is associated with an open
chromatin and an active expression state, reflected by increased histone acety-
lation at ‘transcriptionally active’ H3AcK9, H4AcK16 and tri-meythlation at
H3Me3K4 markers, the loss of repressive histone mono-ubiqutination and the
decrease in global DNA methylation (Yarden and Brody, 1999; Shukla et al.,
2010; Filipponi et al., 2013). The shift towards a ‘transcriptionally active’ genome
would generate competition between transcription start sites for transcriptional
machinery and thus increase the influence of stochastic driven variability. Tran-
scription activation of a given gene would be influenced by availability of tran-
scriptional machinery, which is not a limiting factor in cells under regular tran-
scriptional control. In studies of single cell organisms, expression variability is
influenced by several transcriptional events, including rate and promoter ac-
tivity (Elowitz et al., 2002; Blake et al., 2003; Raser and O’Shea, 2004; Lin and
Amir, 2018).
Changes in DNA methylation and histone modification are also important in
stem cell differentiation both in embryo development and adulthood (Meissner
et al., 2008; Montalbán-Loro, 2015; Toh et al., 2017; Risom et al., 2018). Loss of
BRCA1-associated epigenetic functions may increase cell differentiation states
or inhibit normal mammary cell differentiation. The decrease in, but not loss
of, luminal markers observed in BRCA1 RNA depleted or mutated MCF-7 cells
(Figure 4.8) may be a reflection of a small number of cells that have lost lumi-
nal markers. However, the depletion of BRCA1 RNA in MCF-7 cells showed
no global changes in expression variability, a phenotype expected under this
model of mixed cell states. The lack of gene expression variability may resolve
after greater time exposed to BRCA1 alterations.
Furthermore, BRCA1 is able to directly and indirectly alter the expression of
genes including; ESR1 (Hosey et al., 2007), genes involved in the DNA dam-
age response (Li et al., 2000) and several transcriptional factors (Gorski et al.,
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2011). Chromatin immunoprecipitation data in MCF-7 cells indicated that only
a small fraction (44/1294) of differentially expressed genes exhibited BRCA1 in-
teraction at promoter regions, which included 14 transcription factors, none of
which were variably expressed in this study (Gorski et al., 2011). It is unlikely
that BRCA1-associated transcription drives global variability due to the small
number of transcriptionally regulated targets.
7.1.3 Variable Expression of BRCA1-Associated Candidate Genes
BRCA1-associated variable genes are of particular interest as these can poten-
tially be used as a phenotype to aid in the classification of variants of unknown
clinical significance. However, a major challenge with gene expression vari-
ability is the number of samples required to capture the phenotype. BRCA1
pathogenic variants are rare, and therefore the sample size of individuals with
variants of unknown clinical significance are likely to be small. To overcome
the limitation in sample numbers, variability needs to be captured either at the
individual level or by the development of appropriate models. To investigate
BRCA1-associated variable genes, RNAscope® was successfully performed on
503 breast tumours and revealed an increase in variability of EN1 in BRCA1-
associated breast tumours (Figure 3.12), consistent with observations in breast
tumour microarrays. However, the analysis here was limited to inter-tumoural
variability and intra-tumoural variability was not captured. Manual assess-
ment was not considered as it has been previously assessed in parallel stud-
ies from this laboratory (Morley-Bunker, 2020), illustrating the limitations in
the accuracy of manual signal detection, in particular with dark stained chro-
matin and granulated nuclei, that makes it is difficult to distinguish between
signals and noise. Nevertheless, the results showed that high levels of EN1
expression may be able to identify BRCA1-associated breast tumours. How-
ever, there would remain a large number of false negatives, as many BRCA1-
associated tumours showed low expression. To better understand the utility of
EN1 as a marker of ‘BRCAness’ a method of estimating intra-tumoural variabil-
ity needs to be established and complete tumour sections should be assessed.
RNAscope® fluorescent based assays offer the ease of segmenting signal from
nuclei, at the cost of losing histological features, that would be more amenable
to signal per cell estimates. An ongoing project in collaboration with a breast
pathologist (Dr Gavin Harris, CDHB) and software engineers (Professor Ra-
makrishnan and colleagues, University of Canterbury) aims to develop a tool
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that will better segment nuclei and RNA signals in histological sections, with
the potential to provide signals per nuclei data. The advantage of histological
sections is the ease of identifying different cell types and tissue structures that
may correlate with signal intensity. Additionally, access to slide scanners al-
lows a potential automative approach that would be better suited for clinical
applications. Single cell sequencing also provides data that can estimate intra-
tumoural and inter-tumoural gene expression variability for candidate genes or
globally. However, major challenges with this technology remain around iso-
lating single cells and whether isolating cell types by flow cytometry would be
appropriate. For example, breast epithelial cells and tumour cells express the
epithelial cell adhesion molecule (EpCAM) that can be used to isolate these cell
types (Nguyen et al., 2018). However, the loss of stromal cells may be impor-
tant in contextualising tumour characteristics and influence the gene expres-
sion variability observed in the tumour bulk. To maintain all cell types, a non-
discriminative single-cell isolation method (e.g.the BioRad ddSeq Single-Cell
Isolator) would be better suited, however, a greater number of cells sequenced
would be required.
Loss of BRCA1 function models in MCF-7 and MCF-10A cells failed to mimic
gene expression variability observed in tumour analysis (Chapter 4). How-
ever, limitations in experimental design may obscure the translation between
tumours and cell lines. In particular, it was difficult to optimise the conditions
to allow ‘natural’ variation between isogenic cell lines. Additionally, individ-
uals carrying pathogenic variants are exposed for a significantly longer time
than the time each cell model was exposed to altered BRCA1. Understand-
ing gene expression variability in non-diseased breast tissue and early DCIS
would help clarify the timing of gene expression variability in BRCA1 carriers.
Furthermore, the small number of samples limited the ability to detect small
changes in gene expression variability. Nevertheless, pathway analysis of dif-
ferentially variable genes suggested alteration in RNA processing in both tu-
mour and cell line analyses. In the tumour analysis, genes involved in enhancer
and RNA polymerase binding were variably expressed, whilst in MCF-10A cell
models genes involved in RNA catabolism were enriched. Interestingly, Chap-
ter 6 identified that one mechanism of rs11075995 associated gene expression
variability might be through FTO RNA demethylation activity. The rs11075995
variant is associated with ER negative breast cancer risk. Taken together, there
is a theme of altered RNA stability and ER negative breast cancer development.
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7.2 Variable Expression Quantitative Trait Loci
GWAS have identified thousands of common variants associated with hun-
dreds of traits, however, linking variants to causal genes has been difficult, es-
pecially as the majority of these variants occurs in non-coding regions (Edwards
et al., 2013; MacArthur et al., 2017). Through large multi-consortia collabora-
tion more than 200 risk variants have been identified that associated with either
breast cancer or subtype-specific breast cancer risk (Supplementary Table D.1),
this includes 32 loci identified in May 2020 (Zhang et al., 2020). Approximately
900 target genes have been identified as potential causal genes associated with
breast cancer risk variants using a range of different genomic data including
tissue-specific eQTL (Michailidou et al., 2015, 2017; Ferreira et al., 2019; Zhang
et al., 2020). In Chapter 6, veQTL analysis identified a further 60 genes that
were associated with 27 breast cancer risk variants (Table 6.2). The 32 newly
identified variants were published subsequent to the results presented here and
remain untested by veQTL analysis.
The variant rs11075995 produced the strongest veQTL signal for four genes
(CYP11B1, CYP17A1, HSD3B2 and STAR), all of which are involved in C21-
hormonal biosynthesis. Additionally, individuals homozygous for the risk al-
lele (A/A) had reduced expression of the RNA demethylase FTO, where rs11075995
is located in the second intron of FTO. Local production of steroid hormones
have been previously observed in advanced prostate cancers, whereby the lo-
cal production of androgens is thought to contribute to treatment resistance
(Dillard et al., 2008). The results of breast tissue veQTL analysis suggests that
individuals homozygous for the rs11075995 risk allele may be able to synthe-
sise steroid hormones in breast tissue that might increase breast cancer risk.
The variability in expression may be a result of a genotype by exposure effect,
whereby individuals homozygous for the rs11075995 risk allele have the capac-
ity to ‘switch on’ local C21-biosynthesis in the presence of high cholesterol. Ad-
ditionally, these genes all contain the target site for FTO-specific RNA demethy-
lation, which can alter RNA processing (Mauer et al., 2019). These hypotheses
need to be experimentally validated by firstly identifying any physical inter-
actions that rs11075995 locus makes that may link to enhancer or promoters of
CYP11B1, CYP17A1, HSD3B2 and STAR. These chromatin immunoprecpication
experiments would need to be performed with non-disease breast tissue, as the
veQTL interactions were only observed in breast tissue. Additionally, the vari-
able expression of CYP11B1, CYP17A1, HSD3B2 and STAR may be indirectly
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linked to rs11075995 through changes in FTO expression. Under this hypothe-
sis the knock-down of FTO in breast cell lines may lead to variable expression of
each of the target genes that would be abrogated by FTO over-expression. Ad-
ditionally, RNA decay assays can be used to assess the stability of expression
with and without the presence of FTO. Ultimately, recapturing these observa-
tions in a larger cohort with cholesterol data would be essential to determine
any environment by genotype effect.
There are many loci that have been identified through GWAS, in which the
causative mechanisms with the trait remain unknown. Molecular QTL analy-
ses including veQTL, eQTL, sQTL and meQTL can be used independently or
collectively to aid researchers in identifying candidate genes associated with
loci. The co-occurring of QTL signals may strengthen the connection of a locus
with a gene, for example a variant may alter the expression of a gene (eQTL)
through changes in methylation (meQTL) (Pierce et al., 2018). Additionally, al-
ternative QTL analyses may give explanations for the variable expression trait
that is captured by veQTL analysis. In particular, identifying changes in abun-
dance of splicing isoforms (sQTL) and methylation changes can each explain
gene expression phenotypes. There remain significant challenges with molec-
ular QTL analyses, in particular due to the large number of tests performed
leading to a larger number of false positives. For small effect sizes, there is a
requirement for 100-1000 of samples to be profiled. Additionally, to maintain
biological relevance, molecular data should be collected from the appropriate
tissue(s) (i.e. tissue the disease presents in), however, due to limited access to
normal tissue this may not be possible. The GTEx dataset is therefore a valu-
able resource to explore potential eQTL associations in non-diseased tissues.
Furthermore, restricted access to genotype data can allow researchers the abil-
ity to investigate other gene expression traits, such as veQTL (Chapter 6) and
sQTL analysis.
7.3 Future Research
There are a number of applications and future studies that can be explored as a
direct result of the studies throughout this thesis. As BRCA1-associated breast
tumours showed greater gene expression variability compared to other breast
tumours, it is of interest to understand the underlying mechanisms involved.
One hypothesis proposed is that the development of greater clonal populations
Chapter 7. Discussion 183
within a tumour, through both greater plasticity and genomic instability, gen-
erated greater gene expression variability. To test this hypothesis, RNAscope®
in combination with IHC can estimate expression of a given gene in tumour
cells that express different cellular markers. These cell markers can characterise
cell state (e.g. CK19 for luminal, CK14 for basal and VIM for mesenchymal)
or clinical markers (e.g. ER, PgR, HER2 and Ki67). The identification of an
appropriate RNA target remains challenging. EN1 did show inter-tumoural
gene expression variability in tumour cores, however, no obvious heteroge-
neous staining was observed and methods to accurately measure this are still
needed. It is possible that whole tumour sections may be required to accurately
identify any clonal populations, and that tissue cores are too small to capture
different clonal niches. To overcome these limitations, single-cell RNA sequenc-
ing could be used to estimate gene expression levels and predict cell types for
each cell in a given tumour sample. As there are significant costs, both finan-
cially and computationally, it would be prudent to use a pilot study to generate
non-discriminative single-cell libraries and assess the impact of stromal cells on
gene expression variability. Once determined, it may be possible to reduce the
number of cells sequenced per samples by purifying desired cell populations.
Assessing gene expression variability in non-diseased breast tissue could ex-
clude tumour heterogeneity as a driving factor of BRCA1-associated gene ex-
pression variability. The Cancer Society Tissue Bank and KConFab have col-
lected samples from individuals that have undergone prophylactic mastectomy
and carry pathogenic variants in BRCA1 or BRCA2, thus offering a valuable re-
source for RNA extraction. Additionally, control breast tissue can be acquired
from individuals who have undergone breast reductive surgery. It is unknown
whether sample tissues would be fixed in formalin or fresh-frozen and whether
fixed tissue is appropriate for gene expression variability analysis. Fixation and
time in fixative have negative impacts on RNA qualities that can effect down-
stream applications, including RNA quantification methods. Therefore, it is
desirable to obtain fresh-frozen samples for RNA quantification.
Similarly, measuring variability in healthy non-breast tissue may lead to the
identification of a mechanism of BRCA1-associated tumour tissue-specificity.
Prophylactic mastectomy and salpingo-oophorectomy are offered as clinical
management strategies for individuals carrying a pathogenic BRCA1 or BRCA2
variant, therefore these tissues are available for research, assuming appropriate
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ethical approvals. However, most other tissues, with the exception of blood,
are not routinely collected and therefore it makes it difficult to investigate dif-
ferences between normal human tissues. Instead, it would be simpler to use
Brca1 mouse models and generate transcriptome profiles from a range of tis-
sues before breast tumour development. There needs to be careful consider-
ations when selecting the appropriate mouse model to perform such experi-
ments. The ideal model would develop spontaneous mammary and ovarian
tumours with minimal genetic alterations and where tissue could be collected
for RNA isolation before tumourigenesis. The Brca1∆11/∆11 Tp53+/- mouse model
may present the most appropriate model, as mice develop mammary tumours
in the first year of life (Cao et al., 2003). Mice with only a single or bi-allelic
Brca1 mutation develop tumours in multiple non-breast tissues or die during
embryonic development (Ludwig et al., 2001; Dine and Deng, 2013). Addi-
tionally, conditional Brca1 knock-out models may be useful, however, these are
typically developed with tissue-specific Cre expression (e.g. Wap-Cre for mam-
mary tissues) resulting in tissue-specific Brca1 knock-out, making these models
not suitable to comparing tissue-specific effects (Xu et al., 1999; Dine and Deng,
2013).
The changes observed in luminal markers in MCF-7 cells with BRCA1 knock-
down or mutation are intriguing. At first, future studies need to fully char-
acterise the expression of basal and luminal markers in the isogenic MCF-7
BRCA1 mutant cell lines. Assessing these at markers at the single-cell level
using RNA ISH, IHC or ICC is critical, as the loss of BRCA1 function may shift
a small population of luminal MCF-7 cells to a basal-like phenotype. These
small population changes in phenotype would be lost in ‘grind and bind’ type
methodologies.
7.4 Conclusion
These studies successfully demonstrated the utility of gene expression variabil-
ity analysis to identify candidate breast cancer risk associated genes. BRCA1-
associated breast tumours displayed greater gene expression variability com-
pared to BRCAx tumours. Additionally, 36 variably expressed genes were iden-
tified in at least two independent breast cancer cohort that were associated
with BRCA1 pathogenic variants. Three genes (DSC3, EN1 and IGF2BP3) of
which were also found to be differentially variable in basal-like breast tumours
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compared non-basal tumours. RNA in situ hybridisation (RNA ISH) was used
to explore EN1 expression in 503 breast tumour cores, including 151 BRCA1-
associated tumours. Consistent with mircoarray analyses, RNA ISH found the
expression of EN1 was variable in BRCA1-associated tumours. A further 60
genes were identified as potential breast cancer susceptibility genes through ve-
QTL analysis with common risk variants, including the association of rs11075995
with four genes (CYP11B1, CYP17A1, HSD3B2 and STAR), all of which were in-
volved in C21-steroid biosyntheisis. Loss of BRCA1 via RNA knock-down or
mutation in MCF-7 cells demonstrated a potential transition from a luminal to
basal subtype. The application of gene expression variability analysis may lead
to a better understanding of the mechanisms involved in the development of
disease. Furthermore, these methods may transform how researchers interpret




Lysogeny broth (LB) medium consisted of 10 g peptone, 2.55 g yeast extract,
10 g NaCl, in 1 litre distilled H2O. This was autoclaved before use. LB agar
plates were made by the addition of 7.5 g agar to 500 mL LB medium, this
was autoclaved and poured Petri dishes (approximately 25 mL per dish) and
allowed to set.
A.2 SOB Medium
Super optimal broth (SOB) medium consisted of 20 g tryptone, 5 g yeast extract,
0.5 g NaCl, 10 ml 250 mM KCl in 1 litre distilled H2O. This was autoclaved
before use.
A.3 Nuclei Lysis Solution
Nuclei lysis solution consisted of 10 ml 2 M tris (pH8), 0.8 ml 0.5 M EDTA (pH8)
and 6.6 ml 3 M NaCl made up to 200 ml with distilled H2O. The solution was
autoclaved before use.
A.4 Direct Lysis Buffer
The Direct lysis buffer consisted of 1.776 g Tizma-HCl, 1.06 g Trizma base (20
mM Tris pH 8.0), 1.46 g EDTA (5 mM), 23.38 g NaCl (0.4 M), 15 ml 20% SDS
(0.3%), 6 ml (Tween-20) (0.6%) made up to 1 litre with distilled H2O.
186
Appendix A. Reagent preparations 187
A.5 Phosphate buffered saline
For a 10x solution 10 PBS tablets (Gibco) were dissolved in 500 ml of H2O. Once
dissolved the solution was autoclaved and store for use.
A.6 RF1 buffer
The RF1 buffer consisted of 5.44 g RbCl, 4.45 g MnCl2.4H2O, 13.5 ml 1M KCH3COO
(pH 7), 0.66 g CaCl2 and 77.6 ml glycerol in 450 ml distilled H2O. This is pH ad-
justed to 5.8 with 0.2 M acetic acid and then filter sterilised.
A.7 RF2 buffer
The RF2 buffer consisted of 1.05 MOPS (pH 6.8), 0.127 g RbCl, 1.16 g CaCl2.2H2O,
18.06 ml glycerol in 105 ml distilled H2O. This is pH adjusted to 6.8 with 0.1 M





TABLE B.1: MCF-7 complete media
Component Volume Final Concentration
DMEM 500 ml –
FBS 50 ml 10%
Anti-Anti 5 ml 1%
Anti-Anti, Antibiotic-Antimycotic
B.1.2 Conditioned media
Conditioned media was made with equal volumes of MCF-7 complete media
and media that had conditioned on growing MCF-7 cells for 24-48 hours. The
mixture was filtered through 0.22 µM filter before use. Condition media was
used with 24 hours or was stored at -20◦C for up to two weeks.
B.1.3 Freezing media
MCF-7 cells were resuspended in MCF-7 complete media with 20% FBS and
10% DMSO.
TABLE B.2: MCF-7 freezing media
Component Volume Final Concentration
MCF-7 complete media 900 ml –
FBS 100 µl 20%
DMSO 100 µl 10%
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B.2 MCF-10A
Human BRCA1185delAG/+ MCF-10A cells and the matched wild type MCF-10A
were purchased from Horizon Discovery Ltd (Waterbeach, UK).
B.2.1 Complete media
Each component was resuspended as per manufactures recommendation and
aliquoted for storage: EGF was resuspended at 100 µg/ml in dH2O. Aliquots
were stored at -20◦C
Hydrocortisone was resuspended at 1 mg/ml in absolute ethanol. Aliquots
were stored at -20◦C
Cholera toxin was resuspended at 1 mg/ml in sterile H2O. Solution was left for
10 minutes before aliquoted and stored at 4◦C
Insulin was resuspended at 10 mg/ml in sterile H2O containing 1% glacial
acetic acid. Solution was allowed to reconstitute for 20 minutes before being
aliquoted and stored at 4◦C
Horse serum was aliquoted to prevent freeze thaw
TABLE B.3: MCF-10A complete media
Component Volume Final Concentration
DMEM/F-12, HEPES 500 ml –
Horse serum 25 ml 5%
EGF (100 µg/ml) 100 µl 20 ng/ml
Hydrocortisone (1 mg/ml)a 250 µl 0.5 mg/ml
Bovine insulin (10 mg/ml)b 500 µl 10 µg/ml
Cholera Toxin (1 mg/ml) 50 µl 100 ng/ml
a Resuspend to stock concentration with absolute ethanol
b Resuspend in dH2O containing 1% glacial acetic acid
Complete media was made by adding the respective additives, listed in Ta-
ble B.3, together and filtering contents through a 0.22 µM filter. Anti-anti was
added at 1% final concentration to filter media.
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B.2.2 Freezing media
For freezing MCF-10A cells were resuspended in complete media supplemented
with 7.5% DMSO and 1 ml aliquots were transferred into cyrovials. For MCF-
10A BRCA1185delAA/+ cells were resuspended in complete media supplemented
with 50% FBS and 5% DMSO.
TABLE B.4: MCF-10A freezing media
Component Volume Final Concentration
MCF10-A complete media 925 µl –
DMSO 75 µl 7.5%
TABLE B.5: MCF-10A BRCA1185delAA/+ freezing media
Component Volume Final Concentration
MCF-10A complete media 500 µl –
FBS 500 µl 50%
DMSO 50 µl 5%
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Appendix C
Oligonucleotides
TABLE C.1: Off-targets for gRNA guide Cas9 clevage predicted by Cas-OFFinder
gRNA Name Chr Position Strand Mismatches Gene
BRCA1_gRNA1 chr13 24944243 - 3 TPTE2P1
BRCA1_gRNA1 chr22 16645922 + 3 TPTEP1
BRCA1_gRNA1 chrX 110782982 + 1 CHRDL1
BRCA1_gRNA2 chr15 76224331 + 3 ETFA
BRCA1_gRNA2 chr17 81003915 - 3 CHMP6
BRCA1_gRNA2 chr6 122778689 - 3 FABP7
BRCA1_gRNA2 chr9 134065726 - 3 BRD3
BRCA1_gRNA3 chr8 123970613 - 3 FER1L6
BRCA1_gRNA3 chr12 28432878 - 3 CCDC91
BRCA1_gRNA3 chr12 71962377 - 3 TPH2
BRCA1_gRNA3 chr12 93506856 - 3 MRPL42
BRCA1_gRNA3 chr3 117717384 + 3 RP11-384F7.2
BRCA1_gRNA3 chr7 33038223 + 3 NT5C3A
BRCA1_gRNA3 chr13 46629123 + 3 LRCH1
BRCA1_gRNA3 chr2 232193247 - 3 DIS3L2
BRCA1_gRNA3 chr22 33854932 + 3 LARGE
BRCA1_gRNA4 chr8 69766728 - 3 SLCO5A1
BRCA1_gRNA4 chr3 120062309 - 2 GSK3B
BRCA1_gRNA4 chr4 101679252 - 3 BANK1
BRCA1_gRNA4 chr5 36952777 + 3 NIPBL
BRCA1_gRNA4 chr1 234314909 - 3 SLC35F3
BRCA1_gRNA4 chr10 70955461 + 3 LOC1053878349
BRCA1_gRNA4 chr6 7814634 + 3 BMP6
BRCA1_gRNA5 chr8 23718932 + 3 RP11-175E9.1
BRCA1_gRNA5 chr8 105022733 - 3 ZFPM2
BRCA1_gRNA5 chr3 129716652 - 3 TMCC1
BRCA1_gRNA5 chr7 20677769 - 3 ABCB5
BRCA1_gRNA5 chr5 97097967 - 3 LIX1
BRCA1_gRNA5 chr1 19304310 - 3 AKR7A2
BRCA1_gRNA5 chr1 57927025 - 3 DAB1
BRCA1_gRNA5 chr2 209533829 + 3 MAP2
BRCA1_gRNA5 chr19 47818157 - 3 TPRX1
BRCA1_gRNAdel chr3 141123702 + 3 SPSB4
BRCA1_gRNAdel chr13 100201321 + 3 FCCA
BRCA1_gRNAdel chr19 30859709 + 3 CTC-400I9.2
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TABLE C.2: ssDNA oligonucleotides for gRNA













TABLE C.3: Primer properties used in colony PCR
Oligonucleotides∗ Sequence (5 –> 3) Length Tm GC% Self Self 3‘
U6 fwd GAGGGCCTATTTCCCATGATTCC 23 60.82 52.17 5 1
BRCA1_gRNA1 AAACTCCATGAGTTGTAGGTTTCT 24 58.06 37.5 8 0
BRCA1_gRNA2 AAACCTCTTCGGTAACCCTGAGCC 24 64.43 54.17 5 1
BRCA1_gRNA3 AAACTTGGGGTTTTCAAATGCTGC 24 61.46 41.67 5 3
BRCA1_gRNA4 AAACCCTATCATTACATGTTTCCT 24 56.06 33.33 6 0
BRCA1_gRNA5 AAACCTGTTTCTACCTAGTTCTGC 24 58.69 41.67 6 2
BRCA1_gRNAdelAA AAACCTCTGGGTCCTTAAAGAAAC 24 58.86 41.67 6 5
U6 fwd primer is the forward primer to the remaining primers. All products are 240 bp
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TABLE C.4: Primer sequences to detect CRISPR-Cas9 guided edits
Oligo Sequence (5 –> 3) Length Tm GC% Self Self 3‘ Product size
BRCA1
gRNA1 fwd
TGCTTTCAAAACGAAAGCTG 20 55.7 40 7 3 309
BRCA1
gRNA1 rev
CTCTTCTTGGCTCCAGTTGC 20 58.84 55 4 2 309
BRCA1
gRNA2 fwd
GGAGTCCTAGCCCTTTCACC 20 59.46 60 5 0 386
BRCA1
gRNA2 rev
GAAAGGATCCTGGGTGTTTG 20 56.31 50 8 1 386
BRCA1
gRNA3 fwd
AATGCTGAAGACCCCAAAGA 20 57.02 45 2 0 305
BRCA1
gRNA3 rev
CTTGTTTCCCGACTGTGGTT 20 58.32 50 3 0 305
BRCA1
gRNA4 fwd
TCATGCCAGCTCATTACAGC 20 58.33 50 4 2 372
BRCA1
gRNA4 rev
TCCCCATCATGTGAGTCATC 20 56.69 50 5 3 372
BRCA1
gRNA5 fwd
GGCAACGAAACTGGACTCAT 20 58.48 50 3 2 399
BRCA1
gRNA5 rev
CTCAGGTTGCAAAACCCCTA 20 57.71 50 6 2 399
BRCA1
delAA fwd
CAGGAAAGCCTGCAGTGATA 20 57.59 50 6 2 142
BRCA1
delAA rev
ACATTCTCTGCCCACTCTGG 20 59.38 55 3 3 142
TABLE C.5: Primer-probe assays from IDT
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TABLE D.1: Known Breast Cancer Risk Variants
GTEx_arrayID Location Variant Reference
1_10566215_A_G_b37 1_10566215 rs616488 Michailidou, K. et al. (2013)
1_114448389_C_T_b37 1_114448389 rs11552449 Michailidou, K. et al. (2013)
1_118230221_T_C_b37 1_118230221 rs7529522 Michailidou, K et al. (2017)
1_121280613_A_G_b37 1_121280613 rs11249433 Thomas, G. et al. (2009)
1_145644984_C_T_b37 1_145644984 rs12405132 Finucane, H. K. et al. (2015)
1_149927034_A_C_b37 1_149927034 rs12048493 Finucane, H. K. et al. (2015)
1_155148781_G_A_b37 1_155148781 rs4971059 Michailidou, K et al. (2017)
1_18807339_T_C_b37 1_18807339 rs2992756 Michailidou, K et al. (2017)
1_201437832_C_T_b37 1_201437832 rs35383942 Michailidou, K et al. (2017)
1_202187176_G_A_b37 1_202187176 rs6678914 Garcia- Closas, M. et al. (2013)
1_203766331_A_G_b37 1_203766331 rs4951011 Cai, Q. et al. (2014)
1_204518842_C_A_b37 1_204518842 rs4245739 Garcia- Closas, M. et al. (2013)
1_217220574_G_A_b37 1_217220574 rs11117758 Michailidou, K et al. (2017)
1_242034263_A_G_b37 1_242034263 rs72755295 Finucane, H. K. et al. (2015)
1_41380440_C_T_b37 1_41380440 rs4233486 Michailidou, K et al. (2017)
1_42137311_T_G_b37 1_42137311 rs79724016 Michailidou, K et al. (2017)
1_46600917_A_G_b37 1_46600917 rs1707302 Michailidou, K et al. (2017)
NA 1_50846033 rs140850326 Michailidou, K et al. (2017)
1_88156923_G_A_b37 1_88156923 rs17426269 Michailidou, K et al. (2017)
10_114773927_A_G_b37 10_114773927 rs7904519 Michailidou, K. et al. (2013)
10_123093901_C_T_b37 10_123093901 rs11199914 Michailidou, K. et al. (2013)
10_123340311_C_T_b37 10_123340311 rs2981578 Meyer, K. B. et al. (2013)
NA 10_123340432 rs35054928 Meyer, K. B. et al. (2013)
10_123349324_A_T_b37 10_123349324 rs45631563 Meyer, K. B. et al. (2013)
10_22032942_A_G_b37 10_22032942 rs7072776 Michailidou, K. et al. (2013)
10_22315843_A_C_b37 10_22315843 rs11814448 Michailidou, K. et al. (2013)
10_5886734_C_T_b37 10_5886734 rs2380205 Turnbull, C. et al. (2010)
10_64299890_A_G_b37 10_64299890 rs10995201 Darabi, H. et al. (2015)
10_80841148_T_C_b37 10_80841148 rs704010 Turnbull, C. et al. (2010)
NA 10_9088114 rs67958007 Michailidou, K et al. (2017)
NA 10_95292188 rs140936696 Michailidou, K et al. (2017)
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NA 11_108345516 rs11374964 Milne et al. (2017)
11_108357137_G_A_b37 11_108357137 rs74911261 Milne et al. (2017)
11_129461171_T_C_b37 11_129461171 rs11820646 Michailidou, K. et al. (2013)
11_1909006_T_C_b37 11_1909006 rs3817198 Easton, D. F. et al. (2007)
11_65583066_G_T_b37 11_65583066 rs3903072 Michailidou, K. et al. (2013)
11_69331642_C_G_b37 11_69331642 rs554219 French, J. D. et al. (2013)
11_69379161_C_A_b37 11_69379161 rs75915166 French, J. D. et al. (2013)
11_803017_A_G_b37 11_803017 rs6597981 Michailidou, K et al. (2017)
12_115836522_A_G_b37 12_115836522 rs1292011 Ghoussaini, M. et al. (2012)
12_120832146_C_T_b37 12_120832146 rs206966 Michailidou, K et al. (2017)
12_14413931_G_C_b37 12_14413931 rs12422552 Michailidou, K. et al. (2013)
12_28174817_C_T_b37 12_28174817 rs7297051 Zeng, C. et al. (2016)
NA 12_85009437 rs202049448 Michailidou, K et al. (2017)
12_96027759_A_G_b37 12_96027759 rs17356907 Michailidou, K. et al. (2013)
13_32972626_A_T_b37 13_32972626 rs11571833 Michailidou, K. et al. (2013)
13_73957681_A_G_b37 13_73957681 rs6562760 Couch, F. J. et al. (2016)
NA 14_105212262 rs10623258 Michailidou, K et al. (2017)
14_37132769_G_A_b37 14_37132769 rs2236007 Michailidou, K. et al. (2013)
14_68660428_T_C_b37 14_68660428 rs2588809 Michailidou, K. et al. (2013)
14_69034682_C_T_b37 14_69034682 rs999737 Thomas, G. et al. (2009)
14_91841069_A_G_b37 14_91841069 rs941764 Michailidou, K. et al. (2013)
14_93104072_T_C_b37 14_93104072 rs11627032 Finucane, H. K. et al. (2015)
15_91512067_G_A_b37 15_91512067 rs2290203 Cai, Q. et al. (2014)
16_4106788_C_A_b37 16_4106788 rs11076805 Milne et al. (2017)
16_52599188_C_T_b37 16_52599188 rs4784227 Ghoussaini, M. et al. (2012)
16_53813367_T_G_b37 16_53813367 rs17817449 Michailidou, K. et al. (2013)
16_53855291_A_T_b37 16_53855291 rs11075995 Garcia- Closas, M. et al. (2013)
16_54682064_G_A_b37 16_54682064 rs28539243 Michailidou, K et al. (2017)
16_56420987_A_G_b37 16_56420987 rs2432539 Michailidou, K et al. (2017)
16_80650805_A_G_b37 16_80650805 rs13329835 Michailidou, K. et al. (2013)
16_87085237_C_A_b37 16_87085237 rs4496150 Michailidou, K et al. (2017)
NA 17_29230521 rs146699004 Finucane, H. K. et al. (2015)
17_40836389_C_T_b37 17_40836389 rs72826962 Michailidou, K et al. (2017)
NA 17_44252468 rs2532263 Michailidou, K et al. (2017)
17_53209774_A_C_b37 17_53209774 rs2787486 Darabi, H. et al. (2016)
17_77781725_A_G_b37 17_77781725 rs745570 Finucane, H. K. et al. (2015)
18_24337424_C_G_b37 18_24337424 rs527616 Michailidou, K. et al. (2013)
18_24570667_T_G_b37 18_24570667 rs1436904 Michailidou, K. et al. (2013)
NA 18_25401205 rs36194942 Milne et al. (2017)
18_29977689_T_C_b37 18_29977689 rs117618124 Michailidou, K et al. (2017)
18_42399590_A_G_b37 18_42399590 rs6507583 Finucane, H. K. et al. (2015)
19_11423703_C_G_b37 19_11423703 rs322144 Milne et al. (2017)
19_13158277_T_C_b37 19_13158277 rs78269692 Michailidou, K et al. (2017)
19_13954571_G_A_b37 19_13954571 rs2594714 Michailidou, K et al. (2017)
19_17401404_C_G_b37 19_17401404 rs67397200 Lawrenson, K. et al. (2016)
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19_18571141_A_G_b37 19_18571141 rs4808801 Michailidou, K. et al. (2013)
19_19545696_G_A_b37 19_19545696 rs2965183 Michailidou, K et al. (2017)
19_30277729_C_T_b37 19_30277729 rs113701136 Milne et al. (2017)
19_44286513_A_G_b37 19_44286513 rs3760982 Michailidou, K. et al. (2013)
NA 19_46183033 rs71338792 Michailidou, K et al. (2017)
2_10135681_C_G_b37 2_10135681 rs113577745 Michailidou, K et al. (2017)
NA 2_111925738 rs71801447 Michailidou, K et al. (2017)
2_121245122_T_C_b37 2_121245122 rs4849887 Michailidou, K. et al. (2013)
2_172972971_G_A_b37 2_172972971 rs2016394 Michailidou, K. et al. (2013)
2_174212894_G_A_b37 2_174212894 rs1550623 Michailidou, K. et al. (2013)
2_19320803_T_C_b37 2_19320803 rs12710696 Garcia- Closas, M. et al. (2013)
2_202181247_C_T_b37 2_202181247 rs1830298 Lin, W. Y. et al. (2015)
2_217920769_G_T_b37 2_217920769 rs4442975 Ghoussaini, M. et al. (2014)
2_217963060_C_A_b37 2_217963060 rs34005590 Wyszynski, A. et al. (2016)
2_218296508_C_T_b37 2_218296508 rs16857609 Michailidou, K. et al. (2013)
2_227226952_A_G_b37 2_227226952 rs12479355 Michailidou, K et al. (2017)
NA 2_24739695 rs200648189 Milne et al. (2017)
2_25129473_A_G_b37 2_25129473 rs6725517 Michailidou, K et al. (2017)
2_29120733_C_T_b37 2_29120733 rs4577244 Couch, F. J. et al. (2016)
20_32588095_T_C_b37 20_32588095 rs2284378 Siddiq, A. et al. (2012)
20_48945911_A_G_b37 20_48945911 rs6122906 Michailidou, K et al. (2017)
20_5948227_G_A_b37 20_5948227 rs16991615 Michailidou, K et al. (2017)
21_16520832_G_A_b37 21_16520832 rs2823093 Ghoussaini, M. et al. (2012)
22_29121087_A_G_b37 22_29121087 rs17879961 Michailidou, K. et al. (2013)
22_29621477_C_T_b37 22_29621477 rs132390 Michailidou, K. et al. (2013)
22_38568833_C_G_b37 22_38568833 rs738321 Michailidou, K et al. (2017)
NA 22_39359355 chr22:39359355 Long, J. et al. (2013)
22_40876234_T_C_b37 22_40876234 rs6001930 Michailidou, K. et al. (2013)
22_42038786_C_T_b37 22_42038786 rs73161324 Michailidou, K et al. (2017)
NA 22_46283297 rs28512361 Michailidou, K et al. (2017)
NA 3_141112870 rs34207738 Michailidou, K et al. (2017)
3_172285237_G_A_b37 3_172285237 rs58058861 Michailidou, K et al. (2017)
3_27416013_C_T_b37 3_27416013 rs4973768 Ahmed, S. et al. (2009)
3_30682939_G_C_b37 3_30682939 rs12493607 Michailidou, K. et al. (2013)
3_46866866_G_A_b37 3_46866866 rs6796502 Finucane, H. K. et al. (2015)
3_4742276_A_G_b37 3_4742276 rs6762644 Michailidou, K. et al. (2013)
3_63967900_A_G_b37 3_63967900 rs1053338 Milne, R. L. et al. (2014).
3_71532113_T_C_b37 3_71532113 rs6805189 Michailidou, K et al. (2017)
3_87037543_A_G_b37 3_87037543 rs13066793 Michailidou, K et al. (2017)
3_99723580_G_T_b37 3_99723580 rs9833888 Michailidou, K et al. (2017)
4_106084778_C_T_b37 4_106084778 rs9790517 Michailidou, K. et al. (2013)
4_126843504_G_T_b37 4_126843504 rs77528541 Michailidou, K et al. (2017)
4_175846426_C_A_b37 4_175846426 rs6828523 Michailidou, K. et al. (2013)
4_38816338_A_C_b37 4_38816338 rs6815814 Michailidou, K et al. (2017)
NA 4_84370124 rs10718573 Michailidou, K et al. (2017)
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4_89243818_C_T_b37 4_89243818 rs10022462 Michailidou, K et al. (2017)
5_111217786_G_T_b37 5_111217786 rs6882649 Michailidou, K et al. (2017)
5_1279790_C_T_b37 5_1279790 rs10069690 Haiman, C. A. et al. (2011)
NA 5_1296256 rs3215401 Bojesen, S. E. et al. (2013).
5_132407058_C_T_b37 5_132407058 rs6596100 Michailidou, K et al. (2017)
5_158244083_C_T_b37 5_158244083 rs1432679 Michailidou, K. et al. (2013)
5_16187528_G_T_b37 5_16187528 rs13162653 Finucane, H. K. et al. (2015)
5_169591487_G_T_b37 5_169591487 rs4562056 Michailidou, K et al. (2017)
5_32567732_C_T_b37 5_32567732 rs2012709 Finucane, H. K. et al. (2015)
NA 5_345109 rs116095464 Michailidou, K et al. (2017)
5_44706498_A_G_b37 5_44706498 rs10941679 Ghoussaini, M. et al. (2016)
5_49641645_T_C_b37 5_49641645 rs72749841 Michailidou, K et al. (2017)
NA 5_50195094 rs35951924 Michailidou, K et al. (2017)
5_56053723_A_T_b37 5_56053723 rs62355902 Glubb, D. M. et al. (2015)
5_58184061_T_C_b37 5_58184061 rs10472076 Michailidou, K. et al. (2013)
5_58337481_T_G_b37 5_58337481 rs1353747 Michailidou, K. et al. (2013)
5_81538046_T_A_b37 5_81538046 rs7707921 Finucane, H. K. et al. (2015)
5_90732225_C_T_b37 5_90732225 rs10474352 Cai, Q. et al. (2014)
6_10456706_C_A_b37 6_10456706 rs9348512 Gaud et, M. M. et al. (2013)
6_130349119_C_T_b37 6_130349119 rs6569648 Michailidou, K et al. (2017)
6_1318878_C_T_b37 6_1318878 rs11242675 Michailidou, K. et al. (2013)
6_13722523_G_A_b37 6_13722523 rs204247 Michailidou, K. et al. (2013)
6_149608874_G_A_b37 6_149608874 rs9485372 Long, J. et al. (2012)
6_151942194_T_G_b37 6_151942194 rs3757322 Dunning, A. M. et al. (2016)
6_151952332_G_A_b37 6_151952332 rs9397437 Dunning, A. M. et al. (2016)
6_152437016_T_C_b37 6_152437016 rs2747652 Dunning, A. M. et al. (2016)
6_16399557_C_T_b37 6_16399557 rs3819405 Michailidou, K et al. (2017)
6_20621238_T_C_b37 6_20621238 rs2223621 Michailidou, K et al. (2017)
6_26680698_G_A_b37 6_26680698 rs71557345 Michailidou, K et al. (2017)
NA 6_28926220 rs9257408 Finucane, H. K. et al. (2015)
6_81094287_G_A_b37 6_81094287 rs12207986 Michailidou, K et al. (2017)
6_82128386_T_C_b37 6_82128386 rs17529111 Siddiq, A. et al. (2012).
7_101552440_G_A_b37 7_101552440 rs71559437 Michailidou, K et al. (2017)
7_130667121_C_T_b37 7_130667121 rs4593472 Finucane, H. K. et al. (2015)
7_139942304_G_A_b37 7_139942304 rs11977670 Sawyer, E. et al. (2014)
7_144074929_G_A_b37 7_144074929 rs720475 Michailidou, K. et al. (2013)
NA 7_21940960 rs7971 Michailidou, K et al. (2017)
7_28356889_T_C_b37 7_28356889 rs17156577 Michailidou, K et al. (2017)
7_91630620_G_T_b37 7_91630620 rs6964587 Milne, R. L. et al. (2014).
7_94113799_T_C_b37 7_94113799 rs17268829 Michailidou, K et al. (2017)
8_102478959_A_T_b37 8_102478959 rs514192 Michailidou, K et al. (2017)
NA 8_106358620 rs12546444 Michailidou, K et al. (2017)
8_117209548_A_G_b37 8_117209548 rs13267382 Finucane, H. K. et al. (2015)
8_124610166_G_A_b37 8_124610166 rs58847541 Michailidou, K et al. (2017)
8_124757661_C_T_b37 8_124757661 rs17350191 Milne et al. (2017)
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8_128355618_A_G_b37 8_128355618 rs13281615 Easton, D. F. et al. (2007)
8_129194641_C_T_b37 8_129194641 rs11780156 Michailidou, K. et al. (2013)
8_170692_T_C_b37 8_170692 rs66823261 Milne et al. (2017)
8_29509616_A_C_b37 8_29509616 rs9693444 Michailidou, K. et al. (2013)
8_36858483_A_G_b37 8_36858483 rs13365225 Finucane, H. K. et al. (2015)
8_76230301_G_T_b37 8_76230301 rs6472903 Michailidou, K. et al. (2013)
8_76417937_A_G_b37 8_76417937 rs2943559 Michailidou, K. et al. (2013)
9_110306115_C_A_b37 9_110306115 rs10759243 Michailidou, K. et al. (2013)
9_110837073_A_G_b37 9_110837073 rs10816625 Orr, N. et al. (2015)
9_110837176_C_T_b37 9_110837176 rs13294895 Orr, N. et al. (2015)
9_110895353_C_T_b37 9_110895353 rs676256 Orr, N. et al. (2015)
9_119313486_A_G_b37 9_119313486 rs1895062 Michailidou, K et al. (2017)
9_129396434_G_A_b37 9_129396434 rs10760444 Michailidou, K et al. (2017)
NA 9_136151580 rs8176636 Michailidou, K et al. (2017)
9_22062134_G_T_b37 9_22062134 rs1011970 Turnbull, C. et al. (2010)
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FIGURE D.1: Brightfield images of MCF-7 cells treated with puromycin concentrations
ranging for 0 µg/mL to 5 µg/mL. Images were taken ever 24 hours and cell death as
monitored by detached and rounded cells. All images were captured at 10x objective
on the Accu-Scope 3032 Inverted Microscope.
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FIGURE D.2: MAplots for each Chlariom D array before (top) and after (bottom) nor-
malisation compared pseudo-array. The psuedo-array was derived from the median
probe intensity across all arrays.
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FIGURE D.3: Scatterplots of mean (Columns 1,3,5 and 7) and standard deviations
(Columns 2,4,6 and 8) for each expression probe compared between basal and non-
basal subtypes independently (Luminal A, Luminal B, Her2 and normal-like) across all
four mircoarray dataset. The linear model (dashed blue line) and LOESS (solid blue
line) illustrates any deviation from no variance (red line). All comparison illustrate a
increased in global variation in basal breast tumours but not a global shift in the mean
expression level.
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FIGURE D.4: Scatterplots of expression probe statistics for tumours classified as ei-
ther basal or non-basal for the 14 cohorts that make up the meta-cohort. Mean probe
expression between the basal tumours and non-basal tumours show little variation.
However, there was greater probe variability in basal tumours measure by the stan-
dard deviation. This is shown by the right shift in linear model (blue) compare to the
line of no variance (red).
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FIGURE D.5: Sampling (top) and dataset simulations (bottom) were were used to dis-
play the effect of sample size on methods to measure variability. Linear modelling (top)
β is under estimated when randomly sampling the meta-cohort for equal size sample
groups. Each point represents the average β for 100 linear models between basal and
non-basal at each given sample size. The standard deviation ratio (SDR, bottom) is
the ratio of two simulated populations. Each point represents the average SDR for 100
independent simulations. The observed β in the meta-cohort (left) and SDR of entire
simulated population (bottom) are depicted as red based lines. The loess curve was
fitted to each set of date (blue).
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TABLE D.2: p-values for the most significantly differentially expressed genes identified
in the meta-cohort. Statistics were calculated between basal and non-basal tumours.
Affy ID Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 Cohort 7
209644_x_at 4.3x10-25 9.5x10-12 1.1x10-3 1.7x10-8 8.2x10-1 6.3x10-1 6.7x10-63
215729_s_at 9.2x10-25 9.4x10-16 9.4x10-1 1.9x10-12 2.8x10-1 1.1x10-4 1.9x10-41
220559_at 7.5x10-23 2.3x10-14 6.2x10-1 4.3x10-12 6.6x10-1 3.6x10-1 1.5x10-55
207039_at 2.3x10-18 2.1x10-10 1.2x10-1 2.3x10-6 2.5x10-1 9.2x10-1 3.9x10-36
213260_at 1.3x10-28 6.1x10-15 2.5x10-1 3.8x10-7 1.1x10-1 7.1x10-2 1.2x10-28
220425_x_at 2.2x10-14 1.1x10-9 9.9x10-1 2.5x10-4 6.0x10-1 5.1x10-1 1.7x10-39
209800_at 1.6x10-17 1.3x10-10 3.5x10-2 2.6x10-6 4.9x10-1 4.1x10-1 4.4x10-19
203439_s_at 2.7x10-15 1.0x10-12 3.5x10-2 1.2x10-10 3.1x10-2 6.5x10-2 1.3x10-25
205044_at 2.1x10-15 5.3x10-12 8.8x10-1 9.4x10-6 1.6x10-1 4.1x10-1 1.6x10-35
209842_at 4.5x10-14 4.0x10-8 5.5x10-1 1.6x10-3 7.1x10-1 9.8x10-1 1.4x10-39
Affy ID Cohort 8 Cohort 9 Cohort 10 Cohort 11 Cohort 12 Cohort 13 Cohort 14
209644_x_at 1.6x10-26 8.2x10-34 1.2x10-17 3.0x10-12 7.3x10-1 3.8x10-4 2.2x10-10
215729_s_at 1.6x10-24 3.9x10-31 2.5x10-9 5.1x10-28 2.0x10-1 6.6x10-1 1.6x10-6
220559_at 5.0x10-36 3.5x10-46 3.4x10-17 2.8x10-21 8.9x10-1 4.1x10-1 8.2x10-4
207039_at 4.4x10-22 2.8x10-32 2.4x10-19 9.3x10-10 2.7x10-1 2.8x10-2 1.8x10-6
213260_at 4.2x10-19 5.0x10-23 2.3x10-11 1.3x10-21 3.2x10-3 8.7x10-2 4.0x10-6
220425_x_at 1.7x10-14 1.9x10-26 1.3x10-6 8.2x10-13 9.5x10-1 1.2x10-1 8.2x10-4
209800_at 4.5x10-18 3.0x10-22 1.0x10-7 1.3x10-12 1.8x10-1 1.3x10-3 8.0x10-5
203439_s_at 2.6x10-18 7.1x10E-7 2.5x10-10 6.1x10-9 2.0x10-1 1.8x10-3 3.7x10-4
205044_at 1.0x10-20 2.5x10E-7 2.1x10-7 5.8x10-6 7.0x10-2 5.0x10-1 2.3x10-3
209842_at 6.0x10-12 6.3x10-17 2.3x10-4 3.0x10-16 2.4x10-1 2.8x10-1 1.0x10-3
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FIGURE D.6: PCA analysis for the top 2500 variably expressed coloured and group for
each cohort A) or subtype B).
FIGURE D.7: Smallest p-value calculated between pseudo-basal and pseudo-nonbasal
tumour group (blue points) compared to the samllest p between basal and non-basal
tumours (red point). Insert depicts the sampled test smallest p-values for pseudo sam-
ples only. All p-values were calculated as modified t test (limma)on the meta-cohort
with a 1000 random permutation of sampling. Sample size for each test represent the
true basal (n=490) and non-basal (n=1626) sizes.
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FIGURE D.8: Gene expression of EN1 (top) and IGF2BP3 (bottom) correlated to gene
dosage.
FIGURE D.9: Dependence of variability statistics on mean. Correlations of mean probe
statistics with standard deviations (SD, top row) and coefficient of variance (CV, bot-
tom) row. Correlations are compared in quantiles of mean expression levels. Each point
a probe from the meta-cohort with the x,y coordinates reflect the mean level and SD or
CV, respectively.
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TABLE D.3: Significant veQTL association in lung tissue
rsNumber ensembl ID Gene Symbol w p-value
rs11814448 ENSG00000241717.1 VWFP1 48.07 2.48E-19
rs11814448 ENSG00000225972.1 MTND1P23 47.39 4.26E-19
rs6815814 ENSG00000225972.1 MTND1P23 43.48 9.42E-18
rs11814448 ENSG00000228549.2 38.77 4.81E-16
rs11814448 ENSG00000178084.1 HTR3C 38.19 7.77E-16
rs11814448 ENSG00000232573.1 RPL3P4 37.91 9.81E-16
rs11814448 ENSG00000198794.7 SCAMP5 36.08 4.54E-15
rs6815814 ENSG00000232177.1 MTND4P24 33.87 2.81E-14
rs11814448 ENSG00000237973.1 MTCO1P12 33.89 2.88E-14
rs11814448 ENSG00000225093.1 RPL3P7 33.89 2.88E-14
rs2594714 ENSG00000241717.1 VWFP1 31.13 2.95E-13
rs11780156 ENSG00000210191.1 MT-TL2 30.30 6.03E-13
rs2594714 ENSG00000225972.1 MTND1P23 29.72 9.94E-13
rs13267382 ENSG00000241717.1 VWFP1 29.02 1.82E-12
rs11814448 ENSG00000259187.1 27.48 7.18E-12
rs13267382 ENSG00000225972.1 MTND1P23 27.31 8.11E-12
rs6815814 ENSG00000259781.1 HMGB1P6 26.78 1.29E-11
rs10069690 ENSG00000237973.1 MTCO1P12 26.63 1.47E-11
rs11814448 ENSG00000237533.1 26.50 1.70E-11
rs11814448 ENSG00000132967.9 HMGB1P5 26.33 1.96E-11
rs11117758 ENSG00000225840.1 25.96 2.66E-11
rs11814448 ENSG00000196656.6 25.72 3.37E-11
rs13294895 ENSG00000152592.9 DMP1 25.39 4.42E-11
rs11814448 ENSG00000172799.5 ZBTB8OSP2 25.11 5.74E-11
rs11814448 ENSG00000260581.1 25.02 6.24E-11
rs11814448 ENSG00000206561.8 COLQ 25.00 6.30E-11
rs1011970 ENSG00000116031.7 CD207 24.65 8.44E-11
rs11552449 ENSG00000128510.6 CPA4 24.39 1.06E-10
rs13329835 ENSG00000230202.1 24.36 1.09E-10
rs2594714 ENSG00000178084.1 HTR3C 24.36 1.10E-10
rs11552449 ENSG00000154736.5 ADAMTS5 24.19 1.27E-10
rs13294895 ENSG00000222078.1 RN7SKP110 24.17 1.30E-10
rs13267382 ENSG00000226278.1 PSPHP1 23.63 2.09E-10
rs11814448 ENSG00000227939.1 RPL3P2 23.52 2.34E-10
rs17156577 ENSG00000224690.2 UBE2D3P3 23.25 2.93E-10
rs6815814 ENSG00000241717.1 VWFP1 23.14 3.22E-10
rs11780156 ENSG00000207870.1 MIR221 22.96 3.81E-10
Appendix D. Additional Figures and Tables 209
rs13267382 ENSG00000172799.5 ZBTB8OSP2 22.83 4.27E-10
rs11814448 ENSG00000230202.1 22.22 7.47E-10
rs999737 ENSG00000139648.6 KRT71 22.06 8.48E-10
rs13294895 ENSG00000230491.1 21.97 9.21E-10
rs7297051 ENSG00000229647.1 MYOSLID 21.69 1.19E-09
rs2236007 ENSG00000222100.1 <NA> 21.60 1.29E-09
rs11814448 ENSG00000259781.1 HMGB1P6 21.26 1.77E-09
rs11780156 ENSG00000202382.1 21.13 1.95E-09
rs10069690 ENSG00000225972.1 MTND1P23 21.07 2.08E-09
rs17156577 ENSG00000196656.6 21.05 2.12E-09
rs6597981 ENSG00000177236.3 20.96 2.29E-09
rs2594714 ENSG00000254052.1 IGHVIII-67-4 20.95 2.30E-09
rs74911261 ENSG00000206727.1 SNORD116-9 37.40 2.36E-09
rs17156577 ENSG00000223070.1 20.91 2.40E-09
rs11814448 ENSG00000261701.2 HPR 20.88 2.51E-09
rs11814448 ENSG00000254052.1 IGHVIII-67-4 20.82 2.64E-09
rs11780156 ENSG00000270071.1 20.69 2.91E-09
rs6815814 ENSG00000132967.9 HMGB1P5 20.68 2.95E-09
rs4784227 ENSG00000225217.1 HSPA7 20.57 3.25E-09
rs2594714 ENSG00000259781.1 HMGB1P6 20.40 3.80E-09
rs17156577 ENSG00000228549.2 20.35 3.96E-09
rs10941679 ENSG00000111536.4 IL26 20.26 4.32E-09
rs11814448 ENSG00000272824.1 20.17 4.76E-09
rs11814448 ENSG00000233368.2 20.02 5.43E-09
rs11780156 ENSG00000113327.10 GABRG2 19.91 5.91E-09
rs1011970 ENSG00000207442.1 SNORD116-6 19.89 6.05E-09
rs4784227 ENSG00000152049.5 KCNE4 19.78 6.67E-09
rs2236007 ENSG00000260507.1 19.70 7.13E-09
rs7707921 ENSG00000211782.2 TRAV8-1 19.59 7.94E-09
rs28539243 ENSG00000226278.1 PSPHP1 19.56 8.13E-09
rs2588809 ENSG00000265676.1 19.50 8.65E-09
rs17156577 ENSG00000167619.7 TMEM145 19.43 9.18E-09
rs13329835 ENSG00000230869.1 AGAP10P 19.40 9.36E-09
rs17156577 ENSG00000254052.1 IGHVIII-67-4 19.39 9.49E-09
rs72755295 ENSG00000201635.1 33.89 1.23E-08
rs74911261 ENSG00000130383.6 FUT5 33.76 1.31E-08
rs117618124 ENSG00000162493.12 PDPN 33.72 1.33E-08
rs7707921 ENSG00000238612.1 18.93 1.44E-08
rs6815814 ENSG00000237973.1 MTCO1P12 18.90 1.49E-08
rs6815814 ENSG00000204894.4 18.87 1.52E-08
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rs7297051 ENSG00000264201.1 MIR4701 18.84 1.56E-08
rs72755295 ENSG00000199291.1 33.33 1.60E-08
rs17156577 ENSG00000178084.1 HTR3C 18.74 1.72E-08
rs941764 ENSG00000225972.1 MTND1P23 18.63 1.89E-08
rs13267382 ENSG00000237533.1 18.62 1.91E-08
rs11814448 ENSG00000238137.2 ARPC3P2 18.53 2.09E-08
rs10069690 ENSG00000237533.1 18.51 2.11E-08
rs11814448 ENSG00000232177.1 MTND4P24 18.47 2.22E-08
rs11814448 ENSG00000241278.1 ENPP7P4 18.46 2.24E-08
rs117618124 ENSG00000166923.6 GREM1 32.59 2.28E-08
rs10069690 ENSG00000238533.1 18.36 2.43E-08
rs11780156 ENSG00000152954.7 NRSN1 18.32 2.52E-08
rs999737 ENSG00000212899.1 KRTAP3-3 18.24 2.69E-08
rs12422552 ENSG00000202141.1 18.22 2.75E-08
rs71557345 ENSG00000269468.1 32.05 2.98E-08
rs6815814 ENSG00000226278.1 PSPHP1 18.09 3.11E-08
rs11780156 ENSG00000161082.8 CELF5 18.02 3.29E-08
rs11780156 ENSG00000202190.1 18.01 3.32E-08
rs11814448 ENSG00000230869.1 AGAP10P 17.94 3.59E-08
rs11780156 ENSG00000167654.13 ATCAY 17.91 3.65E-08
rs2594714 ENSG00000232573.1 RPL3P4 17.88 3.77E-08
rs999737 ENSG00000221880.2 KRTAP1-3 17.87 3.80E-08
rs117618124 ENSG00000047457.9 CP 31.36 4.08E-08
rs7707921 ENSG00000267406.1 17.76 4.21E-08
rs999737 ENSG00000131737.5 KRT34 17.72 4.33E-08
rs11814448 ENSG00000243289.1 AGAP13P 17.73 4.35E-08
rs17529111 ENSG00000121742.11 GJB6 17.72 4.40E-08
rs11780156 ENSG00000223027.1 17.69 4.48E-08
rs11780156 ENSG00000222691.1 RNU6-733P 17.65 4.62E-08
rs7707921 ENSG00000259389.2 H3F3AP1 17.64 4.69E-08
rs11814448 ENSG00000253239.1 IGLVI-70 17.63 4.79E-08
rs11814448 ENSG00000253228.1 NRBF2P4 17.60 4.93E-08
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TABLE D.4: Significant veQTL assoication in ovary tissue
rsNumber ensembl ID Gene Symbol w p-value
rs11814448 ENSG00000232177.1 MTND4P24 65.62 7.44E-13
rs12710696 ENSG00000237073.1 30.20 2.37E-11
rs1830298 ENSG00000242371.1 IGKV1-39 25.99 4.20E-10
rs13294895 ENSG00000249650.1 42.92 1.46E-09
rs1830298 ENSG00000137078.4 SIT1 23.45 2.53E-09
rs11814448 ENSG00000259781.1 HMGB1P6 38.78 8.51E-09
rs11814448 ENSG00000272824.1 38.33 1.01E-08
rs11814448 ENSG00000099365.5 STX1B 36.87 1.77E-08
rs6597981 ENSG00000177236.3 19.59 4.35E-08
FIGURE D.10: Tissue-specific expression of IRX3 stratified by genotypes at the
rs11075995 locus. T/T homozygous major allele (Green), A/T heterozygous (Orange),
A/A homozygous minor allele (Blue).
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